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Abstract
The thesis describes the development of a method for determining the antigenicity of dif-
ferent regions of the surface of a protein. The method involved the construction of a set
of mutant antigens in which cysteine residues had been introduced at different points in
the surface of the antigen. Each mutant protein was tethered through the surface cysteine
residue and a bifunctional chemical cross-linker to solid phase, allowing the creation of
an array of mutant antigens, each oriented so as to expose or to mask different topolog-
ical regions of the antigen surface. Indeed, as expected, binding of a set of monoclonal
antibodies proved sensitive to the orientation of the antigen. By use of this array of ori-
ented antigen it became possible to compare the different regions of the antigen surface
for binding to rabbit antiserum, and thereby to create a topological map of the antibody
response. When the immunisations were undertaken with use of Freund's adjuvant, the
antibody response to ;3-lactamase was mainly directed against a region centered on a
flexible loop. Furthermore it comprised antibodies cross-reactive to both native and de-
natured protein. By contrast, in the absence of Freund's adjuvant, the antibody response
was more evenly distributed, and with few cross-reactive antibodies. This suggested that
Freund's adjuvant denatures ;3-lactamase (as was confirmed experimentally), and that
the appearance of dominant epitopes may follow the presentation of denatured protein
to the immune system. These observations have implications for understanding the basis
for dominance of B-cell epitopes, and also for design of vaccines.
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Chapter 1
Introduction
1.1 Aim of this work:
The aim of this work is to map the relative distribution of B-cell epitopes on the three-
dimensional surface of a protein antigen and to study the relationship between the surface
structures and the antigenicity distribution.
1.2 The immune response
The immune response can be arranged into two parts, innate immunity and adaptive
immunity. Innate immunity is an inherited potential to respond to pathogens and it will
not change after a challenge by a pathogen. In contrast, the adaptive immunity, which
comprises Band T cells, is able to launch an antigen specific response and retain the
antigen specificity long after the initial response. It wiI1 upon later rechallenge by the
same or a very similar pathogen provide a quicker and more powerful immune response.
This specific memory was discovered in 1798 by Edward Jenner [Jenner, 1798] who
noticed that individuals who had encountered cow pox were "secure from the infection
of the small pox." He also showed that he could vaccinate a young boy against small pox
the same way.
1
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1.2.1 B cells
2
B cells are responsible for humoral adoptive immunity through production of antibodies.
Antibodies bind extracellular pathogens or toxins and block their ability to infect or de-
stroy body tissue. A second function of antibodies is to opsonise material for clearance
by phagocytic cells. The fact that non-cellular substances can protect against foreign
antigens was first demonstrated by von Behring and Kitasato in 1890 [von Behring and
Kitasato, 1890], They injected sera from animals that were immunised with and resistant
to cholera toxin into normal animals and showed that this protected the latter against the
toxin. The "anti-toxines" responsible for the protection are today known as antibodies.
In 1947 Fagraeus [Fagraeus, 1947] demonstrated that antibodies are produced by plasma
cells (activated B cells). In particular she showed that the number of plasma cells in the
spleen increases simultaneously with the amount of circulating antibodies and that tis-
sue from the red pulp, where the plasma cells are located, liberate significant yields of
antibodies in cell culture. She also showed that lymph follicles which are rich in lym-
phocytes, but have no plasma cells, have much lower capacity to produce antibodies.
The mechanism behind the generation of antibodies puzzled investigators for a long
time and the research has been driven by several theories. Paul Ehrlich suggested in
1898 a model, "the side-chain theory", to explain the explosive production of antibodies
after exposure to antigen [Ehrlich, 1900]. He postulated that cells have a large number
of different predefined receptors (side-chains) on the surface and that at least one recep-
tor is able to bind any given antigen. The specific receptor would, when binding to the
antigen, be released into the blood stream. New receptors would then be produced to
replace the released receptors.
Landsteiner [1936] later showed that the immune system can make antibodies to an
apparent unlimited range of antigens. Since no protein structures were known at that
time he used chemicals "haptens" coupled to carrier proteins as antigens. Through anal-
ysis of the antibodies ability to precipitate the antigens he noticed that antibodies can be
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produced against many novel molecules and that the antibodies were able to discrimi-
nate subtle differences in the haptens. Ehrlich's theory did not explain how the immune
system has enough predefined receptors to respond to such a range of antigens. One
explanation was attempted in a model introduced as "the template theory" and refined by
Pauling [1940]. It postulated that the antibodies of one predefined sequence fold onto the
antigen and essentially that the antibody polypeptide sequence can have many possible
conformations with similar folding energy. The antibody therefore uses the antigen as a
template to obtain a specific conformation.
But this theory was unable to explain several observations as pointed out by Jerne in
1955 [Jerne, 1955]. In particular, a secondary antigen stimulus provokes a more active
production of antibodies than does the primary stimulus and the immune system contin-
ues producing antibodies long after the stimulus. Jerne introduced "the natural selection
theory". This postulated that a vast repertoire of diversified antibodies is produced and
secreted by cells and that binding of antibody to an antigen, followed by phagocytosis
of the antibody-antigen complex, triggers production of a large number of copies of the
same antibody. Jerne envisaged that the phagocytosing cell duplicated the antibodies and
not the cell from which the antibody clone originated. In contrast, Burnet [1957] linked
the antigen-antibody recognition to the antibody production by saying that the antibody
production was carried out by the same cell clone as produced the initial antibody clone.
He proposed a repertoire of randomly diversified cells, each bearing antibodies with a
single specificity. Binding of these surface receptors to the antigen was postulated to lead
to production of antibodies and replication of the cell. One of the early experiments sup-
porting Burnet's theory was carried out by Nossal and Lederberg [1958]. They showed
that single cells harvested from rats immunised with a flagella protein from two different
strains of Salmonella would make antibodies to one or the other strain, but not to both.
This demonstrated that the antibodies produced by each cell have a single specificity.
During the 1990s, it became possible to test the essential features of the Burnet model
- the idea of Darwinian selection from a large repertoire of diverse antibodies. Winter
and colleagues [Winter, 1998] created a large combinatorial antibody library in which
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antibody fragments were displayed on the surface of filamentous bacteriophage. The
repertoire (> 107) was selected for binding to a wide range of antigens, leading to the iso-
lation of antibody fragments with diverse activities and binding affinities characteristics
of primary antibody responses.
Some of the earliest clues to how the receptor diversity is created was presented by
Hozumi and Tonegawa [1976]. They fractionated genomic DNA that had been digested
by restriction endonuclease BamHI on an agarose gel. mRNA molecules, encoding
the constant and variable domain of the antibody, were then analysed for hybridisation
with genomic DNA fragments of different sizes. The genomic DNA fragments that hy-
bridised with the mRNA molecules were significantly smaller if the DNA was isolated
from mouse plasmacytoma cells (malignant B-cells) instead of cells of 12 to 13 days old
mouse embryos. This suggests that the distance between the gene segments encoding
the constant and variable domain was reduced in the plasmacytoma and that somatic re-
arrangement of the antibody genes takes place in B-cells. Similar hybridisation studies
in the same laboratory with fragments of cDNA encoding the light chain of the anti-
body molecule showed that two gene segments (termed V and J) encoding the variable
domain also are brought closer together by somatic recombination [Brack et al., 1978].
By cloning and sequencing the hybridising DNA fragments from embryonic DNA and
myeloma it was shown that the V is directly linked to the J segments after the recombi-
nation [Bernard et aI., 1978]. V and J segments have also been identified in heavy chain
of the antibody in addition to a third segment called the D segment [Tonegawa, 1983].
One of each V, D and J or V and J segments are put together in the heavy chain or light
chain respectively in the rearrangement process. The whole process results in each cell
having only one receptor specificity.
Seidman and his colleagues showed that cDNA corresponding to one of the 25 known
light chain V segments identified in mice plasmacytomas, hybridised with six EcoRI
fragments of genomic DNA from mouse plasmacytoma cells [Seidman et al., 1978].
Cloning and sequencing of the fragments showed that these were closely related V seg-
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ments. This suggested that the genome may contain large sets of distinct and related V
genes. Some of the later estimates of the number of different antibody gene segments in
the genome were mainly based on hybridising cDNA of known segment sequences with
mRNA from spleen cells or peripheral blood lymphocytes. Bentley [1984] showed that
the about 25 known human germ-line V", (see below) genes hybridised with more than
50% of K, chain mRNA from such cells. The total amount of mRNA was estimated by
using a DNA probe which hybridises with a constant sequence which is present in all
the of K, chain mRNA molecules. From this Bentley concluded that there are about 50
or fewer V", in the human genome. The different gene segments have later been more
rigorously identified and counted by using the polymer chain reaction (PCR) to amplify
the germ line sequences followed by sequencing of the amplified segments [Cook and
Tomlinson, 1995]. Knowledge of invariant sequences that surround these gene segments
in the germ line, but are deleted in the rearranged antibody sequence, allowed specific
amplification of the germ line segments only.
There are two types of light chains in humans, K, and A; each of these are assembled
from 40 or 30 V segments and 5 or 4 J segments respectively [Janeway et al., 1999].
This gives a combinatorial diversity of 320 (= 40x5 + 30x4). In humans the 65 V seg-
ments, 27 D segments and 6 J segments of the heavy chains [Janeway et al., 1999] give a
possible diversity of 10,530 (= 65x27x67). The combinatorial diversity of the heavy and
the light chain together, based on the numbers of V,D and J segments, is therefore about
3.4.106 (:::::::320x10,530). The expected diversity is even higher due to changes in the
residues in the joining regions; different numbers of nucleotides are added to the ends
of the segments by two different processes (P or N nucleotides) or trimmed off in the
joining event. It has been estimated that this gives a primary antibody diversity of 1014
[Janeway et al., 1999] which is larger than the total number (1011 [Rich et al., 2001]) of
B cells in the body.
The rearrangement of gene segments in B cells takes place in the bone marrow where
they are produced, followed by a deletion or inactivation of B cells specific for self-
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antigens. This has been shown with transgenic mice that have high numbers of HEL
specific B-cells and also express membrane bound lysozyme in bone marrow cells. The
HEL specific B-cells are eliminated in the bone marrow and do not emerge as peripheral
cells. In contrast, if high levels of soluble HEL are expressed in such transgenic mice,
then the HEL specific B-cells are not deleted but left in a non-responding state (anergy).
These cells do not secrete anti-HEL antibodies and show almost no proliferation in re-
sponse to T-cell stimulation [Goodnow, 1992].
By inspection of alignments of partial sequences of mouse antibody light chains
in the 1970s [Weigert et al., 1970] it was proposed that the genes encoding antibody
molecules accumulate mutations. This process, known as somatic hypermutation, leads
to mutations which are focused in the binding region of the antibodies (as described in
more detail later). Griffiths et al. [1984] studied the antibody response to 2-phenyloxazolone
through sequencing of mRNA of hybridomas made from different stages of the immune
response. Comparison of the hybridoma sequences with the known germ-line sequences
showed that somatic mutations had taken place in the second week of the immune re-
sponse, concomitantly with an increase in antibody affinity. Their results suggested that
the affinity maturation of antibodies is driven by somatic mutations. It is now generally
accepted that the B cells with increased affinity for the antigen can have a selective ad-
vantage over other clones for further cell division and survival.
1.2.2 T cells
Some of the earliest evidence of the cell based immunity was reported by Landsteiner
and Chase [1942] who showed that delayed hypersensitivity could be transferred by cells
but not by serum. Landsteiner transferred cells or supernatants from peritoneal exudates
of animals immunised against picryl chloride to non-immunised animals. Only animals
receiving cells showed a skin reaction to picryl chloride in oil after 24 hours. Delayed
hypersensitivity is a local tissue reaction and is today known to depend on T cells that
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have previously been sensitised by the same antigen.
More knowledge on the role of T cells in the immune response came from experi-
ments carried out by Claman et al. [1966]. They transferred thymus cells (T cells) and/or
bone marrow (B cells) from donor mice to mice that had been irradiated to remove the
recipient's own immune cells. The irradiated mice were then injected with sheep ery-
throcytes. Cell samples from the spleen of the irradiated mice were later assayed for their
ability to release antibodies that could lyse new sheep erythrocytes that were embedded
in agar with guinea pig complement. Both Band T cells had to be injected for efficient
cell lysis demonstrating the cooperation of T and B cells.
The T cells can be divided into two groups; T-helper cells, which are crucial for the
onset of both humoral and cellular immune responses, and cytotoxic T cells which elim-
inate infected cells. T-helper cells are mainly regulatory and intimately involved in the
B-cell and cytotoxic T-cell response. T-helper (TH) cells are divided into the subgroups
THI and TH2 which both differentiate from THO. IL-12 promotes development of THI
cells and IL-4 promotes TH2 cells [Murphy and Reiner, 2002].The levels of these sub-
groups are important for regulating the contributions of the humoral and the cellular side
of the immune response. THI cells release IFN/, and primarily promote cell-mediated
immunity whereas TH 2 cells release interleukins (ILs) as IL-4, IL-5, IL-lO and IL-13
and promote humoral immunity [Akira et al., 2001]. Interaction between cell surface
molecules on TH 2 as CD40L and the T-cell receptor (described later) and their ligands
on B cells are also important for activation of the B cells. The presence of activated THI
or TH 2 cells are in tum dependent on the type of infection and regulated by the cytokines
released by cells at the location of the immune response.
In 1982 Allison and his colleagues made a monoclonal antibody (mAb) against T-
cell lymphoma [Allison et al., 1982] that recognised a protein present on T cells but
absent on B cells. The protein was a dimer and could be separated into two subunits
estimated to be about 39,000 Da and 41,000 Da under reducing condition. Shortly there-
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Figure 1.1: Diagram of the T-cell receptor. The molecule consists of two polypeptide
chains Cl: (blue) and f3 (red), linked together with a disulphide bonds (black line). The
variable regions (Va + V/3)form the antigen binding sites.
after a mAb was made by Haskins et al. [1983] against a chicken ovalbumin (cOVA)
specific T-cell hybridoma. The mAb blocked the production of interleukin 2 (JL-2) by
the T-cell hybridoma in response to cOVA and antigen presenting cells but not from
other cOVA specific T-cell hybridomas. Furthermore the rnAb also blocked binding of
the cOVA T-cell hybridoma to antigen presenting cells but only if the antigen presenting
cells had been preincubated with cOVA. Not only did this confirm the specific nature of
the mAb interaction, but this also suggested that the target of the rnAb was a membrane
protein. The antibody was found to precipitate a dimeric protein with estimated sizes
subunits of about 40-44,000 Da, about the same size as the protein found by Allison
and his colleagues. The dimeric protein was proposed by Haskins and her colleagues to
be the T-cell receptor which later has been confirmed by other experiments. The T-cell
receptor consists of two chains, termed Cl: and f3 (Figure 1.1) each with an N-terrninal
immunoglobulin like variable (V) region and an immunoglobulin like constant (C) re-
gion.
The T-cell receptor defines, like the B-ceU receptor on the B cells, the antigen speci-
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ficities of T cells. The receptor is present in several copies with a single specificity
on each T-cell clone. The T-cell receptor, in contrast to the B-cell receptor, does not
recognise the antigen in solution but bound as a peptide in the major histocompatibility
complex (MHC) proteins (Figures 1.2 and 1.3). The MHC is a cell surface molecule
and consists of two main classes. MHC class I in general displays peptides derived from
cytoplasmic proteins including self-proteins and is present on most cells in the body.
Foreign peptides displayed this way can indicate that the host cell is infected or trans-
formed, and cytotoxic T cells detecting foreign peptides in complex with MHC class
I destroy the hosting cell. The oblong groove in this MHC is closed in both ends and
displays a peptide of 8-10 residues. The peptides are anchored to the MHC through C-
terminal hydrophobic or basic residues and other residues close to the N-terminus. The
peptides come from proteins degraded by proteasomes in the cytoplasm. The peptides
are transported into endoplasmic reticulum (ER) by TAP-l and TAP-2 (Transporter asso-
ciated with antigen processing) and associate with the MHC in the ER. In contrast, MHC
class II normally displays peptides of proteins obtained by phagocytosis and is predom-
inantly found on specialised antigen-presenting cells. The peptide in complex with a
MHC class II molecule comes from degraded endocytosed proteins and is loaded on the
MHC complex in the endosomal compartment. The MHC class II groove is open in both
ends and displays peptides of varying length (>12 residues, typically 13-30 residues).
The peptides are anchored to the MHC through residues in key positions through the
peptide sequence.
Large repertoires of naive T cells with different surface receptor specificities are ini-
tially produced. The diversities of their receptors are created by somatic rearrangements
of gene segments in a similar way to the B-cell receptor and each T-cell bears a single
receptor specificity. The T-cell receptor a chain is assembled from about 70 D segments
and 61 J segments and the {3 chain is assembled from 52 D segments, 2 D segments
and 13 J segments [Janeway et al., 1999]. The combinatorial diversity of both the a
and the {3 chain is therefore about 5.8.106 (~ 70x61 x 52x2xI3). Additional diversity
due to residues added between the gene segments has been suggested to give a possible
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Figure 1.2: Diagrams and cartoons based on the crystallographic structures of MHC
class I {Smith et al., 1996} and MHC class II {Murthy and Stern, 1997} molecules. The
peptide binding cleft in class MHC class I molecules isformed by the a chains in contrast
to MHC class II in which the cleft is formed by both the a and the j3 chain.
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Figure 1.3: T-cell receptor (red) in complex with a MHC class molecule (green). The
antigenjragment is shown in green. The T-cell receptor is turned 90 degrees compared
to Figure 1.1. Only the the extracellular domains are shown in the figure. The structure
shown here was solved by Garboczi et al. [l996].
diversity of 1018 [Janeway et al., 1999], which is much higher than the number ofT-cells
in the human body. The T-cells are first selected for binding to MHC and then those
specific for self-antigens are deleted. The selection takes place in thymus where den-
dritic cells, macrophages and epithelial cells play important roles in presenting peptides
of self-proteins to the T cells together with signals necessary for survival or programmed
cell death.
There are differences and similarities in antigen recognition by B cells and T cells.
The B-cell receptor recognises the three-dimensional structure of the antigen. The T-cell
receptor, by contrast, recognises a peptide fragment of the antigen in complex with the
MHC. But although the T-cell receptor recognises a short linear sequence of the antigen,
it is dependent on the structure of these residues in context of the MHC [Garboczi et aI.,
1996].
The recognition of antigen segments as T-cell or B-cell epitopes are apparently inde-
pendent. But some investigators have argued that there may be a correlation between the
distribution of B-cell and T-cell epitopes in the antigens. Watts and colleagues [Watts
and Lanzavecchia, 1993] analysed the ability of different tetanus toxin Ctt) specific B-cell
clones to activate a panel of tt-specific T-cell clones in vitro. Some of the T-cell clones
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were poorly stimulated by some of the B-cell clones, as detected through proliferation
of the T cells. Addition of soluble antibodies from the poorly stimulating B cells also
inhibited stimulation of the same T cells by other B-cell clones. This suggested that
the poor stimulation by some B-cells was not due to general low antigen presentation by
these cells and further that the antibodies specifically suppress the display of some T-cell
epitopes.
Similar studies were carried out by Guermonprez and colleagues [Guermonprez
et aI., 1999] with antibodies of known affinities. They added hen egg lysozyme (HEL)
pre-incubated with different monoclonal antibodies, to antigen presenting cells in the
presence of different T cell clones and T-cell activation was detected through IL-2 pro-
duction by the T-cells. The results from these in vitro experiments suggest that some
of the monoclonal antibodies suppressed the presentation of specific T-cell epitopes dis-
played on the surface. It was proposed that some segments of the antigen in the antigen-
antibody complex may be protected during intracellular processing of the antigen. Note
that the study described above was carried out with relatively high affinity antibodies;
low affinity antibodies in primary immune responses may not show such influence on
the distribution of T-cell epitopes.
1.2.3 The antibody molecule
Antibodies (Figure 1.4) are immunoglobulins (Igs). Edelman [1959] showed that the
antibody molecules can be separated into smaller fragments by reduction of disulphide
bonds. Two identical heavy chains and two identical light chains are linked together
with disulphide bonds. Titani et aI. [1965] and Hilschmann and Craig [1965] showed
through sequencing of peptides from proteolytically digested antibodies that the anti-
bodies consist of a variable domain with diversity in the amino acid sequence, and a
constant domain. Three complementarity determining regions (CDRs) in the variable
part of each heavy chain and three CDRs in the variable part of each light chain, com-
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prise most of the sequence diversity and form the majority of the antigen binding region
(Figure 1.5). The sequence diversity in the CDRs result from the gene rearrangements
and somatic hypermutation. CDR1 and CDR2 are encoded in the same V segments. In
contrast, CDR3 is encoded by the boundaries between the V and J segments in the light
chain and by the boundaries between the V-D segments and the D-J segments in the
heavy chain. The CDR3s do therefore contribute to most of the sequence variability in
the antibodies. CDR3 of the heavy chain, which also has much higher frequency of N
and P nucleotides in CDR3 light chain, contributes most to the sequence variation.
Studies of the DNA encoding the antibodies have shown that the somatic mutations
are normally found in a region of 2 kb comprising the V and J gene segments. In-
troduction of immunoglobulin transgenes with different modifications into B-cell lines
have shown that the transcription enhancer elements are important for recruitment of
hypermutation to this region [Neuberger et aI., 2000]. The molecular basis of the so-
matic mutations is not fully understood, but sequencing of immunoglobulin genes and
comparison with their germline counterparts have revealed several important features as
reviewed in Wagner and Neuberger [1996]. The somatic mutations are predominantly
found in the variable domains of the antibody and seldom seen in the constant regions
(see Figure 1.4). Both framework and CDR residues are mutated although the CDRs
tend have the highest mutation rate. Higher mutation rates have been detected in CDRI
compared to CDR2 and CDR3 [Neuberger and Milstein, 1995] in which the diversity is
mainly contributed respectively by the different germline V-gene segments and by so-
matic recombination. The residues that are frequently targets for mutations are termed
"hotspots" (in contrast to "cold spots" that are rarely targeted). Most of somatic muta-
tions are single nucleotide substitutions. The substitutions are not completely random
but show some preferences for certain nucleotide substitutions and also some codon pref-
erences.
The variable region of the antibody is joined to the constant region which defines
the biological functions of the immunoglobulin molecule. The antibodies can be di-
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Figure l.4: Diagram (left) and backbone structure (right) of the IgG molecule. The
molecule consists of two heavy chains (H, in blue) and two light chains (L, in red), linked
together with disulphide bonds as shown on the left with black lines. The variable regions
(VH + Vd include the CDRs which form the antigen binding sites. All Ig molecules
have the same overall shape although they have different number of disulphide bonds
and glycosylation patterns. IgM and IgE have four constant domains in the heavy chain
(Cn ) in contrast to three constant domains in the rest of the Ig classes. IgM can form
pentamers and IgA can form dimers in association with a protein known as the J (joining)
chain. The coordinates in the backbone structure are taken from Harris et al. [1998 J
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Figure 1.5: The upper image shows the main chain of the variable region of the im-
munoglobulin molecule seen from the side as in Figure 1.4. The CDRs are shown in
different colours. The lower image shows a surface representation of the same molecule,
rotated to show the antigen binding region comprised by the CDR regions. The molecule
shown here is from Fan etal. [1992].
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Table 1.1: Cytokines known to influence isotype switching in mice. [Janeway et al.,
J999J.
Cytokines IgM IgG3 IgG 1 IgG2b IgG2a IgE IgA
IL-4 Inhibits Inhibits Induces
IL-5
Inhibits Induces
Augments production
IFN-,
TGF-j3
Inhibits Induces Inhibits Induces Inhibits
Inhibits Inhibits Induces Induces
vided into five classes (isotypes); IgM, IgD, IgG, IgA and IgE depending on the type of
constant region. Each B cell has the potential of producing all classes of immunoglobu-
lin molecules. IgM and IgD are initially produced with transmembrane domains as the
B-cell receptor on the naive B cells. In contact with T-helper cells, activated B cells
undergo isotype switching, which involves deletion at the genomic level and is there-
fore irreversible. Interaction between the CD40 receptor molecule on the B cell with
the CD40 ligand on the T-cell is necessary for the isotype switching and the levels of
cytokines surrounding the B cell has an important impact on the choice of isotype as
summarised for some of the cytokines in Table 1.1. IgG is mainly found in extracellular
fluids. IgA and IgE are primarily secreted in the gut and close to epithelial surfaces re-
spectively. All isotypes can be produced as secreted molecules or with a transmembrane
domain linking them to the plasma membrane as cell receptors.
1.3 Proteins as antigens
Proteins are the most studied class of antigens. The detailed information we have on
the interaction between antibodies and proteins antigens comes from studies with mono-
clonal antibodies [Kohler and Milstein, 1975]. Through X-ray crystallography it has
been possible to visualise the interaction of antibodies and the antigens on the atomic
level.
The first crystallographic structure to be solved of an antibody-antigen complex was
the monoclonal antibody D 1.3 and hen egg lysozyme (HEL). The structure was solved
at 6 A resolution by Amit and his colleagues in 1985 and improved by the same people
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to 2.8 A resolution the year after [Amit et aI., 1986] (Figure 1.6). This showed that D1.3
binds two segments on the surface of HEL which are distant in the linear sequence. The
binding surface of the D1.3, which is about 20 by 30 A, is a relatively fiat surface with
small irregularities complementary to HEL. The binding energy between D 1.3 and HEL
is contributed by both van der Waals forces and hydrogen bonds. Two hydrogen bonds
are formed between the back bone atoms of the antibody and the backbone atoms of the
antigen and four and five hydrogen bonds are formed between the side chain atoms of the
antibody and respectively the side chain or backbone atoms of the antigen. 17 antibody
residues are in close contact with 16 antigen residues and at least one water molecule
is probably also buried in the interface. All six CDRs are in contact with the antigen,
although the residues in the CDRs of the heavy chain contribute to most of the inter-
actions with the antigen. This CDR, which contributes most to the sequence variation
in antibodies, also forms the physical centre in the interface between D 1.3 and HEL.
A single residue in the V-region framework of the antibody also contacts the antigen.
The interface residues on D 1.3 and HEL show no greater movement than 0.6 A in the
complex compared to the free proteins [Mariuzza et aI., 1987]. This suggests that the
binding is essentially between rigid bodies and that there are only small conformational
changes.
Other antibody-antigen structures have been studied and although there are a lim-
ited number of solved structures, they have revealed several features which seem to be
general to most antibody-antigen interactions [Braden and Poljak, 1995, La Conte et aI.,
1999]. Antibodies bind protein antigens over large sterically and electrostatically com-
plementary surfaces, stabilised by van der Waals forces, hydrogen bonds and in some
cases ion pairs. Most of the binding specificity is determined by the CDRs on both
heavy and light chain. The CDRs on the heavy chain often dominate in the interaction
and of these CDR3 often contributes to most of the binding energy. There are in most
cases only small conformational changes in the interface of the antigen and antibody as
a consequence of the binding interaction.
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Figure 1.6: The antigen HEL (green) in complex with antibody Dl.3 (blue). The complex
was solved with the antibody as a Fab fragment (Vf[, VL, Cf[ 1 and CL, see Figure 1.4)
and only the variable domain is shown in this figure. The left image represents the
backbone structure plus the side chains in the interface. The right image shows an atom
representation of the complex. The coordinates are taken from Fischmann et al. [J 991}.
CHAPTER1. INTRODUCTION 19
The average footprint of an antibody is about 850 A 2 (see Table 1 Lo Conte et aI.
[1999]) and with 15 to 21 residues in contact on the antibody and roughly the same
number or residues on the antigen. Binding studies with site directed mutagenesis fur-
ther suggest that a small number of the interface amino acids contribute to most of the
binding energy [Novotny et aI., 1989, Smith and Benjamin, 1991a]. These observations
are mainly based on antibodies from secondary responses (after somatic hypermutation).
Structures of anti-peptide and anti-hapten antibodies have also been solved. An anal-
ysis by MacCallum et aI. [1996] and his colleagues of the binding interfaces on sev-
eral such antibodies suggests that smaller molecules (haptens and peptides) tend to bind
residues that are central in the CDR interface of the antibodies. In contrast, proteins nor-
mally make contact with a wider set of residues, as expected from the larger interfaces
they provide. MacCallum and his colleagues further showed by grouping the antibodies
according to their antigens, proteins or peptides, that the binding site of anti-peptide
antibodies tend form a central groove compared to the relatively flat binding sites in
anti-protein antibodies.
1.3.1 Three groups of anti-protein antibodies
Antibodies found in serum can be divided into three groups (Figure 1.7). The first group
only binds to antigen in denatured form and the second group only binds the antigen in
native form (respectively groups A and C of Figure 1.7). In this thesis I will refer to these
groups as denatured-specific and native-specific antibodies. A third group of antibodies
(group B of Figure 1.7) are able to bind both native and denatured forms of the antigen.
I will refer to this group as cross-reactive antibodies. These antibodies probably bind
different segments of the polypeptide chain that are brought together on the surface of
the folded protein, but are also able to bind the separate segments with detectable affinity.
Lando and his colleagues demonstrated the existence of these three groups of anti-
bodies in sera. They immunised rabbit, sheep and goat with sperm whale myoglobin
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(Mb). Antibodies from the animal sera were affinity purified on cyanogen bromide
(CNBr) cleaved polypeptide fragments of Mb [Lando and Reichlin, 1982a] which are
assumed to be linear forms of the antigen. Binding assays with the eluted antibodies
were then carried out in solution where labelled antigen or antigen fragments were
added to the solution followed by addition of secondary antibodies to precipitate the
antibody-antigen complexes. The results showed that 104_106 more intact Mb protein
than CNBr fragments of the protein (by weight) was needed to compete with labelled
CNBr fragments of the protein for binding to the antibodies. The huge excess of protein
needed for competition shows that a fraction of the affinity purified antibodies had much
higher affinity for the linear form than for the folded protein. These antibodies represent
denatured-specific antibodies.
A fraction of the antibodies that were affinity purified on the CNBr peptides were
also shown to bind labelled native Mb in solution [Lando et aI., 1982b]. These antibodies
were cross-reactive antibodies (group B) as they bound both denatured and native pro-
tein. The antibodies that were affinity purified on the CNBr peptides therefore comprised
both cross-reactive and denatured-specific antibodies. Lando and his colleagues also
found that sera that had been depleted of all antibodies that bound the CNBr fragments
contained antibodies that bound native Mb. These native-specific antibodies (group C)
counted for 30-40% of the total amount of Mb specific antibodies.
The amount of antibodies detected in the three groups depends on the methods used
to analyse the sera as the determination of which antibodies bind to native and denatured
forms of an antigen depends on the sensitivity of the methods. Different methods usually
operate with different affinity thresholds and can be expected to detect varying amounts
of antibodies in the three antibody groups.
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Figure 1.7: The three groups of anti-protein antibodies in sera. Group A binds only
denatured protein and group C binds only native protein. Antibodies from group B bind
both native protein and denatured protein. Group A, Band C are here described as
denatured-specific, cross-reactive and native-specific antibodies respectively.
1.3.2 Conformational and linear epitopes
The region of the protein bound by an antibody is described as an epitope, antibody de-
terminant or antibody combining site [Jerne, 1960]. Jerne defined epitopes as elements
of the native protein which can be bound by antibodies. Elements that only are available
for binding when the protein is denatured were defined as cryptotopes.
More commonly used classifications are topographic (conformational or discontinu-
ous) and sequential (linear) epitopes. An antigen surface that is bound by an antibody
and comprises segments which are distant in the linear antigen sequence is defined as
a topographic or conformational [Sela, 1969a, Sela et aI., 1969b] epitope. The contact
residues on the antigen are brought together on the antigen surface by the folding of the
protein. Whether the antibody is native-specific or cross-reactive depends on the seg-
ments ability to bind the antibody individually or together. By contrast, in sequential
epitopes the binding to the antibodies is only dependent on the sequence and not on the
higher ordered structures in the protein [Sela, 1969a, Sela et aI., 1969b]. The existence of
conformational epitopes have been confirmed in several crystal structures of antibodies
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in complex with antigens, e.g. hen egg lysozyme [Amit et aI., 1986]. Some linear epi-
topes in combination with antibodies have been visualised by X-ray crystallography, e.g.
residues 36-46 from HIV-l protease [Lescar et aI., 1997].
It has been argued that most epitopes are conformational. Barlow et al. [1986] pro-
posed that segments of the protein detected as linear epitopes in binding assays, are
elements of conformational epitopes. They analysed the surface of hen egg lysozyme
(HEL) assuming that the surface areas of the epitopes are similar to the epitope seen in
the structure of a HEL-antibody complex solved by X-ray crystallography. Their analy-
sis was carried out by modelling a simulated antibody probe on the antigen surface and
examining the antigen sequence included in the interface. Taking each atom on the anti-
gen surface in tum they checked the fraction of neighbouring residues that are within
10 A radius. This showed that the footprint of an antibody of this size on the antigen
surface most likely include antigen residues that are more than 10 residues away in the
linear sequence.
1.3.3 Immunogenicity and antigenicity.
Immunogenicity is the potential of a substance (antigen) to evoke an immune response
leading to humoral or cellular products that specifically recognise the substance. Anti-
genicity is the ability to be recognised by the antibody produced in a humoral immune
response. Thus a free hapten is not immunogenic, whereas presented as a haptenated
protein is both immunogenic and antigenic.
1.3.4 Distribution of epitopes on the antigen surface
Antigens can originate from transplanted tissue, infectious organisms, allergens or self-
proteins in autoimmune diseases. Proteins are the most diverse group of antigens the
immune system encounters and the possible surface structures on proteins are almost
unlimited. The distribution of epitopes on the antigen surface can be examined in two
steps. First, what parts of an antigen are antigenic? Second, what is the relative dis-
CHAPTER 1. INTRODUCTION 23
tribution of antibodies to the different antigenic regions of a protein? Much data has
been produced by investigators to answer the first question, but very little regarding the
second question.
Which parts of an antigen are antigenic?
The investigation of antigenicity of different parts of antigens has been a long process
with several pitfalls, mainly due to the methods used. The first model antigen with
known crystallographic structure was sperm whale myoglobin [Crumpton and Wilkin-
son, 1965]. Crumpton and Wilkinson showed some of the proteolytic fragments of Mb
could partly inhibit the precipitation of Mb by antiserum, which indicated that these re-
gions were antigenic.
Atassi and his colleagues later claimed to have solved the precise and entire anti-
genic structure of sperm whale myoglobin [Atassi, 1975] and HEL [Atassi and Lee,
1978]. They described five peptides of six to eight amino acids and three peptides of
five to six amino acids that accounted for the complete antigenic anatomy of Mb and
HEL respectively. They reported that all IgG specific for Mb and HEL in sera of ani-
mals immunised with these proteins can be absorbed by these peptides. However, later
results from other laboratories are inconsistent with these claims. For example Lando
and his colleagues [Lando et al., 1982b] found, as described earlier, that 30-40% of anti-
myoglobin antibodies do not bind any of the three major cyanogen bromide fragments
of Mb that together account for the entire protein sequence. Others have also showed
that several monoclonal antibodies to Mb do not bind any of these fragments [Berzofsky
et al., 1982].
Benjamin and colleagues [Benjamin et al., 1984] evaluated data collected through
several studies of antibody responses to the model antigens myoglobin, lysozyme, cy-
tochrome c and serum albumin. The methodologies differed. For example the epitopes
on myoglobin were identified by mapping studies of serum antibodies with peptides and
of monoclonal antibodies by homologues of Mb (method described later), whereas the
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epitopes for serum albumin were identified by competition assays with monoclonal anti-
bodies and the mapping of serum antibodies with fragments of serum albumin. Taken
together the collection of epitope data suggests a more complex picture of antigenic sur-
faces than earlier described. Benjamin and his colleagues concluded; "The surface of a
protein antigen consists of a complex array of overlapping potential antigenic determi-
nants; in aggregate these approach a continuum. Most determinants depend upon the
conformational integrity of the native molecule". This has gained a general acceptance
in the later literature.
The relative distribution of antibodies on the protein surface
Benjamin and his colleagues demonstrate in their reappraisal [Benjamin et al., 1984]
that most if not all the parts of an antigen surface will be recognised by antibodies if a
sufficiently large number of humoral immune responses are considered. Although they
mention that some parts of the antigens seem to attract more antibodies than others they
did not evaluate the relative distribution of antigenicity over the antigen surfaces. A large
body of earlier literature on B-cell epitopes describe the presence of dominant epitopes
(e.g. [Morgan et al., 1992] or [Worobec et al., 1985]). Dominant epitopes have also
been linked to the intrinsic features of the antigens. Westhof and colleagues [Westhof
et al., 1984] showed that there is a positive correlation between the identified dominant
epitopes in tobacco mosaic virus protein, myoglobin and lysozyme with the backbone
mobility of the proteins. However, the presence of dominant epitopes seems surprising
from an evolutionary point of view as the failure to recognise any part of the antigen
represents a loophole for pathogens. It would therefore be expected that the constant
battle against rapidly evolving pathogens should direct the immune system to respond
efficiently and therefore equally well to all protein surfaces.
Although the presence of dominant epitopes is mentioned multiple times in the lit-
erature, the data supporting existence of dominant epitopes on native protein are weak.
Thus although the studies of monoclonal antibodies in complex with antigens have al-
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lowed us to see epitopes in molecular detail, they do not provide information about the
relative surface distribution of the antibodies. Serum antibodies include all this infor-
mation. But the composition of antigen specific antibodies in serum is very complex.
This makes it difficult to analyse their epitope distribution. One means has been the use
of synthetic peptides to analyse the binding characteristic of antibodies. But although
peptides may simplify the problem of epitope mapping they will be ignored by native-
specific antibodies.
Assays aimed at mapping both native-specific and cross-reactive antibodies do there-
fore require native protein. Protein homologues have been used in such assays [Urbanski
and Margoliash, 1977, Jemmerson and Margoliash, 1979] as they have small variation
surface residues. Differential binding of serum antibodies to different homologues may
allow identification of some of the conformational epitopes. The model proteins used
in these studies were typically proteins with highly conserved sequence from different
species such as mitochondrial cytochrome c and bird egg lysozymes.
Again this method has severe limitations, as there are a limited number of native
homologues. Weber and his colleagues [Weber et al., 1992] used a method they called
Homologous Scanning Mutagenesis to create more variants as illustrated with human
growth hormone (hGH). Short segments of hGH were replaced with the corresponding
segments of homologues and the new chimaeric proteins were then analysed for the abil-
ity to bind serum antibodies raised against the wild type hGH in mice. The results sug-
gested that five of the 19 substituted regions dominated the antibody response in mice.
But the method has its own limitations. For example variants of chimaeric protein with
different mutations in the same segment showed very different binding activity to serum
antibodies. The mutant hGH with segment 54-74 transplanted from human prolactin
showed significant reduction in binding for only one of five sera whereas the mutant
hGH with segment 57-73 transplanted from porcine growth hormone showed significant
reduction in binding for all five sera. This suggests that the differential binding of serum
antibodies to the wild type and the mutants was dependent on the specific sequence and
CHAPTER 1. INTRODUCTION 26
not only on the surface location of the substitutions.
There was, to my knowledge, no method that can be used to systematically identify
the relative distribution of epitopes of serum antibodies on the three-dimensional protein
surfaces. This was the motivation behind the epitope mapping assay developed during
this work.
{3-Lactamase as model antigen
The use of antigens with homologues in the immunised species would be expected to
complicate the relationship between epitope distribution and intrinsic properties of the
antigen as the distribution could be strongly influenced by regulation mechanisms of the
antibody response to the host antigen [Jemmerson and Margoliash, 1979] as discussed
later in more detail. A bacterial protein, {3-lactamase, with no expected homologues in
the immunised species was therefore chosen as a model antigen.
{3-Lactamase (Figure 1.8) provides bacteria with resistance to {3-lactam antibiotics
such as penicillin and ampicillin. The gene encoding the protein was originally found
in the transposable element Tn3 [Heffron et al., 1979]. The protein is a monomer and
consists of both {3-sheets and a-helixes and has a molecular weight of 30,000 Da. It
has two cysteines which form an internal disulphide bond. The surface area is 11,200
A2 which corresponds to roughly the sum of the binding areas of 13 mutually exclusive
antibodies, assuming an binding interface of 850 A2 (as described earlier). The struc-
ture of the protein is known and it is well expressed in bacteria. {3-Lactamase has an
enzyme activity which can be detected with chromogenic substrates. This should allow
verification of the presence of native protein as the enzyme activity requires the native
conformation of the protein.
Different strategies for mapping the epitopes of native-specific and cross-reactive
antibodies were considered. The chosen strategy was to make a variety of cysteine mu-
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Figure 1.8: The left image shows the secondary structure of {3-lactamase. The protein
is a monomer with a molecular weight of 30,000 Da. The right image shows a surface
representation of the protein. The surface is defined by the centre of a spherical probe,
with a radius 1.4 A, rolled over the protein atoms. The surface area is 11 200 JP. The
structure shown here was solved by lelsch et al. [1993].
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tations in the surface of ,B-lactamase and to couple these to a solid surface through a
bifunctional chemical cross-linker. The orientation of the antigen on the solid surface,
defined by the cysteine position, would be expected to mask specific regions of the sur-
face from binding to antibodies.
Chapter 2
Mapping monoclonal antibodies
2.1 Introduction
The key to map the topological epitopes was to mask the different surface regions of the
antigen by coupling to a solid surface as shown in Figure 2.1. A cysteine introduced
on the antigen surface by mutagenesis was chemically attached to a biotin-linker (biotin
molecule with a linker) which in tum was captured by streptavidin on a solid surface.
The biotin-linker together with the streptavidin molecule masks the surrounding antigen
surface. This was expected to completely exclude binding of antibodies in the proximity
of the cysteine.
The antigenicity of the whole antigen surface can be analysed by systematically plac-
ing the cysteine residue, the tethering point, in different surface locations and thereby
creating an array of the antigen in different orientations. The distribution of cysteine
residues should be chosen so that any antibody would be excluded from binding by at
least one cysteine position. The areas of the surface that were masked from antibody
binding by the biotinylation and capture on the solid surface, will here be referred to as
"cysteine target regions" (CTRs). Monoclonal antibodies were first used to evaluate the
method as they offer more defined conditions than sera.
29
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Figure 2.1: Mapping of monoclonal antibodies on the antigen surface. Different regions
(only three in this example) of the antigen surface are blocked by a biotin-linker which
is tethering the antigen to streptavidin coated ELISA plate wells through a cysteine on
the antigen surface (see text). Tethering though the binding region (red) does not allow
binding of the antibody. In contrast, presentation of the antigen in different orientations
allows binding of the same antibody.
2.2 Results
2.2.1 Cysteine mutations and biotinylation of j3-lactamase
The surface of the model antigen ,B-Iactamase was systematically divided into 23 evenly
distributed regions (see Figure 2.2). (The total antigen surface of 11,200 A 2 corresponds
to about 13 non-overlapping antibody-antigen interfaces of 850 A 2.) A free cysteine was
placed in the middle of each region by mutagenesis. The positions for the cysteine mu-
tations were chosen by eye using the computer software GRASP [Nicholls et al., 1991]
to visualise the three-dimensional protein surface. Mutations were made among surface
residues such that the sulphydryl groups would be expected to be surface accessible.
The distance between neighbouring cysteine positions was about 20 A. One mutant with
a single surface cysteine was then prepared for each of the chosen cysteine positions.
The mutants were K34C, N52C, K55C, E63C, Q90C, NlOOC, ElIDC, T1I4C, T140C,
K146C, N154C, N175C, E197C, L201C, A202C, K215C, A227C,E24DC, D254C, Q269C,
T271 C, E281 C, K288C and 3D8C (with a cysteine added on the C-terminus after the pep-
tide affinity tags). The use of the C-terminal cysteine mutant 308C is described in the
next chapter. All mutants were expressed in E. coli although at different levels (see Table
2.1). The panel of cysteine mutants was biotinylated with a sulphydryl specific biotin-
linker (see Figure 2.3) which had a 29 A spacer arm that linked the biotin molecule to the
CHAPTER 2. MAPPfNG MONOCLONAL ANTfBODIES 31
Figure 2.2: The epitope mapping regions defined by the 23 cysteine mutations. The 23
surface residues mutated into cysteines are in green. The black lines illustrates how the
antigen surface is divided into different regions.
protein through a disulphide bond. An important condition for the current mapping assay
to work was specific biotinylation on the cysteines. Mass spectrography results indicate
that only one biotin-linker was attached to each protein molecule (representative data are
shown in Figure 2.4) as expected for the thiol-specific biotinylation. The mutants had
the expected additional mass of about 450 Da for the addition of the biotin-linker and no
evidence of further additions of biotin.
2.2.2 State of the ,B-lactamase mutants
The state of the fJ-lactamase mutants were analysed to ensure that ali the mutants in-
eluded native protein. The presence of denatured protein among the mutants was also
analysed. The importance of this population will become more apparent during mapping
of serum antibodies in the next chapter.
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Table 2.1: The table shows an overview of the {3-lactamase mutants used in the epitope
mapping assay. The mutants were expressed in the periplasm of E. coli. The relative
enzyme activities were measured when the mutants were biotinylated and immobilised
on a streptavidin coated ELISA plate. The enzyme activity of 308e is set to 1.0. The
enzyme activities of the wild type {3-lactamase and 308e, representing the wild type with
an added Caerminal cysteine, were compared in solution. kcatfor wild type {3-lactamase
with Nitrocefin in PBS pH 7.4 at 22°e was 164 S-l and Km was 4.58.10-5 M. The
denatured specific-monoclonal antibody P64.1 was used to detect traces of denatured
protein among the biotinylated mutants (see figure 2.5).
Mutant
Wild type
K34C
N52C
K55C
E63C
Q90C
N100C
EI10C
Tl14C
Tl40C
K146C
N154C
N175C
E197C
L201C
A202C
K215C
A227C
E240C
D254C
Q269C
T271C
E281C
K288C
308C
Expression Relative Binding to
per litre activity monoclonal
of culture antibody
[mg] P64.1
12.35 1.034*
1.16 1.034 +
2.57 0.926
1.57 0.997 +
3.57 0.946
1.79 0.550
2.18 0.980
1.47 1.031 Poorly
4.42 1.119
8.47 0.981
3.27 1.002 +
7.81 0.971
0.27 0.869 +
3.96 0.990
13.75 1.007
8.50 0.995
8.19 1.023 +
16.38 1.151
7.00 0.758
12.53 1.003
5.48 1.065
2.93 0.698
10.69 0.610
2.21 0.864
10.94 1.000
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Figure 2.3: The biotin-linker HPDP used in the epitope mapping assay. The linker
has a pyridyl-disulphide group (left) coupled through a spacer arm (29 A) to a biotin
molecule. The pyridylleaving-group will exchange with the thiol group on the surface
of the protein. The result is a biotin molecule with attached through the linker to the
protein by a disulphide bond. The molecular weight of the HPDP is 539.8 Da.
Analysed through enzyme activity
Enzyme activity can be used to detect native ,B-Iactamase as it requires the native con-
formation of the protein. The relative enzyme activities of the 23 ,B-Iactamase mutants
linked to streptavidin plates are shown in Figure 2.5a. All the mutants had enzyme activ-
ity although some variation was observed. This shows that there was some native protein
immobilised on the plates, and that the amounts of native protein were similar between
the different mutants.
Analysed with monoclonal antibodies
Small amounts of denatured ,B-lactamase were expected to be difficult to detect through
changes in enzyme activity and a denatured-specific monoclonal (P64.1) was therefore
used as a probe. The 23 cysteine mutants were biotinylated and immobilised on a strep-
tavidin coated ELISA plate. Binding of the monoclonal antibody was detected with la-
belled anti-mouse antibodies (Figure 2.5b). The signals detected indicated the presence
of some denatured protein for 5 of the 23 mutants. The two ,B-lactamase mutants, K34C
and N175C, that most efficiently bound P64.1 were poorly expressed in E. coli (Table
2.1). ,B-Lactamase mutant 308C was not recognised by the same monoclonal antibody
(data not shown).
The enzyme activity kcatlKm for wild type ,B-Iactamase type in solution with Ni-
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Figure 2.4: Mass spectrography results for the biotinylated {3-1actamase mutants. Ex-
pected mass for the wild type (with tags) is 30948.99 Da. The data recorded for the
mutants suggest homogeneous populations of protein with only one biotin-linker per
protein molecule.
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Mutants on streptavidin plate
Figure 2.5: State of {3-lactamase mutants. a)Biotinylated {3-lactamase mutants were
immobilised in ELISA wells coated with streptavidin. The relative enzyme activities of {3-
lactamase mutants were measured with the chromogenic substrate Nitrocefin. 308C has
an enzyme activity very close to L201 C and A202C (separate experiment). A denatured-
specific monoclonal antibody (P64.1) was used to evaluate if any of the {3-lactamase
mutants containedfractions of denatured protein. The biotinylated {3-lactamase mutants
were immobilised on streptavidin coated ELISA plates. The background is 0.02.
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trocefin (in PBS pH 7.4 at 22°C) was 3.58.106 M-1s-1 where Km was 4.58.10-5 M.
The kcat of the biotinylated 308C under the same conditions was 159 S-l compared to
164 S-l for the wild type. (Osuna et al. [1995] reported a ratio kcatlKm of 4.23.58.106
M-1s-1 for the wild type ,B-Iactamase.)
2.2.3 Production of monoclonal antibodies
Monoclonal antibodies were produced against wild type ,B-Iactamase. This work was
done under close supervision and with help from Tone Varaas at the Central Laboratory,
The Norwegian Radium Hospital, Oslo. The monoclonal antibodies were made with
spleen cells from one mouse that had been immunised with ,B-Iactamase. The mouse
was initially injected twice subcutaneously with ,B-Iactamase in Freund's complete ad-
juvant (FCA) followed by a subcutaneous injection with ,B-Iactamase in Freund's in-
complete adjuvant (PIA), all with three weeks intervals. The mouse was then injected
intravenously each of the four days prior to the cell fusion with ,B-Iactamase in PBS.
The media from the small cultures of fused cells were assayed for antibodies that bound
native or denatured ,B-Iactamase. The native antigen was displayed as biotinylated 308C
captured on streptavidin coated plates. The denatured antigen was ,B-Iactamase coated
directly on onto ELISA plates that were subsequently dried. The absence of native pro-
tein on these plates was verified by adding the chromogenic substrate Nitrocefin. The
presence of protein was verified with anti-serum. The screening of media from 960 cul-
tures gave about 450 cultures that tested positive on native protein and 70 cultures that
tested positive on denatured antigen. Some of these media aliquots did also give signal
on both native and denatured antigen. Cells from 72 cultures were sub-cloned. 11 of
the sub-cloned cells were then grown in larger cultures (Table 2.2). This included two
native-specific, seven cross-reactive and two denatured-specific antibodies. IgGs from
five of these cultures were purified on protein G. The yields ranged from 5-10 mg for
200 ml cultures.
The monoclonal antibodies' abilities to immobilise ,B-Iactamase from solution were
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Table 2.2: Monoclonal antibodies displayed on ELISA plates were used to immobilise
j3-lactamase added in solution. The enzyme activity of j3-lactamase was used to detect
bound protein. None of the monoclonal antibodies block the enzyme activity (data not
shown). *The monoclonal antibodies were also assayed for their ability to bind biotiny-
lated j3-lactamase captured on streptavidin coated ELISA plates (data not shown). The
denaturation was done by reducing an internal disulphide bond and carboxymethylate
the two cysteines.
Detected Binds native
j3-lactamase j3-lactamase*
[mOD/min]
Binds denatured
j3-lactamase*
P50.2
P51.1
P58.3
P59.1
P64.1
P65.2
P66.1
P67.2
P68.1
P69.1
P70.1
Background
0.66 +
15.84 +
2.56 +
9.84 +
0.36
0.36
0.67 +
0.40 +
0.36 Poorly
27.78 +
16.25 +
0.29
+
Poorly
+
+
+
+
+
+
+
+
also examined. The monoclonal antibodies were captured on ELISA plates coated with
anti-mouse antibodies. j3-Lactamase was then added in solution and allowed to bind to
the monoclonal antibodies. The bound j3-lactamase was detected with the chromogenic
substrate Nitrocefin. The results are shown in Table 2.2. There were large differences
in the antibodies ability to bind j3-lactamase from solution. This probably reflected the
relative affinity of the antibodies for the antigen.
2.2.4 Mapping of monoclonal antibodies
The nine subcloned monoclonal antibodies that bound the native protein were mapped
with the method described in the introduction of this chapter. In an enzyme-linked im-
munosorbent assay (ELISA) the monoclonal antibodies were analysed for their ability
to bind the 23 biotinylated mutants immobilised on streptavidin coated ELISA plates.
Bound monoclonal antibodies were detected with secondary antibodies conjugated to
an enzyme (horseradish peroxidase). The results are shown in Figures 2.6, 2.7 and 2.8.
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Most of the monoclonal antibodies were excluded by more than one of the cysteine target
regions (CTRs). This supports the idea that the panel of mutants was suitable for detect-
ing binding regions of serum antibodies specific for any parts of the antigen surface. The
biotin-linker's ability to exclude binding seems to depend on the antibody affinity for the
antigen. Monoclonal antibodies which poorly immobilised ,B-Iactamase from solution
(e.g. P68.1, see Table 2.2) were partly excluded by biotin attachment points over larger
parts of the surface. The most precise determination of binding site was achieved for
the antibodies that efficiently immobilised ,B-Iactamase from solution as seen with P69.1
and P70.1.
The binding regions of the monoclonal antibodies are shown on the three-dimensional
surface in Figures 2.9 and 2.10. The CTRs with most dramatic decrease in binding of
each monoclonal antibody cluster together on the antigen surface and are presumably in-
cluded within the antibodies' footprints. Other CTRs with intermediate signals are close
on the antigen surface.
2.3 Discussion
Mapping topographic epitopes requires folded protein. All the mutants had enzyme
activity and were recognised by one or both the native-specific antibodies P51.1 and
P59.1. This shows that all the mutants contained folded protein. Furthermore most
of the mutants contained no denatured protein as shown by a denatured-specific anti-
body. Five of the mutants did contain some denatured protein that was recognised by
the denatured-specific antibody. But these five mutants had similar enzyme activities to
the rest of the mutants (and as indicated above all bound equally well to at least one of
the native-specific antibodies). This suggests that the fraction of denatured protein in the
five mutants must be small. The uniform levels of folded protein for each mutant allow
direct comparison of the mutants binding monoclonal antibodies.
The resolution of the epitope mapping is dictated by the size of the excluded antigen
CHAPTER 2. MAPPING MONOCLONAL ANTIBODIES 39
P50.2
0.8
Ec
0
Lt)
<0 0.6Ec
0
Lt)
'<t
0 0.4Q.
'iiic
Cl
i:7.i 0.2
0
0.7P51.1
0.6
E 0.5c:
0
Lt)
<0
E 0.4
c:
0
Lt)
'<t
0 0.3
Q.
'iii 0.2c:
Cl
i:7.i
0.1
0
P58.3 0.6
0.5
Ec
0 0.4Lt)
<0
Ec
0 0.3Lt)
'<t
0
Q. 0.2'iii
c:
Cl
i:7.i
0.1
0 AZAmozm~mAzzmr>A>moo~mA~~rn~mm~~~~~~~~~N~~~NNNNN~~N~WOO~~~~~~<OOo~N~~m~~~~OOOOOoo~om~~~~N~~O~<oO~~~o000000000000000 OO~
Mutants
Figure 2.6: Monoclonal antibodies PSO.2, PSI.I and PS8.3 were assayedfor their ability
to bind the 23 different {3-lactamase mutants. The biotinylated mutants were captured
on streptavidin coated ELISA plates. The cysteine mutations with low signal map close
together on the surface for each monoclonal antibody.
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Figure 2.7: Monoclonal antibodies P59.1, P66.1 and P67.2 were assayedfor their ability
to bind the 23 different fJ-lactamase mutants. The biotinylated mutants were captured
on streptavidin coated ELISA plates. The cysteine mutations with low signal map close
together on the surface for each monoclonal antibody.
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Figure 2.8: Monoclonal antibodies P68.1, P69.1 and P70.1 were assayed for their ability
to bind the 23 different J3-lactamase mutants. The biotinylated mutants were captured
on streptavidin coated ELISA plates. The cysteine mutations with low signal map close
together on the surface for each monoclonal antibody.
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PSO.2 PS1.l
Figure 2.9: The footprints of monoclonal antibodies PSO.2, P'il.I, PS83, PS9.i, PS9.i,
P6i.i and P67.i on the surface of fJ-lactamase. Each monoclonal were assayed for
binding to the biotinylated fJ-lactamase mutants which were immobilised on streptavidin
plates. The CTRs that inhibited binding by 9S% or 8S% of maximal signal (see Figures
2.6 and 2.7) are shown in red and orange respectively. All these CTRs are visible in the
figure. The other CTRs are shown in blue.
PS8.3
P61.1
PS9.1
p67.1
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Figure 2.10: The footprints of monoclonal antibodies P68.2, P69.} and P70.} on the
surface of {J-lactamase. Each monoclonal were assayed for binding to the biotinylated
{J-lactamase mutants which were immobilised on streptavidin plates. The CTRs that
inhibited binding by 95% or 85% of maximal signal (see Figure 2.8) are shown in red
and orange respectively. All these CTRs are visible in the figure. The other CTRs are
shown in blue.
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Figure 2.11: A rough estimate of the area in which the antibodies can be expected to
bind as indicated by the ellipses (see text).
surface and the distribution of biotin-linker attachment points (CTRs). As indicated in
chapter 1 the surface area of ,6-lactamase corresponds to roughly the sum of the bind-
ing areas of 13 mutually exclusive antibodies, assuming an binding interface of 850 A2
(see chapter 1). Indeed, most of the monoclonal antibodies were excluded from bind-
ing to the antigen surface by several CTRs. However the footprint of each monoclonal
antibody is best defined by the locations of the CTRs that do not exclude the antibody.
(Clearly the surface cysteine of a CTR that excludes a monoclonal antibody may itself
lie outside the footprint). This sets an outer perimeter to the footprint. By illustration
(Figure 2.1l) these CTRs fall in an ellipse with surface area of llOO A 2 for P50.2 and
1300 A2 for P68.2. As expected this is somewhat greater than the typical footprint of
an antibody. (Here the excluding CTRs have been defined as those giving> 85% re-
duction in signal.) The resolution of the method therefore appears capable of defining
the epitope within a surface area that is about 50% larger than a typical antibody foot-
print. The resolution of the method could presumably be improved by using more CTRs.
Chapter 3
Development of epitope mapping
method for serum antibodies
3.1 Introduction
The method presented in chapter 2 applies to monoclonal antibodies. The challenge was
here to map the epitope distribution of serum antibodies. The principles of the solution
are illustrated in Figure 3.1. The method is based on exclusion of antibodies from prede-
fined surface regions as shown for monoclonal antibodies (chapter 2) but was modified to
subtract serum antibodies to all surface regions except the biotinylated regions (CTRs).
The remaining antibodies to the chosen CTRs could then be quantified.
The same panel of 23 cysteine mutants was used for the mapping of serum antibodies
as for the monoclonal antibodies. The biotinylated mutants were in this case captured on
streptavidin coated magnetic beads. Beads with the different mutants were then mixed
with separate aliquots of the sera. The serum antibodies that bound the antigen were
then pulled out of solution together with the beads. Multiple cycles of depletion were
necessary, as described in methods on page 132. The antibodies remaining after 10 cy-
cles of depletion and specific for the masked CTR, were then detected using unmasked
antigen. ,B-Lactamase 308C was in general used as unmasked antigen. The aliquots were
also tested with the same masked antigen as used for depletion. In the event of complete
45
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Figure 3.1: The principles in the method used to map the relative distribution of serum anti-
bodies on the protein surface. a) The binding regions (only three in this example) are coloured in
red, blue and yellow and the corresponding antibodies in the same colours. The grey antibodies
are not specific for this antigen. The goal is to detect antibodies to each of the regions separately.
b) The antigen is biotinylated on a cysteine mutated into the region of interest as shown here
with the red region. The biotinylated protein is captured on magnetic streptavidin beads which
are then mixed with serum. All the antigen specific serum antibodies can bind the antigen sur-
face, except the antibodies that are specificfor the region masked by the biotin-linker. c) The red
antibodies are the only antibodies specific for native protein left in the solution after pulling out
the beads. d) The amount of antibodies specific for the red region is detected on a solid phase.
Antigen which is biotinylated on the surface, at a point far away from the region of interest, are
captured on streptavidin coated ELISA plates. This leaves the region of interest exposed to bind-
ing of the red antibodies. Secondary antibodies conjugated to an enzyme are used to determine
the amount of red antibodies. e) Control: Depleted serum from (c) is tested for ability to bind
antigen when the red region is masked by the biotin-linker.
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depletion no antibodies were expected to bind in this control. The method described
here should allow detection of all antibodies that bind to the native protein and should
not detect any denatured-specific antibodies (group A).
In contrast to mapping of the monoclonal antibodies as presented in chapter 2 where
the epitopes were indicated by reduction in signal, the epitopes in the mapping method
presented here are indicated as an increase in signal.
3.2 Results
3.2.1 Mapping of serum antibodies
Earlier results (see chapter 2) had shown that each biotinylated mutant protein was im-
mobilised in similar amounts on the plates. This was also verified by using completed
serum (Figure 3.2a).
The epitope patterns in sera from several animals were determined with the map-
ping method described above and are presented in subsequent chapters together with
the immunisation regimes. An example of an epitope pattern with serum from rabbit
I is in shown in Figure 3.2b. The values labelled "Exposed" show the binding of anti-
bodies when each CTR was exposed or unmasked and therefore represent the amount of
antibodies specific for each CTR. The signals "Masked" were the signals for antibody
binding when the same positions were masked in the detection step. The difference in
signal between "Exposed" and "Masked" represents the CTR specific antibodies. The
signals show relative high variation on the CTRs compared to the complete serum (Fig-
ure 3.2a) and a peak is seen in for the CTRs Q90, NIOO, EIlO and TII4.
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Figure 3.2: Image a) shows binding of serum antibodies (undepleted serum) to the bi-
otinylated mutants. Image b) shows the mapped distribution of antibodies on the antigen
surface for rabbit 1. The amount of antibodies detected to each region is displayed in
black bars. The grey bars show the amount of antibodies to the remaining surface that
were not successfully subtracted from the serum. The serum concentration in the map-
ping assay was 1:10,000.
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3.2.2 Detection of region specific antibodies by enzyme activity
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The main goal with the mapping method was to identify the epitope patterns of native-
specific and cross-reactive antibodies; the two antibody groups that bound the native
protein. As an additional assay, the binding of serum antibodies to the different surface
regions were assayed by the enzyme activity of ,B-Iactamase which depends entirely on
the native state of the protein. Serum antibodies from rabbit 1 were isolated against the
23 different surface regions by depletion as described above and were then affinity puri-
fied on native antigen. After pH 2.5 elution and neutralisation the affinity purified anti-
bodies were captured in ELISA wells coated with anti-rabbit antibodies. ,B-Lactamase
was added and the bound ,B-Iactamase detected with the chromogenic substrate Nitro-
cefin. The patterns detected here and as above are shown in Figure 3.3. The epitope
patterns are qualitatively similar. This reinforces the view that the pattern detected cor-
responds to the pattern of topological epitopes.
3.2.3 Size of exclusion zones centred on the CTRs
The biotin-linker was attached to a cysteine on the antigen surface in one end and strep-
tavidin in the other end and was expected to exclude binding of antibodies specific for
epitopes in close proximity of the cysteine. All antibodies that had footprints on the
antigen surface that include the biotinylated cysteines were expected to be completely
excluded from binding to the antigen. This was investigated below.
Serum antibodies from rabbit 3 were isolated against CTR-201 by depletion with
mutant L201C as in the epitope mapping assay described in the introduction of this
chapter. These antibodies were then analysed for their ability to bind each of the 23
biotinylated ,B-Iactamase mutants when captured on streptavidin coated ELISA plates.
The results are shown in Figure 3.4. As expected, antibodies in the serum depleted
with the biotinylated mutant L201C did not bind the same biotinylated mutant when
captured on the ELISA plate. Low signals were also expected in the cysteine positions
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Figure 3.3: Serum antibodies from rabbit 1 which are detected by enzyme activity of
{3-lactamase (a) or with secondary antibodies (b). a)Serum antibodies specific to the
23 different regions of {3-lactamase was isolated as described in the main mapping
method. They were affinity purified on native protein before captured in ELISA plate
wells coated with anti-rabbit antibodies. {3-lactamase was then added in solution. The
relative amount of bound native {3-lactamase was then measured with a chromogenic
{3-lactamase substrate. The background (0.725) was relative high. b)The data in image
are the same as in Figure 4.1a.
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that were close to L201C, as the footprint of each antibody was expected to cover more
than one of the cysteine positions on the surface. The strongest reduction was seen for
A202C, E197C and N52C. These were also the closest positions (7.4, 10.4 and 15.8 A
from residue L201). The intermediate signals of other CTRs near L201C suggested a
relation between the ability to block and the distance from the centre of the epitope.
This is supported by the scatter plot in Figure 3.5. There was almost a linear relationship
between signal and the distance from the surrounding CTRs to CTR-201 (the closes to
the centre of the epitope). On the plot only distances less than 40 A (measured by straight
lines) are strictly meaningful due to the curvature of the protein. The data suggest a
reduction to 40% of the maximum signal at 20 A and a reduction to 20% of the maximum
signal at 14 A.
3.2.4 Depletion by antigen on plates: a way of reducing the signals
on "Masked"
Streptavidin coated beads were initially used for depletion in the mapping assay as they
have a large surface area. They were therefore expected to efficiently bind and deplete
serum antibodies. However, anti-serum from one of the rabbits (rabbit 2) contained anti-
bodies that were not efficiently depleted with the antigen mutants on beads, but were
detected on the same mutants captured on streptavidin coated ELISA plates as shown
in Figure 3.6a. This suggests that the antiserum of rabbit 2 contained antibodies with
low affinities that were difficult to deplete. However, when "High density" streptavidin
coated ELISA plates were used for depletion of serum antibodies the depletion was suc-
cessful (Figure 3.6b). This may reflect the great importance of the avidity of the antigen
for capture of the low affinity serum antibodies.
The effect of immobilising the biotinylated ,B-Iactamase mutants on beads versus
plates in the depletion step were examined with one of the anti-sera that gave relatively
low signals on "Masked" with both methods. The epitope patterns obtained with both
methods are shown in Figure 3.7. The two methods gave similar data.
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Mutants on streptavidin plate
Figure 3.4: Resolution of mapping assay. a) Biotinylated fJ-Iactamase mutants L201 C
on streptavidin beads were used to pull out (subtraction step) antibodies from the serum
binding the fJ-Iactamase surface that are not masked by the biotin-linker. The remain-
ing antibodies were analysed for their ability to bind the panel of 23 biotinylated (3-
lactamase mutants when immobilised on streptavidin coated plates. b) Undepleted
serum detected with the panel of 23 fJ-lactamase mutants. The enzymatic detection was
terminated after different time intervals to allow best internal comparison for the two
data sets. The serum was from test-bleed three, rabbit 3. The dilution of the serum was
1:10,000 during the depletion step and 1:30,000 during detection of remaining anti-
bodies.
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Figure 3.5: The resolution of the region specific depletion used in the mapping assay.
The serum antibodies isolated against specific CTR-201 (Figure 3.4) positions as in the
main mapping assay. Their ability to bind the different biotinylated j3-lactamase mutants
captured on a ELISA plate is plotted against the distance between the cysteine position
used in the isolation process (depletion step) and in detection on the ELISA plate. The
data are adjusted for the signal from whole serum (Figure 3.4b) and normalised to the
average value for data points above 40 A. The fitted line is given by the equation t=
0.032x - 0.25 (R=0.93).
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Figure 3.6: The epitope pattern detected for rabbit 2 under two different conditions. The
epitope distribution was quantified by the mapping method described in introduction of
this chapter. The biotinylated (3-lactamase mutants were immobilised on streptavidin
coated beads (a) or plates (b) during the depletion step. The amount of antibodies de-
tecied to each region is displayed in black bars (exposed). The grey bars (masked) show
the amount of antibodies to the remaining surface that was not successfully subtracted
from the serum.
CHAPTER 3. DEVELOPMENT OF EPITOPE MAPPING METHOD 55
0.35
0.3
0.25
Ec
0 0.2ioco
E
c
0co 0.15~
0
0
0.1
0.05
0
• Mapped with antigen on plateo Mapped with antigen on beads (x1.3)
~z~mDzm~m~zzmr~~~mOD~m~
W (J1 (]1 Q) CD ........ ........ ........ ........ ........ ........ ........ ...... l\) I\) ro ro I\) I\) I\) I\) ro I\)
.". I\) (J1 WoO ~ ~ .". .". (J1 --.Jco 0 0 ~ I\) .". (J1 Ol --.J0::> 0::>
OoOOOOO""OOl""(J1--.J~I\)(J1--.Jo""co~~o::>000000000000000000
Mutants used for depletion
Figure 3.7: The epitope pattern detectedJor rabbit 4 under two different conditions. The
epitope distribution was quantified by the mapping method described in introduction oj
this chapter. The biotinylated (3-1actamase mutants were immobilised on streptavidin
coated beads (black bars) or plates (grey bars) during the depletion step. The data sets
are normalised to give the same average value [or the to methods. Serum was used at a
concentration 1:30,000. .,
3.2.5 Subtraction of the signals on "Masked"
The number of (3-lactamase specific antibodies in serum (see 3.8) can be expressed ~s
N-2
L Si + Sa + Sb
i=l
(3.1)
where Si is the number of molecules of antibodies capable of binding to a patch i of
the surface and Sa and Sb are the number of antibodies capable of binding patch a and
b respectively. If the serum is then depleted with masked CTR-a then the number of
antibodies capable of binding free antigen is
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Masked Exposed
Figure 3.8: The surface of {J-lactamase is divided into a total of N small patches in-
cluding patches a and b from which antibody is excluded when covalently attached to a
surface at a or b respectively.
(3.2)
where k is the average depletion factor. However the number of antibodies available for
capture when CTR-a is masked (and Sa = 0) is
(3.3)
and the number of antibodies available for capture when CTR-b is masked is
",N-2
S L..-i=l Sia = k + Sa (3.4)
-
With a number of molecules S and volume v the concentration c would be s]». Assuming
an equal binding constant K then the number of bound antibodies n = Kc = (K s) / v.
The number of molecules na and nb bound on the antigen when CTR-a or CTR-b are
masked respectively is then
K ",N-2
(
L..-i=l Si Sb)n =-. +-
a V k k (3.5)
and
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K ""N-2
(Ui=l Si )nb =-. + Sa
V k (3.6)
The difference in molecules bound to CTR-b and CTR-a can therefore be described by
K ""N-2 ""N-2 K_ ((Ui=l Si ) (Ui=l Si Sb)) _ ( Sb)tu, - na - --;; . k + Sa - k + k - --;;.Sa - k (3.7)
The number of molecules bound will be proportional to the ELISA signal E. This gives,
with a constant C equal to the signal per molecules bound,
Were C' = (CK)/v. The difference f1EA = Eb - Ea describes the signal measured
in the assay when a CTR-a is masked during depletion followed by detection on CTR-b
(mutant 308C in the assay) minus the signal when detected on the same masked CDR (a).
Comparing the signals f1Ex and f1Ey for two adjacent patches x and yon the surface,
the difference between these signals directly reflects the difference in number of antibody
molecules binding to x and y. Thus
'( Sb) C'( Sb) '(f1Ex - f1Ey = C Sx - k - Sy - k = C Sx - Sy) (3.9)
Note that this does not depend on the value of Sb or k as all the signals are taken with
respect to the same reference point b. Furthermore, from equation 3.7 as
(3.10)
if Sx »~,then f1Ex = C'sx, likewise f1Ey = C'Sy
f1Ex c», Sx===}--=--=-
f1Ey C'Sy Sy
(3.11)
In this case the ratios of the signals f1Ex to f1Ey would reflect directly the ratios of
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antibodies that bind each patch x and y.
The experiment achieves Sx » ~.An upper limit for the value of Sb (S308C) was
determined for rabbit 1 by depleting the serum with CTR-308 followed by detection on
CTR-90, and vice versa. The signal to the former was about 116of the latter (data not
shown), and therefore the value Sb is low (and lower than the average). Furthermore the
depletion factor k was large; thus the reduction of the signals on "masked" CTRs in the
mapping assay was at least a 12 times smaller with depleted serum compared to unde-
pleted serum for rabbit 1 (data not shown). Hence Sx »~.
In subsequent chapters (chapter 4, 5 and 6) signals for masked CTR has been sub-
tracted from that of unmasked CTR.
3.2.6 Reproducibility of the epitope mapping assay
The epitope mapping assay had a high degree of reproducibility. This is illustrated in
Figure 3.9. The epitope distribution in the same serum was determined in two separate
experiments. 15 of biotinylated mutants were used in the mapping assay. The serum
concentrations were two-fold different in the two experiments. The signals from these
two sets samples were developed enzymatically in two separate assays and were there-
fore displayed with the same average value (by multiplying the signals with grey bars
by 1.12). The epitope patterns are almost identical. Similar reproducibility was also
observed when the antigen mutants were displayed on beads during the depletion.
3.3 Discussion
The epitope assay provided identical conditions for detecting antibodies specific for any
part of the antigen surface. Antibodies specific for each of the 23 CTRs were detected on
the wild type antigen and the data collected allowed comparison of the antibody response
to the different parts of the antigen surface. Previous assays for mapping epitopes on na-
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Figure 3.9: The mapping of surface distribution of antibodies to 15 different surface
regions. The two columns for each region are done in separate experiments. The serum
dilutions were 1:12,500 and 1:25,000 for the black and the grey bars respectively. The
two sets of signals are displayed with the same average value (by multiplying signals
with grey bars with 1.12). Serum from rabbit 4.
CHAPTER 3. DEVELOPMENT OF EPITOPE MAPPING METHOD 60
tive proteins using sera have depended on exclusion of antibody binding to the antigen
surface by conservative variations in the surface residues. However this would not neces-
sarily exclude antibodies, or indeed exclude antibodies equally well in different surface
regions. The readout and interpretation of such assays is very complex, as seen with Ho-
mologous Scanning Mutagenesis used by Weber and his colleagues [Weber et aI., 1992]
(see chapter 1). For example the antigen specific antibodies were detected when bound
to the mutants (rather than essentially wild-type, as here), and a complex normalisation
procedure was required to evaluate the significance of the signals detected, as the mu-
tants did not have equal capacity to bind antibodies in the unmutated regions. This assay
is therefore difficult to use in a relative analysis of the antigenicity distribution on the
antigen surface.
The mapping assay described here depended on exclusion of antibody binding to the
antigen by masking. A key feature is that the ,B-Iactamase mutants used in depletion
were folded (as shown by enzyme activities). As important is that the ,B-Iactamase (mu-
tant 308C) used in the detection step was also folded and therefore not recognised by
monoclonal antibodies specific for the denatured form. Only antibodies specific for the
native form of the antigen (native-specific and cross-reactive antibodies) were expected
to be detected in the mapping assay.
The results from the mapping assay using the enzyme activity of ,B-Iactamase read-
out also supports the supposition that the epitope distribution was that on native protein.
Only native ,B-lactamase that bound the serum antibodies could contribute to the signal
as denatured ,B-Iactamase had no enzyme activity. Even though the signal was low in this
assay and the background relatively high, the general epitope distribution detected were
qualitatively the same as detected in the main mapping assay. The format of the assay
may have had some influence on the detected pattern. The binding was not enhanced
by avidity effect and the relative contributions to the signals by the antibodies with high
affinity were therefore expected to be higher. Some of the antibodies may also have in-
hibited the enzyme activity of ,B-Iactamase and therefore not contributed to the signal.
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A mix of 1:100 of this rabbit serum (rabbit 1) in PBS with O.l/lg/ml ,B-lactamase gave a
3S% reduction of the enzyme activity compared to a ,B-lactamase solution without serum
present (data not shown). The introduced cysteines with the shortest surface distance to
the active site were NlOOC, E110C, K21SC, E240C, Q269C and T271C. Antibodies
against these regions could potentially have inhibited the enzyme activity.
The epitope mapping assay does not identify specific surface residues on the antigen
that were directly involved in antibody binding but topological regions. The size of the
regions was investigated by the following experiment (see Figures 3.4 and 3.S) in which
each of the CTRs was used for detection rather than a single CTR (CTR-308). The serum
was first depleted with one cysteine mutant (CTR-201) and then assayed for binding to
the panel of 23 other CTRs. The readout depends on two exclusion processes. The first
(during the depletion) leaves in solution antibodies excluded by CTR-201. The second
exclusion is during the detection step. The results show (Figure 3.S) that the signal for
serum antibodies to CTR-201 is significantly reduced only if the distance between the
centre of CTR-201 and the other CTRs is < IS A, which is about the radius of the foot-
print of an antibody ((7r-1. 8S0 A2)! ~ 16 A). This means that only antibodies with
footprints that were very close to or overlapping with the cysteine position had been ex-
cluded in CTR-201 and were present after the depletion step.
The relative epitope distribution could in principle be determined by using unde-
pleted serum to the panel of biotinylated and immobilised ,B-lactamase mutants. The
differences in signals would show the contribution of antibodies to the different CTRs
(see equation 3.1). In practise however, these differences are submerged in experimental
noise. Efficient depletion of the antibodies was therefore necessary to get accurate esti-
mates of epitope distribution.
The mapping assay was based on depletion by the masked antigen. However, low
affinity antibodies are not expected to be depleted. Indeed the sera from rabbit 2 gave
high signals binding on the masked antigen in the detection step, suggesting incomplete
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capture. To deal with this, avidity effects were harnessed for efficient depletion. Strepta-
vidin coated beads rather than plates were initially used for depletion as it was surmised
that the beads would provide a larger surface area. The streptavidin beads with biotiny-
lated mutants provided a surface area of 24 cm". However multiple streptavidin coated
ELISA plate wells with in which the sera could subsequently be depleted on immobilised
biotinylated antigen provided a similar surface area (11 cm? ~ 11 x 0.95 crrr"). Using
"High density" streptavidin coated ELISA plates provided good conditions for capture
of the antibodies as supported by the results.
The conditions for binding the antibodies to the antigen during the detection step did
not necessarily need to match the conditions during the depletion step. The key require-
ment was that if the affinity of an antibody was too low to be depleted, then the detection
assay should be designed to be insensitive to binding of such a low affinity antibody.
The epitope patterns represent combinations of concentrations and affinities of the
serum antibodies. The concentrations of the antibodies were probably a major contri-
bution to the epitope pattern as discussed later. The distribution of epitope affinities
on the antigen surface or the epitope distribution of only high affinity antibodies would
give important additional information about the epitope distribution. Surface plasmon
resonance (Biacore) was therefore used in an attempt to measure affinities of the serum
antibodies. However the serum concentrations were too low to get detectable signals
with the Biacore even at high densities of antigen on the chip.
Chapter 4
Mapping epitopes of serum antibodies
4.1 Introduction
The epitope mapping method presented in chapter 3 generates data on the relative epitope
distribution on the native protein. The method was used in this chapter to compare the
epitope distributions of sera from different animals.
4.2 Results
4.2.1 Immunisation and epitope mapping
Two rabbits (rabbits 1 and 2) were immunised with ,B-Iactamase in Freund's adjuvant
(see Table 4.1). Both animals were injected with the antigen in Freund's complete adju-
vant (FCA) followed by boosts with the antigen in Freund's incomplete adjuvant (PIA).
The epitope distribution in the sera were analysed subtracting the signals "Masked" from
the signals "Exposed" as discussed in chapter 3. The serum from rabbit 2 was mapped
with the biotinylated ,B-Iactamase immobilised on plates in stead of beads to reduce the
high signals on "Masked" as described earlier. The results are shown in Figure 4.1. (Raw
data are presented in Figure A.2, page 148.) There were relatively large variations in the
amount of antibodies over the surface. There were regions with almost three times the
average signal as seen for CTR-114 in rabbit 1 and CTR-90 in rabbit 2. There were also
six to seven CTRs with less than half the average signal. The CTRs with high or low
63
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Table 4.1: Immunisation regimes. All the animals were each immunisation day injected
subcutaneously at four sites on the back. The rabbits were injected with j3-lactamase in
500 j11PBS alone or mixed with 500 j11Freund's Complete Adjuvant (FCA) or Freund's
Incomplete Adjuvant (FIA). The barstar was in lOa j11PBS mixed with 100 j11FCA or
FIA. The mice were injected with j3-1actamase in 100 j11PBS mixed with 100 j11FCA or
FIA. The test-bleeds were taken 10 or 7 days after the antigen injections for the rabbits or
the mice respectively. Rabbit 5 was injected with carboxymethylated (CM) j3-lactamase.
Rabbits 3, 4, and 5 are described in later chapters.
1st injection 1st boost 2nd boost
Animal Antigen Day 1 Day29 Day 57
Rabbit 1 j3-lactamase 500 j1g in FeA 500 j1g in PIA 500 j1g in PIA
Rabbit 2 j3-lactamase 500 j1g in FeA 500 j1g in PIA 500 j1g in PIA
Rabbit 3 j3-lactamase 500 j1g in PBS 500 j1g in PBS 500 j1g in PBS
Rabbit 4 j3-lactamase 500 j1g in PBS 500 j1g in PBS 500 j1g in PBS
+ barstar 100 j1g in FeA 100 j1g in PIA 100 j1g in PIA
Rabbit 5 CM-j3-lactamase 500 j1g in FeA 500 j1g in PIA 500 iig in PIA
Day 1 Day22 Day43
Mouse 1 j3-lactamase 250 j1g in FeA 30 j1g in PIA 20 j1g in FIA
Mouse 2 j3-lactamase 250 j1g in FeA 30 j1g in PIA 20 j1g in PIA
Mouse 3 j3-lactamase 250 j1g in FeA 30 j1g in PIA 20 j1g in PIA
Mouse4 j3-lactamase 250 j1g in FeA 30 j1g in PIA 20 j1g in PIA
signals seemed to group together in the linear sequence for rabbit 1. The two clusters
with high signals were from Q90 to E140 and T27l to E281. The intervals with low sig-
nals were from K34 to E63e and N146 to N175. The results from rabbit 2 also indicated
some clusters of low signals close to the Cvterminus. The highest signal in this rabbit
(on Q90) fell within the cluster with highest signals in rabbit 1.
The same epitope data were plotted on the protein surface to get a better picture of
the three-dimensional distribution as shown in Figure 4.2. The Cl'Rs with high signals
for rabbit 1 form two clusters on the surface of the protein (red, orange and yellow).
There was also a large continuous surface region with low signals (blue and violet). The
eTR with highest signal for rabbit 2 (CTR-90) was only 23 A away from the CTR with
highest signal in rabbit 1 (eTR-114) on the protein surface. The regions with low and
intermediate signals were not in the same surface regions for the two rabbits.
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Figure 4.1: The relative distribution of serum antibodies to different surface locations.
The results for rabbit 1 and 2 are shown in image (a) and (b) respectively. The signals
are normalised to give an average of 1. The signals on "Masked" are subtracted and
negative values are set to zero. The average value is indicated with a full line. The
dotted lines indicate half the average signal and double the average signal. The sera
concentrations in the mapping assay were 1:10,000 and 1:50,000 for rabbit 1and 2.
The serum from rabbit 2 was mapped with the biotinylated j3-lactamase immobilised on
plates in stead of beads to reduce the high signals on "Masked" as described in chapter
3. The rabbits primarily injected with antigen in FCAfollowed by antigen in FIA infirst
and second boost.
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Rabbit 1
Rabbit 2
Figure 4.2: The epitope distributions of sera antibodies from rabbits 1 and 2 on the
three-dimensional surface of {3-lactamase are shown in image (a) and (b) respectively.
The protein is rotated 1800 around the vertical axis in the two images. The background
colour of the protein is white. The surface around each cysteine position (sulphydryl
group). in a radius of seven Angstroms. is coloured according to the relative amount of
antibodies detected to the particular region. The values for the detected antibodies are
translated into the colours of the rainbow with regular intervals. Red corresponds to the
highest value and violet corresponds to the lowest value. The signals on "Masked" are
subtracted. Note that the regions coloured around each detection point are significantly
smaller than the typical footprint of an antibody.
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Four mice (mice 1,2,3 and 4) were also immunised with ,B-Iactamase in Freund's ad-
juvant (see Table 4.1). All the mice were injected with the antigen in Freund's complete
adjuvant (FCA) followed by boosts with the antigen in Freund's incomplete adjuvant
(FIA). The epitope distribution in the sera were analysed. The results are shown in Fig-
ure 4.3. (Raw data are presented in Figure A.3 on pages 149 and 150.) The mice sera
did also show relative large variations in the amount of antibodies over the surface. The
highest values in the mice range from about 5 to 12 times the average value. They did all
fall in the same antigen surface region as for rabbit 1 and 2. The sera did also give low
signal on several CTRs. Sera from all the mice gave less than half the average signal on
close to or more than half of the CTRs.
4.2.2 Dominant epitope in rabbits and mice
The epitope distributions described were averaged for the rabbits (n=2) and the mice
(n=4) to reveal the most prominent features as shown in Figure 4.4. The most obvious
characteristic for both the rabbits and the mice was the high signals within the loop re-
gion D85 to V119. The loop region is indicated in red in Figure 4.6. All six animals
had the highest signal in this part of the protein. There was no other obvious dominant
epitope in these animals although a tendency of higher signal around CTR-197 could be
seen.
4.2.3 Correlation between epitopes and surface properties
The rabbits immunised with ,B-Iactamase in Freund's adjuvant all had highest antibody
response against the loop region D85 to V119 shown in Figure_4.6. Loops tend to have
high flexibility. Indeed the CTRs in the interval D85 to V119 have the highest backbone
mobility as seen in Figure 4.7. The average polypeptide backbone flexibility (crystal-
lographic B-values, [Jelsch et aI., 1993]) corresponding to a window of seven residues
around each CTR were checked for correlation with the ELISA signals. This gave corre-
lation coefficients of 0.60 and 0.61 for the average rabbit and mouse signals or 0.70 and
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Figure 4.3: The relative distribution of serum antibodies to different surface locations
for sera from mice. The signals are normalised to give an average of 1. The signals
on "Masked" are subtracted. The average is indicated with a full line. The dotted lines
indicate half the average signal and double the average signal. The serum concentration
in the mapping assay was 1:5,000. The mice (mouse 1,2,3 andfour in image (a), (b), (c)
and (d) respectively) were primarily injected with antigen in FCAfollowed by antigen in
FIA in first and second boost.
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Figure 4.4: The average epitope distributions of for rabbits 1 and 2 in image (a) and
. mice 1, 2, 3 and 4 in image (b). The signals are normalise to an average value of 1.0.
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0.46 if the epitope data from the same animals were weighted by using the exponential
ELISA signals. (Correlation data for all the animals are shown in Table A.l and A.2,
pages 152 and 153.) This suggests that there is a positive correlation between ELISA
signals and the backbone mobility. Scatter plots with the backbone flexibility and ELISA
signals are shown in Figure 4.5.
Figure 4.8 shows how the sequences with highest backbone mobility locate on the
surface. The red surface in this figure includes the CTRs with highest signals for the
rabbits immunised with Freund's adjuvant. The epitope data are not based on the linear
sequence but on the three-dimensional surface. A refinement of the correlation calcu-
lations was therefore carried out by calculating the average flexibility (crystallographic
B-values) of the polypeptide backbone attached to side chains comprising a CTR. For
this purpose each CTR was assumed to include all surface residues within a 10 A radius
centred on each sulphydryl of the cysteine mutants. This gave correlation coefficients of
0.71 and 0.61 for the average rabbit and mouse signals or 0.74 and 0.47 if the epitope
data from the same animals were weighted by using the exponential ELISA signals.
4.3 Discussion
The results described here are the first examples in the literature of relative epitope data
on a three-dimensional protein surface. The systematic data allows a more a thorough
analysis and comparison of the antibody responses than earlier epitope data.
The results are consistent with earlier results for other protein antigens. Most if not
all the antigen surface was antigenic as also described earlier by Benjamin et al. [1984].
The sera from all the animals immunised with ,B-Iactamase further showed highest anti-
body response in the loop region D85 to V119. The epitope dominance seen for the loop
region D85 to V119 in all the sera is unlikely to be the result of a random antibody re-
sponse against the different surface regions. A large part of the earlier literature reports
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Figure 4.5: Scatter plot of the ELISA signals and average backbone mobility for a win-
dow of seven amino acids around the CTRs for the rabbits (n=2) in image a and the mice
(n=4) in image b.
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Tl14
Figure 4.6: {3-Lactamase is shown in light blue, except the flexible loop region D85 to
V119 which is in red. The protein is shown from the same angle as in the left images
of the Figures 4.2 and 5.3. Sera from aLLthe animals immunised with {3-lactamase in
Freund's adjuvant showed highest antibody response in this region of the protein.
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Figure 4.7: The backbone mobility (crystallographic B-values) of{3-lactamase is plotted
along the protein sequence. The values are averaged over a window of seven residues
along the protein sequence.
\
Figure 4.8: The {3-lactamase residues with the highest backbone mobility (B-values
above 12 ,P, see Figure 4.7) are coloured in red on a white background. The protein is
shown from the same angles as in the presentations of the mapping data earlie r in this
chapter.
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Figure 4.9: The backbone mobility (B-values) of fJ-lactamase is plotted along the protein
sequence together with the normalised values for rabbits 1 and 2 (average for the two
rabbits). The B-values are averaged over a window of seven residues along the protein
sequence.
similar epitope dominance as mentioned in chapter 1.
The loop region D85 to Vl19 has little secondary structure and high backbone mo-
bility, and the profiles of epitope distribution and backbone mobility along the linear
antigen sequence suggested that they were connected (Figure 4.9). Westhof et al. [1984]
reported the same kind of relation between the backbone mobility and the antigenicity
(measured using small linear peptides) for the model antigens tobacco mosaic virus pro-
tein, myoglobin and lysozyme. The relative values from the mapping assay reported here
allowed a numerical analysis in contrast to the visual inspection used in the earlier work.
These calculations based on the backbone mobility in the sequence around the CTRs
did indeed suggest a positive correlation. This was also supported by the analysing the
backbone mobility for topographic regions of the antigen surface.
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The antibodies produced in response to ,B-Iactamase in Freund's adjuvant had a relatively
uneven distribution on the antigen surface. All the animals immunised with ,B-Iactamase
produced antibodies predominantly to the surface region with the highest backbone flex-
ibility, the loop region D85 to Vl19.
Chapter 5
Epitope distribution without Freund's
adjuvant
5.1 Introduction
The results in chapter 4 describe the presence of a dominant epitope on ,8-lactamase
that correlate with a region of high flexibility. The results were based on sera from ani-
mals which were all immunised with antigen in Freund's adjuvant. This raises questions
whether the presence of Freund's adjuvant could influence the epitope distribution and
if so, whether it was associated with the dominant epitope. These are important ques-
tions since almost all earlier epitope studies with model antigens have been carried out
with this adjuvant. Here immunisation was undertaken with antigen in only phosphate
buffered saline (PBS).
5.1.1 Immunisation with protein in PBS
Two rabbits (rabbits 3 and 4) were immunised with ,8-lactamase without Freund's ad-
juvant (see Table 4.1). The animals were injected three times subcutaneously with ,8-
lactamase in PBS. Rabbit 4 was in addition given the bacterial protein barstar in Freund's
adjuvant in a separate injection with the intention to evoke an antibody response to the
native ,8-lactamase. The lipopolysaccharide (LPS) content in the ,8-lactamase sample
was measured to see if there were other chemicals in the protein sample with adjuvant
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activity [Johnson et al., 1956]. The analysis was carried out by BioWhittaker, Europe.
The samples contained 21.34 EU per millilitre, equivalent to 2.13ng LPS per millilitre.
Hence each injection given to the rabbits contained about 1ng LPS. (This also included
the rabbits immunised with ,8-lactamase in Freund's adjuvant.) It is difficult to know if
the LPS at nanogram levels as used in the current work had a significant adjuvant effect
as no comparative study had been undertaken in the literature. Both the rabbits immu-
nised with ,8-lactamase in PBS produced antibodies (IgG) specific for ,8-lactamase. The
ELISA results with test-bleeds are shown in Figure A.1, page 146. The titres of the
responses in these animals were comparable to the response with Freund's adjuvant. It
is not known if the additional injection of barstar in Freund's adjuvant in rabbit 4 had
any adjuvant effect as both rabbits 3 and 4 made antibodies to the native ,8-lactamase.
The sera of the two rabbits immunised with ,8-lactamase in PBS had increased titers of
IgG which is typical for secondary immune responses [Bandilla et al., 1969]. Two mice
were also immunised with ,8-lactamase in PBS. However the mice did not produce ,8-
lactamase specific antibodies (IgG) in detectable concentrations.
The epitope distributions in the sera from the rabbits were examined by the mapping
method. The results are shown in the Figure 5.1. (Raw data are presented in Figure
AA, page 151.) There are few extreme values in these histograms compared to Figure
4.1 with results from the rabbits immunised with the same antigen in Freund's adjuvant.
The serum from rabbit 3 gave less than half the average signal on only two CTRs and
there were no CTRs with more than twice the average signal. The serum from rabbit 4
gave less than half the average signal on only one CTR and there was no CTR with more
than twice the average signal.
The epitope distributions for the two rabbits immunised with ,8-lactamase in PBS
are averaged in Figure 5.2. There is no obvious dominating epitope in this figure. The
signals were in general closer to the average signal than for the sera from the animals
immunised with Freund's adjuvant. The epitope in loop region D85 to Vl19 observed in
all six animals immunised with ,8-lactamase in Freund's adjuvant did not dominate the
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Figure 5.1: The relative distribution of serum antibodies to different surface locations.
The results for rabbit 3 and 4 are shown in image (a) and (b) respectively. The signals
are normalised to give an average of 1. The signals on "Masked" are subtracted. The
average is indicated with aJullline. The dotted lines indicate half the average signal and
'double the average signal. The serum concentration in the mapping assay was 1:30,000
for both rabbits. The rabbits were given three injections with antigen in PBS.
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Figure 5.2: The average epitope distributions offor the rabbits 3 and 4, both immunised
with {3-lactamase in PBS. The signals are normalise to an average value of 1.0.
antibody response in any of the rabbits immunised with {3-lactamase in PBS.
The surface epitope data for rabbit 3 and 4 are presented on the three-dimensional
antigen surface in Figure 5.3. The signals were, as expected from the histograms, rel-
atively even on the surface. The region with the highest signals for rabbit 3 (CTR-269
and CTR-271) did not fall in the same surface region as for the rabbits immunised with
antigen in Freund's adjuvant. The CTR with highest signal for rabbit 4 (CTR-140) was
spatially close to the CTRs with highest signals for all the animals immunised with {3-
lactamase in Freund's adjuvant. But the signal in rabbit 4 was relatively low compared
to the more extreme values for the sera from the animals immunised with {3-lactamase
in Freund's adjuvant.
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Figure 5.3: The epitope distributions of sera antibodies from rabbits 3 and 4 on the
three-dimensional surface of (3-lactamase are shown in image (a) and (b) respectively.
The protein is rotated 1800 around the vertical axis in the two images. The background
colour of the protein is white. The surface around each cysteine position (sulphydryl
group), in a radius of seven Angstroms, is coloured according to the relative amount of
antibodies detected to the particular region. The values for the detected antibodies are
translated into the colours ofthe rainbow with regular intervals. Red corresponds to the
highest value and violet corresponds to the lowest value. The signals on "Masked" are
subtracted. Note that the regions coloured around each detection point are significantly
smaLLerthan the typical footprint alan antibody.
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0.7
Rabbit 1 Rabbit 2 Rabbit 3 Rabbit 4
Figure 5.4: The variance in the epitope pattern for each rabbit. The variance is calcu-
lated from the data presented in the Figures 4.1 and 5.1. Rabbits 1 and 2 are immunised
with antigen in Freund's adjuvant and rabbits 3 and 4 are immunised with antigen in
PBS.
5.1.2 Variation in antibody response over the antigen surface
The epitope data in this and previous chapter indicated that serum antibodies from the
rabbits immunised with antigen in PBS (rabbits 3 and 4) were more evenly distributed on
the antigen surface than antibodies from the rabbits immunised with antigen in Freund's
adjuvant (rabbits 1 and 2). A numerical value for the variance in signals on the CDRs
was calculated for each rabbit and presented in Figure 5.4. The data show that the rabbits
immunised with antigen in Freund's adjuvant had the highest variation in epitope signals
and supports the impression from the visual inspection of epitope patterns. Only rabbits
were compared this way as no antibody response to ,6-lactamase in PBS was detected in
the mice. It is nevertheless evident that the variance in the epitope distribution is high
for the four mice immunised with ,6-lactamase in Freund's adjuvant.
5.1.3 Correlation between epitopes and surface properties
The average polypeptide backbone flexibility (crystallographic B-values) corresponding
to a window of seven residues around each CTR were checked for correlation with the
.average ELISA signals for rabbit 3 and 4 in the same way as described in chapter 4. This
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Figure 5.5: Scatter plot of the ELISA signals and average backbone mobility for a win-
dow of seven amino acids around the CTRs for the rabbits 3 and 4. Both were immunised
with j3-lactamase in PBS and are combined in the figure.
gave a correlation coefficient of 0.28 or 0.24 if the epitope data from the same animals
were weighted by using the exponential ELISA signals. There is also no obvious trend
in the scatter plot of the antigenicity and backbone flexibility for the rabbits immunised
with j3-lactamase in PBS (Figure 5.5) as suspected with the presented correlation data.
The correlation coefficients for the average backbone flexibility in the surface regions
around the CTRs (see chapter 4) and the ELISA signals were 0.33 or 0.03 if the epitope
data from the same animals were weighted by using the exponential ELISA signals. In
contrast, the weighted ELISA signals for the rabbits immunised with j3-lactamase in Fre-
und's adjuvant (rabbits 1 and 2) showed correlation coefficient of 0.74 with the backbone
flexibility.
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5.1.4 Signals on "Masked" in mapping assay
The ratio of "Exposed"I"Masked" was systematically higher for the rabbits immunised
with ,B-Iactamase in PBS compared to the rabbits immunised with ,B-Iactamase in Fre-
und's adjuvant (Figures A.2 and A.4, pages 148 and 151). The ratios were about 10
and 11 for the rabbits immunised with ,B-Iactamase in PBS compared to 3 and 4 for the
rabbits immunised with ,B-Iactamase in Freund's adjuvant. The lower ratios (or higher
signals on "Masked") in the latter rabbits are expected to be due to low affinity anti-
bodies as they were not successfully depleted from the serum in the depletion step but
were detected on the ELISA plates (see chapter 3). The low affinity antibodies may have
been a result of antibody responses to unfolded protein as discussed in more detail in the
next chapter.
5.2 Discussion
The rabbits immunised with ,B-Iactamase in PBS did not reveal any dominant epitope.
There was also no indication of elevated signal in the loop region D85 to Vl19 for the
sera from these rabbits, the loop region that was dominant in all the animals immunised
with ,B-lactamase in Freund's adjuvant. These results suggest that the epitope distribu-
tion was dependent on the immunisation regime used although sera from only a few
animals were analysed. The antibodies from the rabbits immunised with the antigen in
PBS were further relatively evenly spread on the antigen surface. Each of the sera from
the rabbits immunised with ,B-Iactamase in Freund's adjuvant had relative high variation
in antibody response to the different parts of the antigen surface. This difference in epi-
tope variations with different immunisation regimes also suggests a dependence of the
antigenicity distribution on the immunisation method.
The epitope distributions in sera from the rabbits immunised with ,B-lactamase in
PBS showed little if any correlation with backbone mobility, in contrast to the sera from
-the rabbits immunised with ,B-Iactamase in Freund's adjuvant. This suggests that cor-
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relation between dominant epitopes and backbone mobility reported earlier for tobacco
mosaic virus protein, myoglobin and lysozyme [Westhof et al., 1984] may also have
been artefacts of using Freund's adjuvant which they used in the immunisation.
5.3 Conclusion
Immunisation with ,B-Iactamase in PBS induced production of antibodies with relatively
even distributions on the whole antigen surface. The dominant epitope seen in sera from
the animals immunised with ,B-Iactamase in Freund's was absent in the rabbits immu-
nised with ,B-Iactamase in PBS. Only a weak correlation was detected between the epi-
tope distributions in the rabbits immunised with ,B-Iactamase in PBS and the backbone
flexibility.
Chapter 6
State of the antigen in Freund's
adjuvant
6.1 Introduction
The adjuvant we today know as Freund's complete adjuvant is a mineral oil with a sur-
factant and heat killed mycobacterium. Freund's incomplete adjuvant is the same solu-
tion without the mycobacterium. The oil-based adjuvant is mixed with the antigen in a
water-based buffer to create a stable water-in-oil emulsion which is injected into the an-
imals. Jules Freund showed in 1937 [Freund, 1937, 1947] that administering the antigen
in these emulsions stimulate stronger antibody responses than injecting the antigen in a
water based buffer.
A few papers describe Freund's adjuvant's impact on the state of protein antigens
although with different conclusions. Scibienski [1973] immunisedguinea pigs with hen
egg lysozyme (HEL) with or without adjuvant and found that antibodies induced with-
out adjuvant bound native but not denatured protein while antibodies induced in the
presence of Freund's adjuvant bound both forms of the protein. This suggests that Fre-
und's adjuvant denatured HEL. Berzofsky et al. [1976] studied human hemoglobin (Hb)
in Freund's adjuvant by electromagnetic resonance. The resonance spectrum of the heme
group is dependent on the conformation of the protein. The data showed no denaturation
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of Hb and the different results for HEL and Hb indicate that the denaturation effect of
the adjuvant may depend on the specific protein.
Although some have argued that possible denaturation of protein antigens by Fre-
und's adjuvant may have implications for the distribution of epitopes (Stanworth's com-
ment in Van Regenmortel et al. [1986]), most researchers studying epitopes have shown
little concern about the state of the antigens in the adjuvant. The results in the chapters
4 and 5 of this thesis show that the epitope distributions on ,B-Iactamase were different if
this antigen was injected with Freund's adjuvant or only in PBS. The impact of Freund's
adjuvant on the state of ,B-Iactamase and how this may influence the epitope distribution
was therefore investigated in this chapter. These issues are of great importance since Fre-
und's adjuvant has been used in the vast majority of earlier epitope studies with model
antigens.
6.2 Results
6.2.1 Different ways of emulsifying the protein in Freund's adjuvant
A classic way of mixing Freund's adjuvant with the antigen is to manually push the
solution between two interconnected glass syringes [Weir, 1978]. As manually mixing
of the adjuvant is not necessarily reproducible, emulsification by a magnetic spinner
and a homogeniser, both powered by electrical engines, were evaluated. The emulsions
created by these two methods did not pass the classic test described in Weir [1978], the
emulsion should stay as compact droplets when added to water, and the emulsions were
therefore mixed by the classic method described above.
6.2.2 Assaying denaturation by enzyme activity of ,B-Iactamase
The enzyme activity of ,B-Iactamase is dependent on the native conformation of the
polypeptide chain. The most obvious way to evaluate the state of ,B-Iactamase in Fre-
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und's adjuvant was therefore to add a chromogenic substrate (Nitrocefin) to the adjuvant
emulsion and measure the enzyme activity. But the Nitrocefin was efficiently absorbed
into the oil phase and not the water phase where native ,B-Iactamase was expected to be.
The water phase was therefore separated from the adjuvant followed by analysis of the
included ,B-Iactamase. Ether, hexane or mineral oil was used to destabilise the emulsions
which could then be separated by centrifugation. Freund's incomplete adjuvant was used
in these experiments.
Incubation time and enzyme activity
The water phase rescued from the emulsion had only small amounts of enzyme activity
compared to the enzyme activity of the ,B-Iactamase put into the emulsion. Using ether,
hexane or mineral oil made no obvious difference. But some variations were observed
in the remaining enzyme activity which seemed to depend on the incubation time in
the adjuvant. Ether, which destabilised the emulsion more efficiently than hexane or
oil, was used to analyse the time dependence as it soon became apparent that short
incubation times in the adjuvant were needed to rescue reasonable amounts of native
,B-Iactamase. The enzyme activities in the water phase after different incubation times
in the adjuvant are shown in a semi-logarithmic plot in Figure 6.1. The enzyme activity,
which is proportional to the amount of native ,B-Iactamase, was decreasing dramatically
over time in Freund's adjuvant. The half-life time of the enzyme activity estimated from
this data was about 21 minutes. (It was also noticed that the presence of 5% glycerol
in the water phase when mixing the adjuvant would protect the enzyme activity in the
adjuvant for at least 24 hours although the enzyme activity was not carefully quantified
in this case).
Extraction methods and enzyme activity
The enzyme activity of ,B-Iactamase decreased over time in Freund's adjuvant but the
data in Figure 6.1 do not extrapolate back to 1.0 in the normalised plot and the ether's
impact on the ,B-Iactamase was therefore investigated. ,B-Lactamase in PBS was mixed
with ether and vortexed for two minutes, the maximum time ,B-Iactamase was expected
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Figure 6.1: j3-Lactamase in PBS was emulsified in Freund's adjuvant. The water phase
was extracted after different incubation times in the adjuvant and the enzyme activity in
the water phase was measured with the chromogenic j3-lactamase substrate Nitrocefin.
The value 1.0 represents the enzyme activity of j3-lactamase which has not been in Fre-
und's adjuvant. The fitted line is given by the equation f = 0.251 . e-O.0323min-l.t. The
R-value of the fitted line is 0.9992.
to be in contact with ether in the extraction method. No reduction in enzyme activity
was detected (data not shown). PBS emulsified in Freund's incomplete adjuvant was
then separated from the oil phase by ether and mixed with j3-lactamase to evaluate if any
co-extracted substances could inhibit the enzyme activity. The enzyme activity in the
presence of extracted buffer was about 70% of the activity measured in "fresh" PBS and
did not change over a time span of two hours (data not shown).
6.2.3 Assaying denaturation by proteolysis of j3-lactamase
The adjuvant's impact on the state of j3-lactamase was also examined through suscep-
tibility to proteolysis. Native j3-lactamase was resistant to the proteolytic activity of
trypsin for at least two hours at room temperature when mixed in a ratio 1:100 trypsin
to j3-lactamase (control in Figure 6.2). j3-Lactamase has several recognition sites for
trypsin in the linear sequence and denature j3-lactamase was therefore expected to be
cleaved by trypsin. j3-Lactamase was emulsified in Freund's adjuvant in the presence of
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trypsin and the water phase was after different incubation times separated from the ad-
juvant by adding ether. The trypsin activity was immediately stopped with PEFA-block
followed by loading of the samples mixed with sodium dodecyl sulphate (SDS) on a gel.
The results are shown in Figure 6.2a. Cleaved fragments of ,B-Iactamase appeared after
a short incubation time in the adjuvant. ,B-Lactamase in native form was resistant to the
same amount of trypsin for at least two hours as shown in the control.
,B-Lactamase was also emulsified the same way without trypsin present and after sep-
aration from the adjuvant loaded on the gel shown in Figure 6.2b. No cleaved product
of ,B-Iactamase, as expected, were visible in this gel. Bands corresponding to the size
of two or more ,B-Iactamase molecules were present in this gel. These bands were also
present if hexane or oil were used for extraction of the protein (data not shown), which
means that the cross-linking of the protein was not due to the ether. The cross-linked
,B-Iactamase was absent in the samples with trypsin (Figure 6.2a). This suggests that the
cross-linked protein comprised denatured protein which was proteolysed in the presence
of trypsin.
The extraction of ,B-Iactamase from Freund's adjuvant without any trypsin present
yielded large precipitates with ,B-Iactamase (see lane next to control in Figure 6.2b).
The precipitation may have been a result of high concentration of denatured protein in
the emulsions. The large precipitates were also observed if the antigen was extracted
by hexane or oil, which suggest that they were formed independently of the extraction
method. Little precipitates were seen if trypsin was co-incubated with the ,B-Iactamase
in the adjuvant, which may be due inhibition of the precipitation by proteolysis of the
denatured protein.
The samples with ,B-Iactamase which was cross-linked were also incubated in 8M
urea and 2% SDS at 70°C for 20 minutes. Dithiothreitol (DTT) was added to a concen-
tration of 50mM and the samples were then incubated 10 minutes at room temperature
and 70°C for 15 minutes. Running the samples through a gel (Figure 6.3) showed that
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Figure 6.2: a)j3-lactamase was mixed with small amounts of trypsin and emulsified in
Freund's adjuvant. Aliquots of the emulsion were incubated for different times before
the protein was extracted. The trypsin was inactivated and the samples were loaded
on a gel with SDS. The control was j3-lactamase with the same amount of trypsin for
two hours, but had not been in Freund's adjuvant. b)j3-Lactarnase was emulsified and
extracted the same way as above, but there was no trypsin present. The extracted samples
also contained precipitates that were separately dissolved and loaded on the gel (next
to the control). The samples in image b were incubated with DTT for a short time and
some unreduced protein (band 2) can be seen further down than the reduced form of
the protein (band 1). The control was j3-lactamase incubated with the same amount of
trypsin for two hours, but had not been in Freund's adjuvant.
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Figure 6.3: Gel with fJ-lactamase which was cross-linked in Freund's adjuvant. The
samples were after extraction from the adjuvant incubated in 8M urea and 2% SDS at
700 C before they were loaded on the gel. The protein in the left lane was in addition
treated with 50mM DTT.
the cross-linked protein was still present although appearing a slightly different positions
on the gel. This suggested that the protein was not cross-linked through disulphide bonds
as they would have been expected to be reduced under these conditions.
Thermolysin and trypsin which was"cross-linked with hydrophilic polymers were
also used in the same proteolysis assay with Freund's adjuvant to test if higher rate of
proteolysis could be achieved. The enzymes were after incubation in Freund's adjuvant
inactivated by PEFA-block or phenanthroline respectively. The proteolysis results are
shown in Figure 6.4. Although the figure suggest more extensive proteolysis of the 13-
lactamase, especially with thermolysin, some full-length protein was still seen in this gel
after two hours incubation in the adjuvant.
6.2.4 Assaying denaturation of other antigens by proteolysis
fJ-Lactamase was denatured by Freund's adjuvant as shown in this chapter. The impact
of Freund's adjuvant on the state of some other model antigens used in earlier epitope
studies was also evaluated. Proteolysis experiments with trypsin as described in the
previous sections were carried out with bovine serum albumin (BSA), hen egg lysozyme
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Figure 6.4: {3-Lactamase fragments separated on a gel with SDS after incubation in
Freund's adjuvant in the presence of cross-linked trypsin. The trypsin was cross-linked
with hydrophilic polymers. Aliquots of the emulsion were incubated for different time
intervals before the protein in the water phase.was extracted. The trypsin was inactivated
before the samples were loaded on gels with SDS. Control: {3-lactamase was incubated
with or without the same amount of trypsin for six hours, but had not been in Freund's
adjuvant. The ratio of {3-lactamase to modified trypsin was 1:10 (w/w) b)The same
experiment as in image (a) but with thermolysin instead of cross-linked trypsin. The
ratio of {3-lactamase to thermolysin was 1:50 (w/w)
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Figure 6.5: BSA fragments separated on a gel with SDS after incubation in Freund's
adjuvant in the presence of trypsin. Aliquots of the emulsion were incubatedfor different
time intervals before the protein in the water phase was extracted. The trypsin was
inactivated with PEFA-block before the samples were loaded on a gel with SDS. The
control was BSA incubated with the same amount of trypsin for two hours, but had not
been in Freund's adjuvant. The ratio ofBSA to trypsin was 1:100 (w/w).
(HEL) and horse cytochrome c. The results are presented in Figure 6.5 and 6.6. The BSA
was proteolysed by trypsin in Freund's adjuvant but was resistant to the same trypsin
concentration outside the adjuvant. This suggests that Freund's adjuvant denatured BSA.
No proteolysis of hen egg lysozyme (HEL) and horse cytochrome c in the adjuvant was
observed even at a trypsin to antigen ratio 1:10 (w/w).
6.2.5 Antibody specificities in sera
It was obvious that some of the ,B-lactamase injected in Freund's was denatured and Fre-
und's adjuvant's influence on the antibody specificities in the antiserum was therefore
analysed. The analysis included sera from the two rabbits (rabbits' 1 and 2) immunised
with ,B-lactamase in Freund's adjuvant and the two rabbits (rabbits 3 and 4) immunised
with ,B-lactamase in PBS. Only the IgG fraction, the same as used in the epitope map-
ping, was investigated. There was not enough sera from the mice immunised with im-
munised with ,B-lactamase in Freund's adjuvant for the subsequent analyses and the two
mice immunised with ,B-lactamase in PBS did not produce detectable amounts of IgG.
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Figure 6,6: Hen egg lysozyme (HEL) (a) and cytochrome c (b) fragments separated on a
gel with SDS after incubation in Freund's adjuvant in the presence of trypsin, Aliquots of
the emulsion were incubated for different time intervals before the protein in the water
phase was extracted. The trypsin was inactivated before the samples were loaded on
a gel with SDS, The control was lysozyme!cytochrome c incubated with or without the
same amount oftrypsinfor three hours, but had not been in Freund's adjuvant, The ratio
of BSA to trypsin was 1: 10 (w/w),
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Antibody binding native or denatured protein
The rabbit antibodies were first analysed for binding to native or denatured ,B-Iactamase
in ELISA. The results are shown in Figure 6.7 (See also Figure A.l on page 146).
The biotinylated ,B-Iactamase (308C) was immobilised on streptavidin coated ELISA
plates and was denatured on the plates by reducing the internal disulphide bond by DTT
and carboxymethylating the two cysteines. The biotinylation reagent was in this case
a maleimide activated biotin-linker as the linker used in the mapping assay could eas-
ily be reduced by DTT. (The absence of native antigen was confirmed by adding the
chromogenic enzyme substrate Nitrocefin and the presence of similar amounts of native
and denatured antigen on the plates was confirmed by detecting the C-terminal FLAG-
tag (peptide tag) on the ,B-Iactamase with a secondary antibody). The serum antibodies
from the two rabbits (rabbits 1 and 2) immunised with ,B-Iactamase in Freund's adjuvant
bound both native and denatured protein. The sera from two rabbits (rabbit 3 and 4)
immunised with antigen in PBS bound strongly to native but only weakly to denatured
protein. Serum from rabbit 4 showed hardly any signal on denatured protein.
The same sera were also analysed in western blots. The ,B-Iactamase was partly di-
gested with trypsin, cyanogen bromide or Lys-C before fractionated on a gel with SDS
and then transferred to nitro-cellulose membranes. Serum antibodies were incubated
with the membranes followed by detection of antibody binding with secondary anti-
bodies conjugated to an enzyme. The results are shown in Figure 6.8. The serum anti-
bodies from rabbits 1 and 2, immunised with ,B-Iactamase in Freund's adjuvant, bound
strongly to the proteolytic fragments. The serum antibodies from rabbit 3 bound some
fragments although fewer and with less intense signal than the previous rabbits. The
serum antibodies from rabbit 4 did not recognise the fragments of ,B-Iactamase, only
full or nearly full-size protein was recognised by antibodies in this serum. Adding the
chromogenic substrate Nitrocefin to the membrane demonstrated that the two bands on
the nitro-cellulose membrane recognised by these antibodies to contained native protein
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Figure 6.7: The ELISA results with sera antibodies from rabbits immunised with antigen
in Freund's adjuvant (rabbits 1 and 2 ) or in PBS (rabbits 3 and 4). The antibodies
were assayed for their ability to bind native or denatured (3-lactamase. Only the IgG
fractions of the antibodies were analysed. The biotinylated (3-1actamase was captured
on streptavidin coated ELISA plates. The protein was denatured by reducing an internal
disulphide bond and carboxymethylating the cysteines. The serum taken 10 days after
the second antigen boost was diluted 1:25,000.
(picture not shown). These two bands were probably (3-lactamase that had migrated on
the gel in with the internal disulphide bond in intact or reduced form.
Native-specific and denatured-specific antibodies
Antibodies in sera can be divided into three groups as described in the main introduc-
tion; denatured-specific, native-specific and cross-reactive antibodies of which the latter
group bind both native and denatured antigen. Cross-reactive antibodies could therefore
have contributed to binding on both native and denatured protein in the assays described
in the previous sections. The serum from rabbit 1 was therefore also analysed for the
presence of denatured-specific and native-specific antibodies separately. Serum aliquots
were first depleted for antibodies binding native or denatured protein and the remaining
antibodies were then assayed for binding the same or the other form. The depletion was
carried out by repeatedly moving the serum aliquots between ELISA plate wells with
either denatured or native antigen. The (3-lactamase was biotinylated and captured on
streptavidin coated ELISA plates (native protein) or coated directly on ELISA plates
followed by drying the plates for one hour (denatured protein). (The latter had no de-
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Figure 6.8: Serum antibodies were assayed for their ability to bind fragmented {3-
lactamase in western blots (the five upper membranes). The bands recognised by serum
from rabbit 4 were shown to include native protein by adding the substrate Nitrocefin
to the nitro-cellulose membrane (picture not shown). Rabbit 5 is described later in this
chapter. The lower gels show Coomassie stained gels with the same fragments. The
{3-lactamase was fragmented by trypsin (a), cyanogen bromide (b) and Lys-C (c). Lane
mcoruained protein standards of known sizes.
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Figure 6.9: Serum from rabbit 1 was depleted for antibodies specific for native or de-
natured {3-lactamase. The {3-lactamase was, both during the depletion and the detection
of remaining antibodies, biotinylated and captured on streptavidin coated ELISA plates
(native protein) or coated directly on ELISA plates followed by drying the plates for one
hour (denatured protein). The denaturation was done by reducing an internal disulphide
bond and carboxymethylate the two cysteines. The background signal (no serum) was
0.017.
tectable enzyme activity). The remaining serum antibodies were assayed for binding to
the antigen displayed the same way in ELISA plates. The results are shown in Figure
6.9 and demonstrate that the serum, after depletion of antibodies that bound the native
form of {3-lactamase, still contained antibodies that bound the denatured form of the pro-
tein. These antibodies represented denatured-specific antibodies since the cross-reactive
antibodies had been removed. Serum aliquots depleted for antibodies that bound the
denatured form of the antigen in contained antibodies that bound the native form of the
protein. These antibodies represent native-specific antibodies since the cross-reac_tive
antibodies also in this case had been removed.
Cross-reactive antibodies
The serum from rabbit 1 was further assayed for presence of cross-reactive antibodies.
-Serum antibodies were affinity purified on native or denatured (carboxymethylated) {3-
lactamase (308C). These antibodies were then examined for their ability to bind de-
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Figure 6.10: Cross-reactive serum antibodies Jrom rabbit 1. The antibodies were affinity
purified on native or denatured fJ-Iactamase and then assayed Jor binding to denatured
or native protein respectively. The fJ-Iactamase was biotinylated and captured on strep-
tavidin beads during the affinity purification and on streptavidin coated ELISA plates
during the detection. The protein was denatured by reducing an internal disulphide
bond and carboxymethylate the cysteines. The same amount oj serum and beads were
usedJor all the samples. The background signal was 0.011.
natured or native protein respectively which was presented on ELISA plates as described
earlier. The results are shown in Figureri.lf). The serum contained antibodies that both
could be affinity purified on native protein and bound denatured protein and vice versa.
The presence of these cross-reactive antibodies were also confirmed by western-blot as
shown in Figure 6.11. Serum antibodies affinity purified on native protein were assayed
for binding to fJ-Iactamase fragments on a nitro-cellulose membrane. The serum obvi-
ously contained antibodies that could bind both native protein in the affinity purification
and shorter fragments of the protein as shown on the nitro-cellulose membranes in the
western blots.
6.2.6 Mapping of cross-reactive antibodies
The epitopes of the cross-reactive antibodies were mapped separately as they were ex-
pected to play an important role in the epitope distribution as discussed later. The map-
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Figure 6.11: Western-blot with cross-reactive antibodies. Serum antibodies from rabbit 1
were affinity purified on native {3-lactamase. The eluted antibodies were then allowed to
bind fragments of {3-lactamase on a nitro-cellulose membrane shown in the two lanes on
the left. Bound antibodies were detected with anti-rabbit antibodies conjugated to HRP.
The two lanes on in the middle and the two lanes on the right are Coomassie stained gels
with the same protein fragments as used in the on the membrane. Lanes a and b were
fragments of {3-lactamase digested with cyanogen bromide or Lys-C respectively. Lane
m contained protein standards of known sizes.
ping assay was essentially carried out as described in chapter 3 with the exception that
the depletion step (isolation of antibodies specific for each CTR) was followed by affin-
ity purification of antibodies on native protein (biotinylated 308C) and then analysis of
binding of these antibodies to denatured {3-lactamase. (The protein was denatured by
coating directly on ELISA plates followed by drying the plates for one hour. This (3-
lactamase had no detectable enzyme activity). The result from this epitope mapping are
shown in Figure 6.12 together with the mapping results for the cross-reactive plus the
native-specific antibodies described in chapter 4. The two epitope patterns in this fig-
ure did both show the highest signal in the loop region D85 to V119. The difference in
the signals on CTR-271 and CTR-281 in plot b) and a) may well have been due native-
specific antibodies as these were removed in plot a). Differences in antibody binding to
{3-lactamase captured on beads during the affinity purification or plates during detection,
as discussed in chapter 3, may also count for some of the variations in the epitope pat-
terns between these two plots.
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Figure 6.12: The distribution of cross-reactive antibodies from rabbit 1on the surface
of (3-lactamase (a) and cross-reactive plus native-specific antibodies (b). The latter plot
is the same as in Figure 4.1a. Mapping of the cross-reactive antibodies alone was done
by isolating of serum antibodies against each CTRs, as described for the main assay in
chapter 3, followed by affinity purification on native {3-lactamase and detection of bind-
ing on denatured {3-lactamase. The {3-lactamase had been denatured by coating directly
. on ELISA plates which were then driedfor one hour. Cross-reactive and native-specific
antibodies were mapped together as described in chapter 3. The serum concentrations
were in 1:10,000 in both experiments.
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Figure 6.13: CD scans of native, carboxymethylated and heat denatured {3-1actamase.
6.2.7 Immunisation with denatured protein
One question arising from this work was whether immunisation with denatured pro-
tein can give raise to antibodies recognising native protein. One rabbit (rabbit 5) was
therefore immunised with irreversibly denatured {3-lactamase. The {3-lactamase was
denatured by reducing the internal disulphide bond and carboxymethylating the two
cysteines. Circular dichroism (CD) spectroscopy was used to examine if the carboxy-
methylated protein had any residual secondary structure and the results are shown in Fig-
ure 6.13. Reversible thermal denaturation was not obtained for the carboxymethylated
{3-lactamase and the folding energy of this protein was therefore not be calculated. The
CD curves indicate that the carboxymethylated protein has more secondary structure
than the heat denatured protein but less than the native protein. The carboxymethylated
protein was still believed to be denatured as it had an enzyme activity of about 1:10,000
compared to the native protein. The carboxymethylated {3-lactamase was also highly
susceptible to proteolysis in contrast to native {3-lactamase which was resistant to prote-
olysis under the same conditions as shown in Figure 6.14.
The carboxymethylated {3-lactamase was injected with Freund's adjuvant. The bind-
ing of the serum antibodies from the different test-bleeds to native or denatured {3-
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Figure 6.14: Native and denatured (carboxymethylated) protein treated with trypsin. The
ratio of {3-lactamase to trypsin was 1:100 (w/w) (except lane * which was 1:25 (w/w)).
The samples were run on a gel with SDS. The native samples contain 10f-1gprotein and
denatured samples contain 4.7p.gprotein.
lactamase are shown in Figure 6.15. The serum antibodies did recognise the native
biotinylated {3-lactamase (308C) on a streptavidin coated ELISA plate. This means that
the carboxy methylated {3-lactamase, which was not in native conformation, induced the
production of antibodies that nevertheless recognised the native protein. The ability of
serum antibodies from rabbit 5 to capture {3-lactamase from solution was poor as shown
in Table 6.l. The difference in antibody binding to antigen in solution or immobilised
on a solid surface was probably due to low affinities as binding to the antigen captured
on solid the phase is likely to have been enhanced by the avidity of IgG.
6.2.8 Mapping anti CM-tJ-lactamaseantibodies
The epitope distribution in the sera from rabbit 5, immunised with carboxymethylated
{3-lactamase, was also examined by the mapping method described in chapter 3. The
results are shown in Figure 6.16. The epitope pattern revealed (after subtracting a high
signals on "Masked" as discussed bellow) two surface regions dominating the epitope
distribution on the native {3-lactamase. These are located around the CTRs 90, 110 and
114 and the CTRs 197,201 and 202.
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Figure 6.15: Serum from rabbits 2 and 5 were tested for the ability to bind native {3-
lactamase. Biotinylated {3-lactamase was immobilised on streptavidin coated ELISA
plates. Rabbit 2 and 5 were immunised with {3-1actamase or carboxymethylated {3-
lactamase in Freund's adjuvant respectively.
Table 6.1: Serum antibodies displayed on ELISA plates coated with anti-rabbit anti-
bodies were used to immobilise {3-lactamase added in solution. The enzyme activity of
{3-lactamase was used to detect bound protein (second column). The relative amount
of serum antibodies on the plate was detected by a secondary antibody (last column) to
allow comparison of the signal in column two.
Rabbit Detected Detected
{3-lactamase rabbit antibodies
[mOD/min] [OD]
Rabbit 1 14.35 0.576
Rabbit 2 22.36 0.677
Rabbit 3 25.75 0.614
Rabbit 4 23.98 0.652
Rabbit 5 0.66 0.538
Background 0.19 0.011
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The epitope mapping of serum from rabbit 5 gave high signals on "Masked" (Figure
6.16). It is assumed that this was due to large amounts of antibodies with low affinity
for the native protein. The fact that for some CTRs, the signal "Masked" is greater than
"Exposed" appears to be due to the presence of denatured antigen in these CTRs (mu-
tants) (as established by the monoclonal antibodies in chapter 2).
6.3 Discussion
The results in this chapter show clearly that j3-lactamase was denatured by Freund's ad-
juvant. The half-life time of the native j3-lactamase in Freund's adjuvant was about 21
minutes. The fitted line in Figure 6.1 does not extrapolate back to 1.0 in the normalised
plot, but starts at 0.25. The initial loss of 75% may have been due to denaturation of the
protein during the emulsification process or denaturation during the extraction process
of which the latter would be an artefact in the assay. But none of these interpretations
would change the slope of the line in Figure 6.1. Ether which was used in the extraction
did not denature j3-lactamase in PBS and co-extracted chemicals from Freund's adjuvant
reduced the activity by 30% did only account for a smaller part of the initial loss in en-
zyme activity.
The animals were injected typically one hour after the antigen was emulsified in the
adjuvant. With the half-life time of the native j3-lactamase in the adjuvant of 21 minutes,
approximately 14% would have remained native after one hour, assuming that the initial
75% drop observed in the enzyme activity was due to an artefact of the extraction pro-
cess used in the analysis of the protein. If the initial drop in contrast did take place in the
emulsification process, then only 3.5% of the antigen would have remained native when
injected into the animals. In both cases the vast majority of the j3-lactamase would have
been denatured before injected into the animals. Freund's adjuvant is in addition very
stable in animals [Herbert, 1968] and the antigen would therefore have had even more
time to denature in the adjuvant after injection.
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Figure 6.16: Epitope distribution for rabbit 5. a) Signals on "Exposed" and "Masked"
for each CTR. b) The relative distribution of serum antibodies to different surface lo-
cations for rabbit 5. The signals are normalised to give an average of 1. The signals
on "Masked" are subtracted and negative values are set to zero. The average value is
indicated with a full line. The dotted lines indicate half the average signal and double
the average signal. The sera concentrations in the mapping assay was 1:30,000. The
rabbit was primarily injected with carboxymethylated j3-lactamase in FCA followed by
carboxymethylated j3-lactamase in FIA infirst and second boost.
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The denaturation of ,B-Iactamase in Freund's adjuvant was also verified by adding
trypsin to the emulsion as this proteolysis experiment was independent of the enzyme
activity of ,B-Iactamase. The results clearly show that the protein changed conformation
when it was added to the adjuvant. But there was still a significant amount of full-length
,B-Iactamase left after incubation with trypsin in the adjuvant for two hours, even though
the vast majority of ,B-Iactamase had lost the enzyme activity after same period of time
in the adjuvant. The discrepancy may be due to denaturation or self-digestion of the
trypsin in Freund's adjuvant. Adding large amounts of the trypsin would have made
it difficult to distinguish fragments of ,B-Iactamase from cleaved fragments of trypsin.
Modified trypsin and thermolysin were therefore used in an attempt to identify proteases
which are more resistant to Freund's adjuvant. The modified trypsin was cross-linked
with hydrophilic polymers which may make it more resistant to denaturation in the ad-
juvant. The experiments with the modified trypsin and thermolysin showed a fast initial
reduction of the amount of the full length ,B-Iactamase, but the full length ,B-Iactamase
was not entirely removed by the proteases. The proteases chosen for this experiment
could be completely inactivated before the protein samples were mixed with the dena-
turing sample buffer and heat-treated. This was important to avoid any degradation of
,B-Iactamase after extraction from the adjuvant. The controls showed that the proteases
were successfully inactivated as no framented protein could be seen in samples that con-
tain the proteases but had not been in Freund's adjuvant.
Exposing ,B-Iactamase to Freund's adjuvant caused cross-linking of the protein. The
stability of dimmers and multimers in the presence of DTT and high urea concentra-
tions indicated that they were not cross-linked through disulphide bonds, but through
other kinds of covalent linkage. Treatment with DTT slightly reduced the mobility of
the protein on gels with SDS. This was probably due to reduction of the intact intra-
molecular disulphide bond also present in the native monomeric protein. This suggests
that the cysteines were not involved in the covalent cross-linking. The absence of the
. cross-linked protein in the samples that had been co-incubated with trypsin in the adju-
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vant indicated that the multimers probably were denatured protein. The multimerisation
was not dependent on the extraction method used which implies that it was an effect of
the adjuvant. The cross-linking of the antigen is thought have been caused by peroxides
in the adjuvant, but no analysis was carried out to test this hypothesis.
The ,B-Iactamase, which was expressed and purified from E. coli, was probably na-
tive as discussed in chapter 2, but immunisation with this antigen in Freund's adjuvant
gave sera with antibodies that bound strongly to the denatured protein and some of the
antibodies did only bind the linear form of the protein. This is consistent with the re-
sults which showed that the adjuvant denatured the antigen. The rabbits immunised with
antigen in PBS produced only low titres of antibodies recognising denatured protein as
expected if the injected protein was native.
Both carboxymethylated and fragmented protein were here used as examples of de-
natured protein. The results did therefore give strong evidence for lack of cross-reactive
or denatured-specific antibodies in the serum from rabbit 4 as this serum showed no bind-
ing to the carboxymethylated protein in ELISAs or to the fragments in western blots. The
only bands in the western blots that bound antibodies in this serum, had the apparent size
of full-length protein and were shown to contain native protein. No binding of denatured
protein by serum from rabbit 4 was therefore proved, and the lack of binding to the
smaller fragments suggests that this sera did not bind denatured ,B-Iactamase at all. The
serum from rabbit 3 did to some extent recognise some of the ,B-Iactamase fragments
in the western blots. This did not contradict the ELISA results as even weak binding
was expected to give signal in the western blots due to the high density of homogeneous
antigen fragments in each band.
The rabbits immunised with Freund's adjuvant produced cross-reactive and denatured-
specific antibodies as expected since the adjuvant contained large amount of denatured
antigen. An important question was then if the denatured protein could change the epi-
. tope distribution detected on the native protein. If this was the case then one may expect
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that the cross-reactive antibodies did play an important role in the epitope response as
described in more detail later. These antibodies did dominantly bind the same flexible
loop region, D85 to Vl19, which also dominated the antibody responses in the animal
immunised with ,B-Iactamase in Freund's adjuvant.
Immunisation with chemically denatured protein showed that denatured protein in
the previous experiments may have induced production of antibodies that recognise the
native protein. The chemically denatured protein used could not have refolded inside
or outside the adjuvant as both the cysteines were irreversibly carboxymethylated. Lack
of enzyme activity and susceptibility to proteolysis showed also that the protein was
denatured. The antibodies from this rabbit that bound the native protein were mapped to
CTRs that formed two groups on the surface. All the CTRs in first group were located
in the loop region D85 to Vl19 with highest backbone mobility and also including the
dominant epitope in the animals immunised with ,B-Iactamase in Freund's adjuvant. The
other region included the sequence in ,B-Iactamase with the second highest backbone
mobility (see Figure 4.7). This region did also have relative high response of cross-
reactive antibodies in serum from rabbit 1 as shown in this chapter and was one of the
few regions with antibody response in the four mice immunised with ,B-Iactamase in
Freund's adjuvant.
6.4 Conclusion
The ,B-Iactamase was denatured in Freund's adjuvant. The amount of native ,B-IaGtamase
in Freund's adjuvant went through an exponential decay with a half-life of about 20 min-
utes and some of the ,B-Iactamase had probably also been denatured in the emulsification
process. The vast majority of the ,B-Iactamase was denatured when injected into the an-
imals with Freund's adjuvant. It was further shown that the serum from rabbit 1 had
cross-reactive antibodies which may have linked the denaturation of the protein to the
epitope distributions seen when using Freund's adjuvant. Mapping of the cross-reactive
antibodies or cross-reactive plus native-specific antibodies from this rabbit gave similar
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epitope distributions. It was further shown that displaying denatured protein to the im-
mune system could give rise to antibodies recognising native protein. These antibodies
were directed against two regions on the surface and included the loop region with high-
est signals in the animals immunised with the ,B-Iactamase in Freund's adjuvant.
Chapter 7
Discussion
7.1 Introduction
The immune systems' ability to efficiently fight pathogens is augmented by production
of antibodies that specifically bind the foreign antigens. Revealing which parts of the
antigen that are recognised by antibodies is important for understanding how the hu-
moral immune system works. Itmay also further help us in designing vaccines that aid
the immune system to efficiently fight the pathogens. The data collected by the novel
mapping method presented in this thesis give a systematic picture of the relative epitope
distribution on the three-dimensional protein surface. The results also demonstrate seri-
ous flaws in earlier epitope studies. The work presented here will hopefully aid to a more
precise evaluation of the relationship between the intrinsic properties of the antigen, the
nature of inoculation and the epitope distribution.
7.2 Main discussion
The aim of this work was to find the relative distribution of epitopes on a protein antigen
and to understand the principles behind the epitope distribution. An important property
of the presented epitope data to have in mind during the analysis is that only antibodies
able to bind the native protein, native-specific and cross-reactive antibodies, were de-
tected in the mapping assay. This property separates these data from all epitope data
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based on fragments of the protein antigens. As pointed out in the introduction, a large
portion of anti-protein antibodies do not bind protein fragments [Lando et al., 1982b].
Two rabbits and four mice were immunised with the model antigen ,B-lactamase in
Freund's adjuvant. All six animals had the highest antibody response against the same
loop region of the antigen. This biased antibody distribution is not likely to be the result
of a random selection of the antigen surface in all six animals. There was further no indi-
cation of artefacts in the mapping assay that had caused the observed epitope dominance.
Intrinsic properties of the protein must therefore somehow have influenced the epitope
distribution. One possibility is that the repertoires of antibody receptors on unchallenged
B cells were biased against some surface properties of the antigen. But there were results
that indicated that the immunisation method used modified the epitope distribution. It
was regarded as important to clarify what influence Freund's adjuvant may have on the
epitope distributions as the vast majority of previous epitope studies with model antigens
have been based on immunisation with this adjuvant.
Two rabbits were immunised with native protein in PBS to see what the epitope
distributions look like without the influence of the adjuvant. Comparison of the serum
antibodies from these rabbits with the serum antibodies from the rabbits immunised with
Freund's adjuvant imply that the adjuvant did have an impact on the antibody distribu-
tion even though few animals were analysed. The antibodies produced after injection
of ,B-lactamase in PBS were more evenly distributed over the antigen surface than anti-
bodies produced after injection of ,B-lactamase in Freund's adjuvant. The relatively even
epitope distribution or lack of dominant epitopes did not support that the repertoires of
antibodies on unchallenged B cells were biased against antigen surfaces with particular
properties. The results further implied that data from epitope studies based on immuni-
sation with Freund's adjuvant, which includes the vast majority of earlier epitope studies
with model antigens, need to be reinterpreted.
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The sera from the rabbits injected with ,B-Iactamase in Freund's adjuvant had some
hints to how the adjuvant may have influenced the epitope distribution. There are good
reasons to believe that the ,B-Iactamase initially was native. It was resistant to proteoly-
sis. No cleavage products were seen in the presence of trypsin. The carboxymethylated
protein was in contrast very sensitive to proteolysis and was easily cleaved into smaller
products. The protein used in the immunisation also had the same enzyme activity as
the C-terminal cysteine mutant 308C. The latter contained no denatured protein as ver-
ified with a denatured-specific monoclonal antibody. The rabbit sera froin the rabbits
injected with ,B-Iactamase in Freund's adjuvant contained antibodies that bound strongly
to denatured protein. Some of these antibodies were only able to bind the protein in
denatured state. (The volumes of the mouse sera were too small for a detailed analysis.)
This showed that denatured antigen had been presented to the immune system.
Results from two independent methods demonstrated that Freund's adjuvant de-
natured ,B-Iactamase. The rate at which ,B-Iactamase lost its enzyme activity in the adju-
vant showed that the vast majority of this antigen was denatured before injected into the
animals. A significant amount of the denatured antigen was also covalently cross-linked
in the adjuvant. Although some of the denatured monomeric protein may have folded
back to native conformation when released from the adjuvant it was very unlikely to be
the case for the covalently linked antigen. The presence of serum antibodies specific for
either denatured or native protein suggests that both native and denatured antigen were
presented to the immune system of the rabbits.
The most obvious difference in the specificities of the antibodies from the two groups
of rabbits was that the antibodies produced in response to antigen in PBS bound poorly
to denatured protein in contrast to the antibodies produced in response to antigen in Fre-
und's adjuvant. Some of the antigen delivered in PBS may have been denatured before
being presented to the B cells. But the lack of serum antibodies that bound the de-
natured protein, especially in rabbit 4, implied that very little, if any, of the protein was
. denatured. Lando et al. [1982b] showed that 30-40% of anti-sperm whale myoglobin
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(Mb) antibodies did not recognise peptide fragments of Mb. Their data were based on
serum from animals immunised with Mb in Freund's adjuvant. The results in this thesis
suggest that the fraction of antibodies only binding native protein can be significantly
higher if only native protein is used for immunisation. Lando and Reichlin [1982a] fur-
ther demonstrated that the sera included denatured-specific antibodies which supports
the assumption that denatured protein were present in their immunisation in with Mb in
Freund's adjuvant. The change in amount of antibodies that bind denatured protein was
also shown by Scibienski [1973] in immunisation experiments with hen egg lysozyme
(HEL). He showed that antibodies produced in response to HEL emulsified in Freund's
adjuvant bound both native and denatured HEL, and in contrast, that injection of HEL in
PBS gave antibodies that bound native but not denatured HEL.
These results do also have important implications for epitope data collected with
fragments of antigens when Freund's adjuvant is used in the immunisation. Most of
the antibodies that recognised the linear form of the ,B-Iactamase, including the cross-
reactive antibodies, were produced in response to the protein which was denatured by
the adjuvant. Freund's adjuvant has therefore affected the majority of epitopes detected
by fragments of the antigen.
Freund's adjuvant was clearly connected to the denaturation of the protein. It was
important to establish if this significant impact on the protein structure of denaturation
by Freund's adjuvant was connected to the adjuvant's influence on the epitope distribu-
tion on the native protein. Activation and later selection of B cells is depending on their
ability to bind the antigen. B cells specific for both denatured and native antigen may
have had a selective advantage over B cells specific for a single form of the antigen if
both forms of the antigen were present. Somatic mutation may have altered the B-cell
receptors preference for the form of antigen and the specificities of the antibodies later in
the immune response may therefore not have directly mirrored the distribution of antigen
form that initiated the antibody production.
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The presentation of denatured protein to the immune system may have influenced the
epitope distribution in at least two ways. The B cells may initially have been induced by
native protein to produce antibodies. The B-cell clones bearing cross-reactive antibody
receptors could at later stages have been boosted by denatured antigen. Another expla-
nation could be that denatured protein induced production of antibodies that also were
able to bind some parts of the native protein.
Both theories require that cross-reactive antibodies were present at least in some
stages of the immune responses. The presence of cross-reactive antibodies in the rab-
bits after immunisation with Freund's adjuvant therefore supports the theory that de-
natured protein may have influenced the epitope distribution. The distribution of the
cross-reactive antibodies in rabbit 1 was very similar to the distribution pattern seen for
all the antibodies specific for the native protein (including both cross-reactive and native-
specific antibodies). This therefore supports that the cross-reactive antibodies were an
important part of the epitope distributions. This also strengthens the theory that the anti-
gen which was denaturation by the adjuvant was connected to the epitope distribution on
the native protein.
If the first of the two theories above is correct, that denatured protein can induce
production of antibodies that recognise the native protein, then it should be possible to
immunise with only denatured protein and subsequently detect antibodies on native pro-
tein. Immunisation with chemically and irreversibly denatured protein did give raise to
antibodies that bind native protein even though with low affinities. Antibodies from this
rabbit gave high signal on the same surface region which was dominating the response
in the animals immunised with ,B-Iactamase in Freund's adjuvant. This supports the the-
ory of a connection between the denatured antigen and epitope distribution on the native
antigen, even though it does not prove that the antibodies dominating the epitope dis-
tributions in the animal immunised with unmodified ,B-Iactamase in Freund's adjuvant
were induced by denatured or native antigen.
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The conclusion that denatured protein can induce antibodies that recognise native
protein is different from the hypothesis from Richard Lerner's group who claim that
even small peptides are likely to induce production of antibodies that recognise native
protein [Wilson et al., 1984, Green et al., 1982]. They analysed anti-peptide antibodies
ability to bind the full size protein which was dried onto plastic plates and washed with
methanol. These conditions are likely to denature the antigen molecules. This is con-
firmed by their results as one of the epitopes they detected this way is not accessible on
the native protein.
The knowledge about what the relative epitope distributions looked like with and
without Freund's adjuvant opened the possibility to predict how the adjuvant affects the
epitopes on the different parts of the antigen surface and to explain the observed epitope
patterns. The best clue to how the adjuvant may have influenced the epitope distribution
is probably the positive correlation between backbone mobility and epitope distribution
as observed with sera from the rabbits immunised with antigen in Freund's adjuvant.
This correlation was almost absent for the sera from rabbits immunised with antigen
in PBS and is therefore most likely reflecting an effect of the adjuvant. The dominant
epitope observed in the six animals immunised with antigen in Freund's adjuvant was
in a long loop region. This may be an important connection between the denatured pro-
tein and the epitope distribution on the native protein. A possible explanation is that
antibodies raised against denatured protein were most likely to bind the regions on the
native protein with high mobility since these regions would have had a better chance
of adopting into predefined binding surfaces (paratopes) on the antibodies. This is sup-
ported by the results that showed that immunisation with irreversibly denatured protein
can give rise to antibodies that bind native protein. The antibodies that followed from
this immunisation recognised several surface regions on the native protein that clustered
together in the two patches with highest backbone mobility. One might also think that
antibodies raised against linear forms of the protein would bind sequential epitopes. The
most sequential epitopes on the protein surface are loops and protruding regions [Bar-
low et al., 1986] which in general are also more flexible than regions with secondary
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structure [Novotny et al., 1986]. Linear components of the antigen surface were there-
fore probably important factors for the antibody response to antigen administered in
Freund's adjuvant. This is also supported by the fact that the isolated cross-reactive anti-
bodies from rabbit 1 bound predominantly in the same long loop region. Cross-reactive
antibodies were at very low levels or absent in the two rabbits immunised with antigen
in PBS.
Westhof and his colleagues [Westhof et al., 1984] reported a positive correlation be-
tween the backbone mobility and linear epitopes in myoglobin, lysozyme and tobacco
mosaic virus protein. The epitope data in their study were collected from animals immu-
nised with the antigens in Freund's adjuvant. The results presented in this thesis suggest
that the correlation can be an artefact of using Freund's adjuvant.
Although no strong correlation was detected in this work between backbone flexibil-
ity and epitope distribution from responses to native protein there may well be intrinsic
properties of proteins that to some extent could bias the epitope distribution. The epitope
response may have been the product of as a relatively even distribution on the antigen
surface due to a random selection of B cell clones superimposed by biasing factors as
seen with backbone mobility in the presence of Freund's adjuvant. The presentation of
the complete antigen surface to the immune system, by injecting the antigen in PBS,
reduced the chance of backbone mobility to modify the epitope distribution and only a
weak, if any, correlation was detected with the backbone mobility.
The epitope mapping results from sera of the rabbits immunised with antigen in PBS
support the conclusion in reappraisal by Benjamin et al. [1984] that the whole protein
surface is antigenic or more precisely; "The surface of a protein antigen consists of a
complex an"ay of overlapping potential antigenic determinants; in aggregate these ap-
proach a continuum." The conclusion is based on potential antigenic residues reported
in several earlier epitope studies. The results presented in this thesis did not show that
the epitopes form a continuum on the surface, but verified that most of the antigen sur-
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face is antigenic. Benjamin and his colleagues may well be wrong in arguing that their
discussion is limited to studies where antibodies were elicited by immunisation by native
protein. At least the majority of the studies they discuss were based on immunisation
with Freund's adjuvant, which is likely to denature several antigens as discussed below.
But there are no indications in the data presented in this thesis which indicate that their
main conclusion is wrong.
The collection of data presented in the reappraisal by Benjamin and his colleagues
establishes which parts of the antigen surfaces are recognised by antibodies but it did not
provide information on the relative importance of each epitope. The results presented in
this work extend the knowledge on epitope distribution by adding information on the
relative concentrations of antibodies to different parts of the antigen surface. The fairly
even distribution observed in animals immunised with native protein suggests that the
immune system has evolved to recognise all protein surfaces equally well. This may
be an important aspect of the immune systems battle against pathogens, for example to
avoid that pathogens escape antibody recognition through a selection of surface proper-
ties that are unfavourable for binding of the antibody repertoire.
An aspect of the relative epitope data that should be considered is the kind of distri-
bution they represent. Assays based on ELISA measure combinations of the antibody
concentrations and affinities. The antigen was in the ELISA format used in this work pre-
sented on a solid phase. This did probably allow bivalent binding of the IgG molecules.
Most antibodies with affinities above a low threshold (not quantified) were expected to
bind and contribute to the signal in such epitope mapping assays. This means that the
epitope data presented here most likely represent the concentrations of antibodies to the
different regions of the antigen surface. Data that represent the distribution of epitope
affinities on the antigen surface may reveal more about the antigenicity distribution.
An important question to raise in this context: Are other protein antigens than {3-
lactamase denatured by Freund's adjuvant. Results from two independent methods
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showed that ,8-lactamase was extensively denatured by Freund's adjuvant. This was
also supported by specificities of the antibodies produced against ,8-lactamase in Fre-
und's adjuvant or PBS. Proteolysis experiments showed that also bovine serum albumin
(BSA), a commonly used model antigen, was denatured by Freund's adjuvant. BSA lost
its proteolytic resistance to trypsin, in the same way as ,8-lactamase, when emulsified in
the adjuvant. This was not shown for the commonly used antigens horse cytochrome c
or hen egg lysozyme (HEL). The results from the immunisation studies carried out by
Scibienski [1973] with HEL (described earlier) suggest that Freund's adjuvant denatures
HEL. It can therefore not be excluded that other proteins, like cytochrome c, may be
denatured by Freund's adjuvant without detectable loss in resistance to trypsin with the
method used here. Immunisation with sperm whale myoglobin (Mb) in Freund's adju-
vant carried out by Lando and his colleagues [Lando and Reichlin, 1982a] gave rise to
a fraction of antibodies only binding the antigen in denatured form. Denatured protein
must therefore have been presented to the immune system. They showed that antibodies
isolated by fragments of the protein did not bind whole Mb which implies that the pro-
tein they also used for immunisation was native prior to the emulsification in Freund's
adjuvant and further that the protein was denatured in the immunisation process. Not
all proteins are necessarily denatured by Freund's adjuvant. The electromagnetic reso-
nance spectrum of the heme group in hemoglobin is dependent on the folding state of
the protein. Berzofsky et aI. [1976] examined electromagnetic resonance spectrum of
hemoglobin in Freund's adjuvant and found no denaturation of the protein.
The inoculation regimes may influence the epitope distributions. Delivering the
model antigen in Freund's adjuvant did probably resemble a typical ihfection by the
slow release of antigen due to the stability of the adjuvant in the animals [Herbert, 1968].
The antigen injected in PBS was, in contrast, instantly accessible to extracellular liquid
and was probably displayed to the immune system in a shorter period. Injection of ,8-
lactamase in PBS did still induce secondary antibody responses as judged by the titters
of IgG [Bandilla et aI., 1969]. Most immunisation methods with simple antigens will
have artificial elements. Although injecting antigen in PBS is not the optimal for mod-
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elling a natural infection, complication as denaturation or other epitope discriminating
factors were avoided.
To study the relationship between intrinsic protein properties and antigenicity it is of
great advantage to avoid host regulation due similarities between antigen and the host
proteins. A lot of the previous collected epitope mapping data are based on model anti-
gens with homologues in the immunised species as cytochrome c [Jemmerson and Mar-
goliash, 1979], serum albumin [Benjamin and Teale, 1978], myoglobin [East et al., 1982]
and lysozyme [Metzger et al., 1984]. The study by Jemmerson and Margoliash [1979]
clearly demonstrated the influence of self-protein on the epitope distribution on a homo-
logue antigen. They fractionated antibodies from rabbit serum against horse cytochrome
c into seven subpopulations, comprising all the cytochrome c specific antibodies, by
using other cytochrome c homologues. The binding of all seven sub-populations was
dependent on four of the six amino acids where rabbit and horse cytochrome c differ.
The two remaining positions are adjacent to the other four. The rabbits produced anti-
bodies to the regions where the antigen differed from the self-protein (homologue). The
antibodies produced in these situations will obviously be the outcome of a combination
of initial generation of antibody specificities and host regulatory mechanisms. Informa-
tion on epitope distributions, for example dominant epitopes, identified in such immune
responses will only have meaning when described in relation to the host's homologue
protein. Data from these studies are not useful for evaluating (or predict) relative epitope
distribution based on the antigen structure only. The topographic epitopes presented in
this thesis are mapped on a model antigen with no expected homologue in the immu-
nised species as ,B-Iactamase is bacterial protein. ,B-Lactamase was in this study treated
as a completely foreign antigen which dramatically simplified the connection between
observed epitopes and properties of the antigen surface.
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7.3 Final conclusion
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A method was developed to determine the antigenicity of different regions of the sur-
face of the model antigen j3-lactamase. The method involved the construction of a set of
mutant antigens in which cysteine residues had been introduced at different points in the
surface of the antigen. Each mutant protein was tethered through the surface cysteine
residue and a bifunctional chemical cross-linker to solid phase, allowing the creation of
an array of mutant antigens, each oriented so as to expose or to mask different topologi-
cal regions of the antigen surface. The 23 mutants prepared represented a relatively even
distribution of tethering points on the antigen surface, which at most should have about
13 mutually exclusive antibody epitopes. All the mutants had enzyme activity which
demonstrated that they all contained native protein. Binding of a set of monoclonal anti-
bodies to the mutants was further shown to be sensitive to the orientation of the antigen.
Presentation of the array of oriented antigen to rabbit or mouse serum allowed binding
and subtraction of serum antibodies that were not blocked by the cross-linker. The re-
maining antigen specific antibodies, representing the epitopes that were masked in each
orientation, could then be quantified through binding to the antigen oriented to display
these epitopes. The j3-lactamase used to quantify the antibodies contained no denatured
protein as verified by a monoclonal specific for the denatured form of the protein. The
epitope data were therefore limited to the antibodies that bound native protein. The rela-
tive epitope data from this assay represented topological maps of the antibody responses
and could be used to compare the response in different animals to the three-dimensional
antigen surface.
When the immunisations were undertaken with use of Freund's adjuvant, the anti-
body response to j3-lactamase was mainly directed against a region centered on a flexi-
ble loop. The loop region dominated the antibody response in all six animals immunised
this way. The sera furthermore comprised antibodies cross-reactive to both native and de-
natured protein. These cross-reactive antibodies also dominantly bound the flexible loop.
By contrast, in the absence of Freund's adjuvant, the antibody response was more evenly
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distributed, and with few cross-reactive antibodies. This suggested that Freund's adju-
vant denatures ,B-Iactamase and that the appearance of dominant epitopes may follow the
presentation of denatured protein to the immune system. Analysis of the enzyme activ-
ity of ,B-Iactamase in Freund's adjuvant showed extensive denaturation of the protein in
the adjuvant and a half-life of the native protein of about 21 minutes. The denaturation
was also confirmed through the protein's loss of resistance to proteolysis when mixed
with the adjuvant. The denatured antigen's ability to induce or boost antibody clones
specific for flexible loops on the native protein was also supported by the data showing
that a rabbit immunised with irreversibly denatured protein produced antibodies which
recognised native protein. Mapping of the epitopes on the native ,B-Iactamase showed
that these antibodies bound the two parts of the protein with the highest backbone flex-
ibility. This included the same loop region which dominated the antibody response in
the six animals immunised with the antigen in Freund's adjuvant. The observations have
implications for understanding the basis for dominance of B-ceU epitopes, and also for
design of vaccines.
Chapter 8
Materials and Methods
For a list of chemical and material see page 161.
8.1 General methods
8.1.1 rca amplification
50 J.lIreactions were prepared containing 25 pmol of each primer, 2.5 units of superTaq
DNA polymerase (Enzyme Technologies), 200 J.lM of each dNTP and the recommended
buffer (50 mM KCI, 10 mM Tris·HCI pH 8.8, 1.5 mM MCI2, and 0.1% Triton X-lOO)
and DNA from a picked colony or purified DNA as templates. The samples were de-
natured for five minutes at 94°C followed by 30 cycles: 94°C for one minute, 55°C for
one minute and 72°C for one minute. The cycles were followed by five minutes at 65°C.
The lid was kept at 105°C.
8.1.2 DNA sequencing analysis
The ,B-Iactamase gene was amplified with 30 cycles of PCR synthesis using the primers
5'-CAG GAA ACA GCT ATG AC-3' and 5'-GTA AAA CGA CGG CCA GT-3'. The PCR
products were purified with Qiagen QIAquick PCR purification kit. Sequencing was
performed using the dideoxy chain termination method [Sanger et aI., 1977] with ABI
PRISM BigDye terminator mix. The Sequencing reactions were primed with the primers
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5' -CAGGAAACAGCTATGAC-3', 5' -GTAAAACGACGGCCAGT-3', 5' -GAGCAACTC
GGT CGC CGC ATA-3'and 5'-TTC CCG GCA ACA ATT AAT AGA-3'. Sequences were
analysed on an Applied Biosystems 373 Automated DNA sequencer (Perkin Elmer).
DNA sequence analysis was conducted using SeqEd (Applied Biosystems).
8.1.3 Protein gels
Protein gels were Nowex NuPage 10% or 12% precast Bis-Tris polyacrylamide gels.
The electrophoresis was done at 200 V for 35-40 minutes. The buffer was either MES
(50 mM 2-N-morpholine ethane sulfonic acid, 50 mM Tris Base, 3.5 mM sodium do-
decyl sulphate (SDS), 1 mM EDTA) or MOPS (50 mM 2-N-morpholine propane sul-
fonic acid, 50 mM Tris Base, 3.5 mM SDS, 1 mM EDTA). Antioxidant, supplied by the
manufacturer, was used in the upper chamber at recommended concentration. Samples
were reduced by 50 mM dithiothreitol (DTT). The gels were stained for one hour with
Coomassie (0.1% Coomassie R-250 (from powder) dissolved in 45.5% methanol and
4.6% acetic acid) after incubation in 45.4% methanol and 4.6% acetic acid. The gels
were destained in 5% methanol and 7.5% acetic acid over night.
8.1.4 Detection with antibodies conjugated to HRP
ELISA plates with antibodies conjugated to horseradish peroxidase (HRP) were washed
three times with PBS containing 0.1% Tween (O.l%TPBS) and once with PBS before
developing with 100 ILlTMB (100 ILg/ml 3,3' ,5,5' -tetrarnethylbenzidine in 100 mM
sodium acetate pH 6.0 and 1:5000 (v/v) 30% hydrogen peroxide). Adding 50_ILl 1 M
H2S04 stopped the peroxidase reaction. The colour change was measured by OD450nm-
OD650nm.
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8.2.1 Production of monoclonal antibodies
The production of monoclonal antibodies was carried out under close supervision and
help at the Central Laboratory, The Norwegian Radium Hospital, Montebello, N-03l0
Oslo, Norway.
The production of monoclonal antibodies were essentially done as described in [Har-
low and Lane, 1988]. A Balb/C mouse was injected subcutaneously twice with 100 p,g
j1-lactamase in Freund's complete adjuvant and once with 30 p,g j1-lactamase in Freund's
incomplete adjuvant. (The production of j1-lactamase is described in section 8.2.5.) Each
injection was separated by three weeks. The cell fusion was done four weeks after the in-
jection with Freund's incomplete adjuvant. The mouse was injected intravenously each
of the four days prior to the cell fusion with 50 p,g, 200 ug, 200 p,g and 200 p,g j1-
lactamase in PBS respectively. These injections were done intravenously. 2.4x107 NSO
cells were mixed with 5xl07 spleen cells, fused with PEG 3,000-3,700 and plated in 10
96-well plates with HAT (hypoxanthine, aminopterin and thymidine) selection medium.
The cells were tested after 10 days for antibody production: Media from the cell cul-
tures were analysed for the presence of antibodies that bound to native or denatured
j1-lactamase. The native protein was biotinylated and captured on streptavidin coated
plates. The denatured protein was obtained by coating the j1-lactamase directly on Max-
iSorp 96-well plates in PBS and the plates were dried over night. (The absence of native
protein was verified with the chromogenic substrate Nitrocefin and mouse serum was
used as a positive control for the presence of j1-lactamase on the plates.) Hybridoma
cells were then selected for their ability to produce antibodies that gave high signal on
native, denatured or both forms of the protein. The selected cells were sub-cloned and
retested for expression of specific IgG antibodies. IgG antibodies were purified on IgG
columns and stored with 0.02% sodium azide.
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8.2.2 Construction of the expression vector for j3-1actamase
pHEN-lbtl
The ,B-Iactamase gene, amp-C, was cloned from a vector derived from pBR322. The
sequence was amplified by PCR with the primers 5' -CCC AAG CTT GGG ATG CTT CAA
TAA TAT TG-3' and 5' -CCT CAC TGA TTA AGC ATT GGG CTC TAG ATT AeA AGG ATG
ACG ATG ACA AGC ATC ATC ATC ACC ATC ACT AAG AAT TCC GG-3'. The product
included the ribosomal binding site and leader sequence from pBR322. The gene product
was followed by a FLAG tag, His (6) tag and an ochre stop codon (see figure B.1, page
158). The gene was cloned down stream of a lac promoter in the plasmid pUC119
between restriction sites HindIII and EcoRI. The ampicillin resistance gene in pUC119
was replaced by chloramphenicol resistance as in pBC-SK+ (Strategene). (The AfUII-
XmnI fragment of pBC-SK+ containing the cat gene and the ColEl replication origin
was ligated to the pUC AftIII-Aatll fragment (Aatll site trimmed blunt with T4 DNA
polymerase». The pUCl19 based vector with the chloramphenicol resistance (pRooster)
was a gift from Dr. Peter Wang. The cloned ,B-Iactamase gene was checked by DNA
sequence analysis as described in section 8.1.2.
8.2.3 Site specific mutations
The mutations were carried out after the principles described in [Kunkel, 1985].
Preparation of ssDNA
The ,B-Iactamase expression plasmid pHEN-1btl was electroporated into the bacterial
strain BW313 (due, ung ", F') and plated on an agar plate with chloramphenicol. A
single bacterial colony was used to inoculate 5 ml media (2xTy, 10 j..lg/mlchlorampheni-
col and 1% glucose). This was incubated shacking over night at 37°C. 0.5 ml of the
culture was used to inoculate 50 ml media (2xTy, 10 j..lg/mlchloramphenicol and 1%
glucose). This was incubated shacking until the culture reached an OD6oonm of 0.4.
3x1011 KM13 [Kristensen and Winter, 1998] helper phage were added to the bacterial
culture and incubated without shacking at 37°C for 30 minutes. The cells were spun
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down and resuspended in 300 ml media (2xTy, 10 /-lg/ml chloramphenicol, 50 /-lg/ml
kanamycin, 25 /-lglml uridine, 1% glucose) and grown over night shacking at 30°C. The
cells were spun down and the supernatant with phage particles were filtered with a 0.45
/-lm filter. 75 ml PEG solution (20% polyethylene glycol and 2.5 M NaCl) was added
to precipitate the phage particles. The pellet was resuspended in 10 ml TE buffer pH
7.0. 2.5 ml PEG solution was added to precipitate the phage particles. The pellet was
then resuspended in 3 ml TE buffer pH 7.0. This resulted in 1.7xl012 phage particles per
millilitre. ssDNA was then extracted by mixing the phage solution with equal volume of
phenol followed by the same volume of chloroform.
Site specific mutagenesis
A oligonucleotide containing the mutated codon plus typically 20 bases on each side
and a 5' -end phosphorylation were mixed with the vector in SSC buffer in a volume of
20 /-ll. (The primers used were: K34C: 5' -CAA CTG ATC TTC AGC ATC GCA TAC TTT
CAC CAG CGT TTC, N52C: 5'-TCT CAA GGA TCT TAC CGC TGC AGA GAT CCA GTT
CGA TGT AAC C, K55C: 5' -GCG AAA ACT CTC AAG GAT GCA ACC GCT GTT GAG
ATC CAG, E63C: 5' -GCT CAT CAT TGG AAA ACG TTC ACA GGG GCG AAA ACT CTC
AAG G, Q90C: 5' -GTG TATGCG GCG ACC GAG GCA CTC TTG CCC GGC GTC AAT AC,
NIOOC: 5' -GTG AGT ACT CAA CCA AGT CAC ACT GAG AAT AGT GTA TGC G, ElIOC:
5' -CCA TCC GTA AGA TGC TTA CAT GTG ACT GGT GAG TAC TC, T1I4C: 5' -TCT CTT
ACT GTC ATG CCA TCA CAA AGA TGC TTT TCT GT GAC TG, T140C: 5'-CTT CGG
TCC TCC GAT CGT ACA CAG AAG TAA GTT GGC CGC AG, K146C: 5' -GTG CAA AAA
AGC GGT TAG CTC GCA CGG TCC TCC GAT CGT TGT CAG, N154C: 5' -GTT ACA TGA
TCC CCC ATG CAG TGC AAA AAA GCG GTT AGC TC, N175C: 5' -GTG GTG TCA CGC
TCG TCG CAT GGT ATG GCT TCA TTC AGC TC, E197C: 5'-GGG AAG CTA GAG TAA
GTA GAC AGC CAG TTA ATA GTT TGC GC, L201C: 5' -GGG AAG CTA GAG TAA GTA
GAC AGC CAG TTA ATA GTT TGC GC, A202C: 5' -CTA TTA ATT GTT GCC GGG AAC
ATA GAG TAA GTA GTT CGC CAG, K215C: 5' -CAG AAG TGG TCC TGC AAC ACA ATC
CGC CTC CAT CCA GTC, A227C: 5' -ATC AGC AAT AAA CCA GCC ACA CGG AAG GGC
CGA GCG CAG, E240C: 5' -GAT ACC GCG AGA CCC ACG GCA ACC GGC TCC AGA TTT
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ATC AG, D254C: 5' -GAT ACG GGA GGG CTT ACC ACA TGG CCC CAG TGC TGC AAT
G, Q269C: 5' -GTT CAT CCA TAG TTG CAC AAC TCC CCG TCG TGT AG, T271C: 5' -GTC
TAT TTC GTT CAT CCA TAC ATG CCT GAC TCC CCG TCG TG, E281C: 5'-GCT TAA
TCA GTG AGG CAC CTA TAC AAG CGA TCT GTC TAT TTC GTT CAT CC and K288C:
5'-GTA ATC TAG AGC CCA ATG ACA AAT CAG TGA GGC ACC TAT CTC.) A
sample tube with each primer was placed in a 500 ml beaker of water at 70°C. This was
allowed to cool to room temperature. T4 DNA polymerase buffer (from supplier) was
then added and the volume was adjusted to 100 I,Ll. The tube was placed 'on ice and 2.5
U T4 DNA polymerase and 2 U T4 DNA ligase were added. After five minutes on ice
and five minutes at room temperature the sample was incubated at 37°C for two hours.
3 I,Ll 0.5 M EDTA was added to terminate the reaction. 10 I,Ll was then used to transfect
100 J..lIof CaCl2 competent E.coli HB2151. The mutation was then checked by DNA
sequencing analysis as described in section 8.1.2.
8.2.4 Expression and biotinylation of cysteine mutants
Bacteria from a single colony of HB2151 with the ,B-Iactamase expression plasmid
pHEN-1btl was use to inoculate 10 ml media (2xTy, 10 J..lg/mlchloramphenicol and 1%
glucose). This was incubated shacking over night at 37°C. The 10 ml culture was used
to inoculate 1000 ml media (2xTy, 10 J..lg/mlchloramphenicol and 0.1% glucose). This
was incubated shacking until the culture reached an OD6oonm0.9. IPTG was added up
to 1 mM and the culture was incubated shaking for five hours at 30°C. The bacteria were
pelleted by centrifugation and then resuspended in 50 ml 20% sucrose, 30 mM Tris- HCI
pH 8.0 and 1 mM EDTA. This was incubated on ice for 20 minutes and the bacteria
were pelleted by centrifugation. The supernatant was kept on ice and the bacteria were
resuspended in 50 ml 5 mM MgS04• This was incubated on ice for 20 minutes and
the bacteria were pelleted by centrifugation. The supernatants from both rounds were
mixed and dialysed over night in 50 mM phosphate buffer pH 7.5,500 mM NaCI and
20 mM imidazole (IMAC buffer, 20 mM imidazole). DTT was added to a concentration
of 1 mM. The supernatant was then filtered with 0.45 J..lm filter and loaded onto a 1 ml
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Nickel-NTA column prewashed with IMAC buffer (250 mM imidazole) and equilibrated
with imidazole IMAC buffer (20 mM imidazole). The column was washed with 20 ml
IMAC buffer (20 mM imidazole, 1 mM DTT) followed by 10 ml IMAC buffer (20 mM
imidazole) and then 10 ml IMAC buffer (35 mM imidazole). The protein was eluted
with IMAC buffer (lOO mM imidazole) into tubes on ice containing EDTA to a final
concentration of 1 mM EDTA. The protein concentration was determined by OD280nm,
absorption coefficient 29 400 M-1cm-1 [Sigal et al., 1984]. 1.5 times excess of HPDP
(4 mM in dimethyl sulfoxide) linker was added and incubated rotating for two hours
at room temperature. The samples were loaded on PD10 desalting columns and eluted
with PBS with 1 mM EDTA. The samples were dialysed into 1xPBS, 50% glycerol and
1 mM EDTA. The biotinylated protein was stored at -20°C.
8.2.5 Expression of unbiotinylated ,B-Iactamase
The same procedure was used as described in section 8.2.3 until the protein was loaded
onto the Nickel-NTA column. The column was washed with 10 ml IMAC buffer (20 mM
imidazole) followed by 10 ml IMAC buffer (35 mM imidazole). The protein was eluted
with IMAC buffer (100 mM imidazole). The protein concentration was determined by
OD280, absorption coefficient 29 400 M-1cm-1 [Sigal et al., 1984]. The samples were
dialysed into 1xPBS, 50% glycerol and 1 mM EDTA. The protein was stored at -20°C.
8.2.6 State of ,B-Iactamasemutants
Analysed through enzyme activity
MaxiSorp 96-well plates were coated over night at 4°C with 100 J.lI1 j.lglml streptavidin
in carbonate buffer pH 9.6. The plates were washed three times with PBS. The wells
were then blocked with 200 j.l14% BSA in PBS (4%BPBS) for two hours at room tem-
perature. 100 j.ll 5 j.lg/ml ,B-Iactamase mutants in 0.1%BPBS was added and incubated
shacking for two hours at room temperature. The plates were washed three times with
PBS. The enzyme activity was assayed with 100 j.ll Nitrocefin (50 j.lg/ml Nitrocefin in
PBS). The light absorbency (OD490nm-OD405nm) was measured every 30 seconds for five
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minutes.
Enzyme activity of wild type ,B-Iactamase
The enzyme activity was measured in PBS pH 7.4 at 22°C. Determination of Km was
carried out with 5.10-10 M ,B-Iactamase and Nitrocefin concentrations between 2.5-10-4
M and 2.5.10-6 M. Three samples were measured for each concentration. The ini-
tial conversion rates for the different substrate concentrations were fitted to Michaelis-
Menton equation. kcat was determined with enzyme concentrations between 1.5.10-9
M and 5.10-10 M and a Nitrocefin concentration of 1.25.10-4 M. Wavelength 486 nm
was used to detect the converted Nitrocefin. The extinction coefficient for Nitrocefin at
486 nm is 20,500 M-1cm-1. All rates were corrected by subtracting 14.8% of the rates
detected at 390 nm, the absorption maximum for uncleaved Nitrocefin.
Analysed with monoclonal antibodies
MaxiSorp 96-well plates were coated over night at 4°C with 100 I.d 1 mg/ml strepta-
vidin in carbonate buffer pH 9.6. The plates were washed three times with PBS. The
wells were then blocked with 200 I·d 4%BPBS for two hours at room temperature. 100
I.d 5 J.lg/ml ,B-Iactamase mutants in 0.1%BPBS was added and incubated shacking for
two hours at room temperature. The plates were washed three times with PBS. 100 J.lI
of the monoclonal antibodies P64.l and P65.2 diluted in O.l%TPBS were added to the
wells. The concentrations were 100 ng/well and 0.5 J.lI/well (cell culture media) respec-
tively. 100 J.lIhorseradish peroxidase conjugated anti-mouse antibodies diluted 1:2500 in
0.1%TPBS was added and incubated shaking for one hour. The horseradish peroxidase
was detected as described in section 8.1.4.
8.2.7 Mapping the binding regions of monoclonal antibodies
MaxiSorp 96-well plates were coated over night at 4°C with 100 J.lIl mg/ml streptavidin
in carbonate buffer pH 9.6. The plates were washed three times with PBS. The wells
were then blocked with 200 J.lI4%BPBS for two hours at room temperature. 100 J.lI5
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jLg/ml biotinylated cysteine mutants of ,B-Iactamase in 0.1%BPBS was added and incu-
bated shacking for two hours at room temperature. The plates were washed three times
with PBS. Added monoclonal antibodies to the plate at concentrations that just saturated
the antigen (predicted from separate dilution series). The bound monoclonal antibodies
were detected with 1:5000 dilution of HRP conjugated goat anti-mouse antibodies in
PBS as described in 8.1.4.
8.2.8 Capturing ;3-lactamase from solution with monoclonal anti-
bodies
The assay was carried out in the same way as with serum antibodies (8.5.11) with the
exceptions: Anti-mouse antibodies were used in stead of anti-rabbit and the antibodies
were not affinity purified. The amount of monoclonal antibodies added was 2 jLg in 100
jLIO.1%TPBS.
8.3 Specific methods for chapter 3
8.3.1 Immunisation and test-bleeds of rabbits
The rabbits were all Murex LOP (English Full Lop crossed with New Zealand rabbits.
The resulting hybrid has been crossed for several generations.) The rabbits were be-
tween 4 and 4.5 kg. All injections into the rabbits were done with 0.5 mg ,B-Iactamase
(expressed and purified as described in section 8.2.5). The barstar injected into rabbit
4 was a gift from Dr Chris Johnson. The samples were injected subcutaneously in four
points on the back of the rabbits. Injections with antigen Freund's adjuvant were pre-
pared as described in section 8.5.3. Immunisations with antigen in Freund's adjuvant:
Freund's complete adjuvant was used in the first injection and Freund's incomplete ad-
juvant was used in subsequent injections. Immunisation with antigen in PBS: Injections
with antigen in PBS were prepared by dialysing the ,B-Iactamase into PBS and adjusting
the concentration to 1 mg/ml. Test-bleeds were done 10 days after injection. Sodium
azide was added to the sera to a concentration of 0.02%. The sera were stored at -20°C.
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Test-bleeds (pre-bleeds) taken prior to the first injection showed no antibodies specific
for ,8-lactamase in ELISA.
8.3.2 Mapping method for conformational epitopes (beads)
Plates:
Mapping of epitopes in sera from rabbits 1,3 and 4 and mice 1,2,3, and 4 were carried
out with this method. For the other sera see below. MaxiSorp 96-well plates were
coated over night at 4°C with 100 J.Ll1 mg/ml streptavidin in carbonate buffer pH 9.6.
The plates were washed three times with PBS. The wells were then blocked with 200
J.Ll4%BPBS for two hours at room temperature. 100 J.Llof 5 J.Lg/ml,8-lactamase 308C
(biotinylated through a C-terminal cysteine) or other biotinylated cysteine mutants of
,8-lactamase in PBS with O.l%BPBS was added and incubated shacking for two hours
at room temperature. The plates were washed three times with PBS.
Beads:
Per serum sample to deplete; mixed 20 J.Llprewashed magnetic streptavidin beads with
10 J.Lg of biotinylated cysteine mutants of ,8-lactamase. Incubated shacking for one hour.
The beads were then washed six times with 100 J.Ll0.1%TPBS.
Depletion of specific serum antibodies:
Each serum sample plus the control were treated in the same well on a polyvinyl chloride
plate (Falcon 3912). The sera were used at dilutions below saturation of antigen on
ELISA plates. 120 J.Lldiluted serum (1:5000 to 1:30,000) in .0.1%TPBS was mixed
with 20 J.Llbeads loaded with a biotinylated ,8-lactamase mutant and incubated for five
minutes. The liquid was then separated from the beads. The beads were further washed
twice with 0.1%TPBS for five minutes. The beads were then remixed with the serum
sample. This was repeated five times. After the beads were removed a new 20 J.Llbatch
of beads loaded with the same biotinylated ,8-lactamase mutant was then added and the
same process were repeated. The same depletion procedure was carried out for all the
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,B-lactamase cysteine mutants with separate serum aliquots.
Detection of remaining serum antibodies:
Each sample was diluted 1:2 in O.l%TPBS and split in two (The serum concentrations
stated in the figure legends are after dilution). 100 /11was added to each well with
,B-lactamase biotinylated through a C-terminal cysteine or other cysteines jn specific
surface positions. The plates were incubated shacking for one hour and then washed
three times with 0.1%PBS. 100/11 1:5000 horse radish peroxidase conjugated anti-rabbit
IgG antibodies in PBS was added and incubated for one hour shaking. The horseradish
peroxidase was detected PBS as described in section S.l.4.
8.3.3 Mapping method for conformational epitopes (plates)
This method was used for sera from rabbit 2 and rabbit 5. 100/11 1 /1g/ml,B-lactamase
30SC (biotinylated through a C-terminal cysteine) or other biotinylated cysteine mu-
tants of ,B-lactamase in O.l%BPBS was added to precoated streptavidin plates (High
Bind, Roche) and incubated shacking for two hours at room temperature. The plates
were washed three times with PBS. A sample of 120 /11rabbit serum diluted (1:12,500)
O.l%TPBS was added to a well with a biotinylated ,B-lactamase mutant and incubated
shacking for 15 minutes. The sample was transferred to another well with the same bi-
otinylated ,B-lactamase mutant. This was repeated for 11 wells. The sample was then
transferred to a last well with the biotinylation mutant used for detection (30SC, biotiny-
lated through a C-terminal cysteine) and incubated shacking for one hour. The same
procedure was carried out for all the ,B-lactamase cysteine mutants with separate serum
aliquots. The plates were washed three times with 0.1%PBS. 100/111:5000 horse radish
peroxidase conjugated anti-rabbit IgG antibodies in PBS was added and incubated for
one hour shaking. The horseradish peroxidase was detected PBS as described in section
S.1.4.
CHAPTER 8. MATERIALS AND METHODS
8.3.4 Detecting epitopes by enzyme activity of ;3-lactamase
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Serum antibodies were specifically depleted in 100 j.,llserum aliquots for all the 23 mu-
tants as described in section 8.3.2. 10 J.d beads with ,B-Iactamase 308C (see section
8.3.2) was added to each aliquot and incubated shacking for 20 minutes. The beads were
then separated from the liquid with a magnet and washed once with O.l%TPBS. The
antibodies were eluted by resuspending the beads in ice cold 35 j.,llglycine buffer pH
2.5 with 0.1% Tween and incubated for 30 seconds. The buffer was separated from the
beads and mixed with 65 jiJ ice cold 1M Tris·HCI buffer pH 7.5. The eluted antibodies
were captured on an ELISA plate pre-coated with goat anti-rabbit (100 j.,llat concentra-
tion 10 j.,lg/mlin PBS over night and blocked with 200 j.,ll4%BPBS for two hours). The
plate was incubated for one hour shacking at room temperature followed by three washes
with O.l%TPBS. 100 j.,l11.5j.,lg/ml,B-Iactamase O.l%BPBS was added to the plates and
incubated for one hour shaking at room temperature. The plate was washed three times
in 0.1%TPBS. 100 fd 50 j.,lglmlNitrocefin in PBS was added to each well. The light
absorbency (OD490nm-OD405nm) was measured every 30 seconds for five minutes.
8.3.5 Resolution of mapping assay
Specificity of antibody depletion
A MaxiSorp 96-well plates was coated over night at 4°C with 100 j.,ll1 mg/ml strep-
tavidin in carbonate buffer pH 9.6. The plate was washed three times with PBS. The
wells were then blocked with 200 j.,l14%BPBS for two hours at room temperature. 100
j.,ll5 j.,lg/ml,B-Iactamase biotinylated cysteine mutants of ,B-Iactamase in 0.1%BPBS was
added (one mutant in each well) and incubated shacking for two hours at room temper-
ature. The plates were washed three times with PBS.
1 ml serum aliquots (1:2000 in 0.1%TPBS) were depleted for ,B-Iactamase specific
antibodies with L20lC or A227C as described in section 8.3.2. The serum was diluted
1:3 in 0.1%TPBS. 100 j.,llaliquots were added to 23 wells containing each of the biotiny-
lated ,B-Iactamase cysteine mutants. The plates were incubated shacking for one hour
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and then washed three times with 0.1%PBS. 100 IL11:5000 horse radish peroxidase con-
jugated anti-rabbit IgG antibodies in PBS was added and incubated for one hour shaking.
The horseradish peroxidase was detected PBS as described in section 8.1.4.
8.3.6 Protein fragmentation (for western blots)
Partial digest by CNBr
3.95 mg ,B-Iactamase was dialysed into Millipore purified water. The final protein con-
centration was 5.5 mg/ml. Formic acid was added to a final concentration of 70%. The
sample was split in two. 80 ILlof 60 mg/ml cyanogen bromide (CNBr) in acetonitrile was
added to the protein solution. The sample was incubated for one hour. 1.6 ml Millipore
purified water was added to the samples. The samples were dried in a centrifuge cou-
pled to a vacuum pump. 400 ILlMillipore purified water was added to the samples. The
samples were again dried in a centrifuge coupled to a vacuum pump. The fragmented
protein was dissolved in 5% SDS and diluted to 0.5% SDS with Millipore purified water.
The sample was stored frozen until use.
Partial digest by trypsin
2.25 mg ,B-Iactamase was dialysed into 100 mMTris·HCI pH 8.5 and 1mM EDTA. The
final protein concentration was 8.7 mg/ml. 94.2 ILl8 M urea and 22.5 ILlof 1 mg/ml
trypsin in 1 mM HCI was added to the ,B-Iactamase. This gave a urea concentration of
2 M and a trypsin to ,B-Iactamase ration of 1:100. The sample was incubated for 90
minutes at room temperature. The proteolytic activity of trypsin was stopped by adding
PEFA-block up to a finial concentration of 3.3 mM. The sample. was stored frozen until
use.
Partial digest by Lys-C
620 ILg ,B-Iactamase was dialysed into 25 mM Tris·HCI pH 8.5 and 1mM EDTA. The
final protein concentration was 4.8 mg/ml. SDS was added to a final concentration of
0.5% and the sample was heated to 70°C for 10 minutes. The sample was cooled to room
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temperature. 10 J.LIof 0.5 mg/ml Lys-C was added and the sample was incubated for six
hours at 37°C. The sample was stored frozen until use.
8.3.7 Western-blots with rabbit sera
Partial digest of ,B-Iactamase (1 J.LIcyanogen bromide digest, 0.6 J.LILys-C digest or 4 J.LI
trypsin digest) were run on 12% Bis-Tris gel with MES buffer for 40 minutes at 200 V
(see section 8.1.3). The protein was transferred to nitro-cellulose membranes under an
electric field of 30 volts for one hour. The membranes were blocked over night at room
temperature with 6% Marvel and 4%BPBS. The membranes were washed three times in
PBS. Serum was added in 3% Marvel in 2%BPBS and incubated for one hour shaking
at room temperature. The membranes were washed three times in PBS. Anti-rabbit IgG
antibodies were added in 3% Marvel in 2%BPBS and incubated for one hour shaking
at room temperature. The membranes were washed three times in PBS each with five
minutes incubation. The membranes were developed by using ECL and X-Omat Film
Kodak.
8.4 Specific methods for chapters 4 and 5
Rabbit sera was obtained as described in section 8.3.1.
8.4.1 Endotoxin (LPS) test
BioWhittaker, Europe, carried out the analysis of LPS content in protein samples. The
protein was dialysed into PBS with the same concentration and under the conditions as
used for preparing the antigen for immunisation. The sample was then sent to BioWit-
taker in a glass vial. The Kinetic Chromogenic Test (KQCL, test code 95-103) was
carried out at dilution s 1:10, 1:100 and 1:1000. The result was read from dilution
1:1000.
CHAPTER 8. MATERIALS AND METHODS 137
8.4.2 Immunisation and test-bleeds of mice
All the mice were female BALB/c and at least six weeks when given the first injection.
All injections were done with ,B-lactamase in PBS emulsified in Freund's adjuvant, as
described in section 8.5.3. Freund's complete adjuvant was used in the first injection and
Freund's incomplete adjuvant was used in subsequent injections. The injections were
given with 21 weeks intervals. 100 iig, 30 p,g and 20 p,g was given in the first, second
and third injection respectively. A total volume of 200 11,1was injected subcutaneously
into four points. Test-bleeds were taken seven days after injection. The sera were stored
at -20°C. (Test-bleeds (pre-bleeds) taken prior to the first injection showed no antibodies
specific for ,B-lactamase in ELISA.)
8.4.3 Correlation calculations: surface properties and antigenicity
Surface amino acids in a radius of lOA
The surface amino acids were identified by the Lee and Richards [1971] model with
a solvent probe of 1.4 A. The surface amino acids were defined as residues with sol-
vent accessibility above zero. These calculations were done with the CCP4 supported
software AREAIMOL (http://www.ccp4.ac.uk).Amino acids within a 10 A radius were
identified with the software GRASP [Nicholls et al., 1991].
Backbone mobility
The B-values from the crystal structure of ,B-lactamase were used as data for the mo-
bility of the protein atoms. The B-values for ,B-lactamase were obtained from the file
1btI.pdb downloaded from SCOP database (http://scop.mrc-lnib.cam.ac.uk!scop/). The
average B-values for the backbone atoms of each amino acid were calculated with the
CCP4 supported software BAVERAGE (http://www.ccp4.ac.uk). Contact residues be-
tween different ,B-lactamase molecules in the crystal structure were removed from the
data set to eliminate false mobility data. The contact residues were identified by us-
ing the CCP4 supported software CONTACT (http://www.ccp4.ac.uk). Contact residues
were defined as amino acids containing atoms with less than 3.6A distance (hydrogen
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atoms not included).
Hydrophilicity:
Hydrophilicity values for the amino acids were obtained from Hopp and Woods [1981]
and Kyte and Doolittle [1982].
Accessibility:
The accessibility values were calculated with the CCP4 supported software AREAIMOL
(http://www.ccp4.ac.uk) using a probe of 10 A radius.
Correlation coefficients:
The correlation coefficients were calculated using the software EXCEL (Microsoft).
8.5 Specific methods for chapter 6
8.5.1 Denaturation of ,B-lactamase on streptavidin plates
MaxiSorp 96-well plates were coated over night at 4°C with 100 J.lI 1 mg/ml strepta-
vidin in carbonate buffer pH 9.6. The plates were washed three times with PBS. The
wells were then blocked with 200 j..LI4%BPBS for two hours at room temperature. 100
j..Ll5 j..Lg/ml,B-lactamase 308C (biotinylated with a maleimide-biotin linker through a
C-terminal cysteine) in 0.1%BPBS was added and incubated shacking for two hours at
room temperature. The plates were washed three times with PBS. 120 J.lI0.1 M Tris·HCI
pH 8.0, 10 mM DTT, 1 mM EDTA and 1 M guanidine hydrochloride was added, incu-
bated for one hour at 37°C. The solution was then replaced with 120 j..LI0.1 M Tris·HCI,
10 mM iodoacetamide, 1 mM EDTA and guanidine hydrochloride pH 8.0, incubated
for 30 minutes at room temperature. The plates were washed three times with PBS.
The absence of native ,B-lactamase was tested with Nitrocefin (100 j..Ll50 j..Lg/mlNitro-
cefin in PBS, OD490nm-OD405nm measured). The presence of ,B-Iactamase was detected
with through the C-terminal FLAG tag and the M2 anti FLAG antibody conjugated to
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horseradish peroxidase. The M2 gave 10% lower signal on denatured ,B-Iactamase the
native ,B-Iactamase on the plate.
8.5.2 ELISA with serum on native or denatured f3-1actamase
MaxiSorp 96-well plates were coated over night at 4°C with 100 pIl mg/ml streptavidin
in carbonate buffer pH 9.6. The plates were washed three times with PBS, The wells
were then blocked with 200 pI 4%BPBS for two hours at room temperature. 100 pI 5
pg/ml ,B-Iactamase 308C (biotinylated with a maleimide linker through a C-terminal cys-
teine) 0.1%BPBS was added and incubated shacking for two hours at room temperature.
The plates were washed three times with PBS. The protein was denatured as described
in section 8.5.1. The absence of native protein in the wells with denatured protein was
confirmed by monoclonal antibodies specific for the denatured form (as described in
section 8.2.6) and by enzyme activity of ,B-Iactamase. Sera was diluted in 0.1%BPBS.
The bound IgO were detected as described in section 8.3.2.
8.5.3 Mixing antigen with Freund's adjuvant
Classic method
The ,B-Iactamase was dialysed into PBS and the concentration adjusted to 1 mg/ml.
Equal volumes of ,B-Iactamase solution and Freund's adjuvant were added to a 2 ml
glass syringe. The syringe was connected through a 90° sanitary adapter to a second
glass syringe of the same size. The contents was pushed between the two syringes as
fast as possible for three minutes. The integrity of the resulting emulsion was tested by
dripping the emulsion into a glass beaker with water (described in Appendix 3 Weir, D.
M., Ed., 1978). The emulsion remained as a compact droplet in the water.
Other methods: Magnetic spinner
125 pI 1.mg/ml ,B-Iactamase in PBS and 125 pI Freund's incomplete adjuvant was added
to a cryor tube (1.8 ml) on ice. A small magnetic spinner in the solution was turned by a
magnetic stirrer at 1200 rpm for three minutes.
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Other methods: Homogeniser
250 fl,l1 mg/ml ,B-lactamase in PBS and 250 IIIFreund's incomplete adjuvant was added
to a cryotube (1.8 ml). A homogeniser with a 5 mm probe was applied to the solution at
11,000 rpm for five minutes.
8.5.4 Extracting ,B-Iactamasefrom Freund's adjuvant
Ether quickly breaks down the emulsion and separates the water phase from the oil
phase. Hexane does also brake the emulsion but less efficient. More hexane needs to
be added to break the same volume of emulsion. Adding mineral oil to the adjuvant
dilutes the surfactant and therefore destabilises the emulsion. The water phase can then
be separated from the emulsion by centrifugation.
Extracting ,B-lactamase from the adjuvant with ether
1 ml water-saturated ether was added to 50 III emulsion. The sample was vortexed for
20 seconds and centrifuged for 30 seconds at 16,100g. The bulk ether was aspirated off.
The tube was left open to let the remaining ether evaporate.
Extracting ,B-lactamase from the adjuvant with hexane
1 ml hexane was added to 50 III emulsion. The sample was vortexed for 30 seconds and
. centrifuged for 30 seconds at 16,100g. The hexane was aspirated off. This was repeated
until all the emulsion had broken down.
Extracting ,B-lactamase from the adjuvant with mineral oil .
1 ml mineral oil was added to 50 III emulsion. The sample was vortexed for 30 second
and centrifuged for 30 seconds at 16,100g. The oil was aspirated off. This was repeated
until all the emulsion had broken down.
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8.5.5 Assaying adjuvant induced denaturation by enzyme activity
The 600 I_Ll 1 mg/ml ,8-lactamase in PBS was mixed with 600 {LlFreund's incomplete
adjuvant as described in section 8.5.3. The emulsion was incubated at room temper-
ature. The water phase and oil phase were then separated with ether as described in
section 8.5.4. The enzyme activity in the water phase was assayed with the chromogenic
substrate Nitrocefin. The light absorption at wavelength 490 nm was subtracted from
the absorption at 405 nm. 50 J-li50 J-lg/ml Nitrocefin in PBS was mixed with 50 J-li
sample. The enzyme activity was determined by using a dilution series of ,8-lactamase
with known concentration. The samples of interest were diluted to get enzyme activity
corresponding to 0.25 to 1 ng native ,8-lactamase.
Impact of ether on ,8-1actamase
50 J-li1mg/ml ,8-lactamase and 900 J-liwater-saturated ether was vortexed for 45 seconds.
The enzyme activity was assayed by with a dilution series of the water phase against a
dilution series of ,8-lactamase that had not been in contact with ether.
Testing for adjuvant substances that inhibits the enzyme activity
500 J-liPBS was emulsified with Freund's incomplete adjuvant and extracted by ether as
described in section 8.5.3. ,8-lactamase in PBS was mixed with an equal volume of ex-
tracted PBS. The enzyme activity was in a dilution series of the protein was compared to
the enzyme activity of a dilution series of ,8-lactamase without extracted buffer present.
8.5.6 Assaying adjuvant induced denaturation by proteolysis
,8-Lactamase assayed with trypsin
1 mg/ml in PBS ,8-lactamase was mixed with 1:100 (w/w) trypsin. 600 J-liof the ,8-
lactamase/trypsin solution was mixed with 600 J-liFreund's incomplete adjuvant as de-
scribed in section 8.5.3 . The emulsion was incubated at room temperature. The water
phase and oil phase were then separated with ether as described in section 8.5.3. 1 J-l1100
mM PEFA-block was added to 20 J-liof extracted sample to stop the proteolytic activity
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of the trypsin. 15 j.tlof the sample was then mixed with 5 j.t14xLDS sample buffer and 1
j.tll M DTT. This was incubated at 90°C for 10 minutes before loading on 12% Bis-Tris
gels.
,B-Lactamase assayed with modified trypsin
The experiment was done as above but with trypsin cross-linked by hydrophilic polymers
instead of standard trypsin. The ratio of modified trypsin to ,B-Iactamase was 1:10 (w/w).
,B-Iactamase assayed with modified thermo lysin
The experiment was done as with trypsin but with thermolysin in presence of 2 mM
CaCI2• The ratio of modified thermolysin to ,B-Iactamase was 1:50 (w/w). The thermo-
lysin was inactivated by 1 mM phenanthroline.
BSA, HEL and cytochrome c assayed with trypsin
The experiments were done as with ,B-Iactamase. The bovine serum albumin (BSA), hen
egg lysozyme (HEL) and horse hart cytochrome c was obtained from Sigma. The ratio
of trypsin to BSA was 1:100 (w/w). The ratio of trypsin to HEL or cytochrome c was
1:10 (w/w).
8.5.7 Detection of cross-reactive antibodies
Beads:
Pre-washed magnetic streptavidin beads were mixed with 308C (1 j.tg ,B-Iactamase, bi-
otinylated with a maleimide linker through a C-terminal cysteine, per 1 j.tl beads). In-
cubated shacking for one hour. The beads were then washed six times with 100 j.tl
0.1%TPBS. Some of the beads were then mixed with 1 M guanidine hydrochloride, 10
mM DTT, 1 mM EDTA and 0.1 M Tris·HCI pH 8.0 (100 j.tl per 10 j.tl beads) and incu-
bated for one hour at 37°C. The liquid was then replaced with the same volume of 1 M
guanidine hydrochloride, 10 mM iodoacetic acid, 1 mM EDTA and 0.1 M Tris·HCI pH
8.0 and incubated for 30 minutes at room temperature.
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Plates:
Plates were prepared with native and denatured ,8-lactamase as described in section 8.5.1.
100 /11diluted serum (1:500 to 1:20,000) in 0.1%TPBS was mixed with 20 /11beads
loaded with native or denatured ,8-lactamase and incubated for 15 minutes. The beads
were then separated from the liquid and washed once with 0.1%TPBS. The beads were
resuspended in ice cold 35 /11glycine buffer pH 2.5 with 0.1% Tween and incubated
30 seconds. The buffer was separated from the beads and mixed with 65 /11ice cold 1
M Tris-Hfll buffer pH 7.5. The samples were transferred to wells containing native or
denatured protein and incubated shacking for one hour. The plates were washed three
times with 0.1%TPBS. 100 /11 1:5000 horse radish peroxidase conjugated anti-rabbit
IgG antibodies in PBS was added and incubated for one hour shaking. The plates were
washed three times with O.l%TPBS and once with PBS before developing with 100/11
TMB (100 /1g/ml 3,3' ,5,5' -tetramethylbenzidine in 100 mM sodium acetate pH 6.0 and
1:5000 (v/v) 30% hydrogen peroxide). Adding 50 /111M H2S04 stopped the peroxidase
reaction. The colour change was measured by OD450nm-OD600nm.
8.5.8 Mapping of cross-reactive antibodies
Serum antibodies from rabbit 1 were isolated against different surface regions of ,8-
lactamase as described in 8.3.2. The native-specific antibodies were then affinity pu-
rified on native antigen as described in 8.3.4 with biotinylated ,8-lactamase 308C on
streptavidin beads. 2 volumes (67 /11)of the eluted antibodies aliquots were mixed with
1 volume (33 /11)of O.l%TPBS with 0.3% BSA. The aliquots were then transferred to
an ELISA plate with denatured ,8-lactamase. The two forms of denatured ,8-lactamase
used was carboxymethylated as described in 8.5.1 and dried ,8-lactamase as described in
8.2.1. (The absence of native protein was verified with the chromogenic substrate Nitro-
cefin.) The plates were incubated four one hour shaking at room temperature. The plates
were washed three times with O.l%PBS. 100/111:5000 horse radish peroxidase conju-
gated anti-rabbit IgG antibodies in PBS was added and incubated for one hour shaking.
The horseradish peroxidase was detected PBS as described in section 8.1.4.
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8.5.9 Denaturation of ,B-lactamasefor immunisation
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The ,B-lactamase was prepared as described in section 8.2.5. The protein was then dial-
ysed into 0.1 M Tris-HCl pH 8.0 over night. Added the following chemicals to the given
concentrations; guanidine hydrochloride 3 M, 0.1 M Tris·HCl pH 8.0, EDTA 1 mM and
DTT 10 mM. Incubated for four hours at 37°C. To one volume of protein sample; added
four volumes of 3 M guanidine hydrochloride, 50 mM iodoacetic acid, O.lM Tris-HCl
pH 8.0 and 1 mM EDTA and incubated for one hour at room temperat~re. The protein
was then loaded on a Nickel-NTA column with 0.5 ml packed beads pre-equilibrated
with 3 M guanidine hydrochloride and 0.1 M Tris·HCl pH 8.0. A gradient with 0.1 M
Tris-Hf.l pH 8.0 and from 3 - 0 M guanidine hydrochloride was then run through the
column. The column was finally washed with PBS and the protein eluted with PBS con-
taining 250 mM imidazole. The protein was dialysed against PBS for two hours followed
by dialysis against 50% glycerol, lxPBS and 1mM EDTA over night at 4°C. The sample
was stored at -20°C. The denatured protein was dialysed against PBS over night before
used for immunisation. The protein concentration was determined by OD280, assuming
the same absorption coefficient 29 400 M-1cm-1 as the native protein. The amount of
protein was also estimated on a SDS gel.
8.5.10 Circular dichroism spectroscopy
The protein was in PBS. The protein concentration was 0.60 mg/ml. 0.5 mm cuvettes
were used. 10 scans were executed for each sample. The heat denatured protein was at
90°C. All other samples were at 20°C. The samples were analysed with a Jasco J-720
Spectropolarimeter.
8.5.11 Capturing ,B-lactamasefrom solution with serum antibodies
MaxiSorp 96-well plates were coated over night at 4°C with 100 /111 mg/ml goat anti-
rabbit antibodies. The plates were washed three times with PBS. Affinity purification of
,B-lactamase specific antibodies: 100 /11diluted serum 1:200 in 0.1%TPBS was mixed
with 20 /11beads loaded with native ,B-lactamase (as described in section 8.3.2) and
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incubated for 15 minutes. The beads were then separated from the liquid and washed
once with 0.1%TPBS. The beads were resuspended in ice cold 35 ILl glycine buffer
pH 2.5 with 0.1% Tween and incubated 30 seconds. The buffer was separated from
the beads and mixed with 65 ILl ice cold 1 M Tris·HCI buffer pH 7.5. The samples
were transferred to the MaxiSorp plate and incubated shacking for one hour at room
temperature. The presence of ,B-Iactamase was detected with Nitrocefin as described in
section 8.3.4. Control: 100 ILl 1:2500 HRP conjugated goat anti-rabbit was added to
the other well and incubated for one hour shacking at room temperature. The assay was
developed as described in section 8.1.4.
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Additional figures and tables
A.1 Figures to chapter 3
--+- Rabbit 1, Native beta-Iactamase
_ Rabbit 2, Native beta-Iactamase
- Rabbit 3, Native beta-Iactamase
-.- Rabbit 4, Native beta-Iactamase
---+- Rabbit 5, Native beta-Iactamase
- Oe- - Rabbit 1, Denatured beta-Iactamase
- 0- - Rabbit 2, Denatured beta-Iactamase
- 0- - Rabbit 3, Denatured beta-Iactamase
- tr- - Rabbit 4, Denatured beta-Iactamase
0.7 - o- - Rabbit 5, Denatured beta-Iactamase
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Figure A.l: ELISA results with test-bleeds from rabbit 1, 2, 3, 4 and 5. Biotinylated
native and denature {3-lactamase (308e) was displayed on a streptavidin plate. The {3-
lactamase was denatured by reducing an internal disulphide bond and carboxymethylate
the two cysteines. The sera were diluted 1:25,000.
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A.2 Figures to chapters 4 and 5
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Figure A.2: The figure shows the relative distribution of serum antibodies to different
surface locations. The amount of antibodies detected to each region is displayed in
black bars. The grey bars show the amount of antibodies to the remaining surface that
were not successfully subtractedfrom the serum. The sera concentrations in the mapping
assay were 1:10,000 and 1:50,000 for the rabbits 1 and 2 respectively. The biotinylated
antigen captured on streptavidin beads and plates to specifically absorb the serum for
antibodies to the unmasked antigen surface. Both rabbits were primarily injected with
antigen in FeA followed by antigen in FIA in first and second boost.
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Figure A.3: The figure shows the relative distribution of serum antibodies to different
surface locations for sera from mice. The amount of antibodies detected to each region
is displayed in black bars. The grey bars show the amount of antibodies to the remaining
surface that were not successfully subtracted from the sera. The serum concentration in
the mapping assay was 1:5,000. The mice (mouse 1,2,3 andfour in image (a), (b), (c)
and (d) respectively) were primarily injected with antigen in FCAfollowed by antigen in
FIA in first and second boost.
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Figure A.4: The figure shows the relative distribution of serum antibodies to different
surface locations. The results for rabbit 3 and 4 are shown in image (a) and (b) respec-
tively. The amount of antibodies detected to each region is displayed in black bars. The
grey bars show the amount of antibodies to the remaining surface that were not suc-
cessfully subtractedfrom the serum. The serum concentration in the mapping assay was
1:30,000. The rabbits were given three injections with antigen in PBS.
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Figure A.S: Rabbit 1 (image a) and rabbit 2 (image b). Scatter plot of the ELISA signals
(data in figure A.2) and backbone mobility in the same surface regions (CTRs). The
backbone mobility is the average B-value of the surface residues in a radius of lOAfrom
the cysteine positions.
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Figure A.6: Rabbit 3 (image a) and rabbit 4 (image b). Scatter plot of the ELISA signals
(data in figure AA) and backbone mobility in the same surface regions (CTRs)_ The
backbone mobility is the average B value of the surface residues in a radius of loA from
the cysteine positions.
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Figure A.7: The accessibility of each residue is set to the contact area of a probe of
radius loA rolling over the protein surface. The values are average over a window of
seven residues along the protein sequence.
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Figure A.8: Scatter plot of backbone mobility and accessibility calculated for each of
the CTRs used for epitope mapping. The backbone mobility and accessibility are the
average values for residues in a radius of loA around each masking (cysteine) position.
The backbone mobility is the B-value of the backbone atoms. The accessibility values
are the contact areas of a probe of radius to : rolling over the protein surface. The
correlation coefficient is 0.65. The fitted line is given by the equation f = 10.49x - 23.2
with an R value ofO.65.
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Figure B.l: Thefigure shows the sequence inserted between the restriction sites HindII!
and EcoR! in a modified pUC19 vector. The gene encoding j3-lactamase is followed by
a FLAG tag, His (6) tag and an ochre stop codon. The sequence includes the ribosomal
binding site and leader sequence from pBR322. The pUC19 vector was modified by re-
placing the ampicillin resistance gene with a gene encoding chloramphenicol resistance.
Appendix C
Hydrophilicity models
159
APPENDIX C. HYDROPHILICITY MODELS 160
Table C.I: The table shows the hydrophilicity values given each amino acid in the two
models Hopp& Woods [Hopp and Woods, 1981] and Kyte&Dolittle [Kyte and Doolittle,
1982}.
Hoop& Kyte&
Amino acid Woods Doolittle
Alanine -0.5 -1.8
Phenylalanine -2.5 -2.8
Lysine 3.0 3.9
Proline 0.0 1.6
Threonine -0.4 0.7
Cysteine -1.0 -2.5
Glycine 0.0 0.4
Leucine -1.8 -3.8
Glutamine 0.2 3.5
Valine -1.5 -4.2
Aspartate 3.0 3.5
Histidine -0.5 3.2
Methionine -1.3 -1.9
Arginine 3.0 4.5
Tryptophan -3.4 0.9
Glutamate 3.0 3.5
Isoleucine -1.8 -4.5
Asparagine 0.2 3.5
Serine 0.3 0.8
Tyrosine -2.3 1.3
AppendixD
List of chemicals and materials
Anti-mouse M-4280 Sigma
Anti-mouse-HRP A-2554 Sigma
Anti-rabbit R-2004 Sigma
Anti-rabbit-HRP A-6154 Sigma
BayolF 14500.01 Serva
AB! PRISM BigDye terminator mix 4303150 PE Biosystems
Bis-Tris protein gels NP0302 Invitrogen
Biotin-HPDP 21341 ZZ Pierce
Biotin-Maleimide B-1267 Sigma
BSA A-7906 Sigma
Cyanogen bromide 16774 Fluka
Cytochrome c C-2506 Sigma
Freund's complete adjuvant 263810 Difco Laboratories
Freund's incomplete adjuvant 263910 Difco Laboratories
ECL RPN 2106 Amersham Biosciences
Glass Syringe Luer Lock 2ml SZR285001D Fisher Scientific
Homogeniser probe S8N-5G 361-118 IKA
HSA A-3782 Sigma
lodoacetamide 1-6125 Sigma
Iodoacetic acid 1-2512 Sigma
LDS sample buffer NPOO07 Invitrogen
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Lys-C 1047825 Boehringer
Lysozyme L-6876 Sigma
Mark12 marker LC5677 Invitrogen
M2 antibody F-3165 Sigma
Maxisorp ELISA plates 1989685 Roche
Modified trypsin, sequence grade 1418025 Roche
Nickel-NTA beads 30210 Qiagen
Nitrocefin 484400 Calbiochem
Nitrocellulose membranes LC2000 Invitrogen
Nunc immunoplates Maxisorp 442404 A Life Technologies
PD-10 desalting columns 17-0851-01 Amersham Biosciences
PEG 3,000-3,700 P-2906 Sigma
Rapid-endotest 91-103 BioWhittaker
Sanitary adapter 3 way 008212586 VWR International
SeaBlue marker LC5626 Invitrogen
Streptavel High Bind 96 1989685 Roche
Streptavidin S-4762 Sigma
Streptavidin beads magnetic 112.06 Dynal
TMB T-2885 Sigma
Trypsin T-8642 Sigma
Trypsin, sequencegrade 1418025 Roche
Tween 20 17767-B NBS Biologicals
X-Omat Film Kodak 306722410 VWR International
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